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The current literature concerning performance-enhancing drug (PED) use is 
often highly medicalised.   Limited research exists which delves into the lived 
experience within the context of PED use, particularly in a risk-oriented 
context.  This thesis uses qualitative methods to explore the experience, 
perception and navigation of risks associated with PED use in greater detail.   
The three empirical studies in this thesis are connected via PED use, which is 
self-identified as functional, but perceived as deviant by society.  Study 1 
uses Interpretative Phenomenological Analysis to highlight the experiences 
and challenges of AAS use from the perspective of four women, drawing out 
the impact on their identity.  Study 2 is a thematic analysis study of 
experiences and perceptions of twelve 2,4-dinitrophenol (2,4-DNP) users.  
This study evidenced strong control over every aspect of using a controversial 
and polarising compound.  The thematic analysis of study 3 highlighted key 
influential factors that impact the physician-patient interaction and expands 
on the notion of risk for non-PED using individuals.  The results collectively 
show how the perception and navigation of risks in a PED-use context shape 
the experiences of risk.  These results are explored within a Risk Society 
Model (RSM).  Risk perception is framed through a social-constructionist 
lens to reflect the highly individualistic nature of risk assessment impacted by 
sociocultural influences.   Risk navigation in PED-use is complex and 
multifold, heavily dependent on the nature of the risk and the resources 
available to participants at the time.  These studies highlight the importance 
of understanding lived experiences of risk and hazard management.  These 
results offer a different perspective to those within the current literature and 
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aim to contribute experiential knowledge and understanding upon which co-
productive harm reduction interventions can be built. 
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Chapter 1: Introduction 
 “Whilst the environment and the social world seems to be ‘out of 
control’, the body becomes something of an anchor.”  
(Nettleton, 2009)  
In a constantly evolving global society of rapid scientific progress and ever-
shifting values, few things appear to be in our direct control.  Uncertainty plays a 
more significant role in our lives and becomes a bigger challenge which modern 
society must live with and adapt to (Giddens, 1991; Beck, 1992).  Indeed, the one 
thing individuals can hold on to tangibly is ownership of our physical bodies 
(Nettleton, 2009).   The concept of the body has evolved throughout time, as outlined 
in this quote from Giddens (1991):  
Like the self the body can no longer be taken as a fixed -- a 
physiological entity -- but has become deeply involved with modernity's 
reflexivity.  The body used to be one aspect of nature, governed in a 
fundamental way by processes only marginally subject to human 
intervention.  The body was a ‘given’, the often inconvenient and inadequate 
seat of the self.  With the increasing invasion of the body by abstract systems 
all this becomes altered… the body has become fully available to be “worked 
upon” by the influences of high modernity… (Giddens, 1991: pp 117-118).   
In short, the ever-widening modern array of bodily modifications demonstrate a 
perceptual shift of our bodies from a fixed, immovable object to a pliable, alterable 
form (Nettleton, 2009; Petersen & Lupton, 2000).   In this contemporary context, 
specific modifications are considered “riskier” than others and have immorality 
imposed upon them by society (Monaghan, 2002). Indeed, some forms of risk-taking 
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are glorified and considered acceptable (Adams, 2002).  Nevertheless, within the 
context of health and wellbeing, risk and risk-taking activities often have immoral 
labels attached to them.  In a society ever concerned with “healthism” and the 
promotion of a “healthy” body, activities which “pollute” the efforts to create and 
maintain a healthy body are considered immoral on a societal level (Petersen & 
Lupton, 2000).   The fitness industry, consisting of professionals such as personal 
trainers, nutritionists and clinicians, has become an ever-expanding juggernaut 
focused on risk-avoidance.  The “healthy body” has become a morally-charged 
symbol indicative of self-control, moral worth and worthy of commendation 
(Petersen & Lupton, 2000).  Thereby, activities such as taking drugs, which deviate 
from this socially-reinforced risk avoidance are considered undesirable and morally 
wrong (Petersen & Lupton, 2000).  Performance-enhancing drug (PED) use falls 
within this category.  The use of PEDs in a risk-oriented modern society is associated 
with negative labels; notably, these include the identifiers of “cheater”, “fake”, 
“violent” and “narcissistic” (Monaghan, 2002);  
It has been suggested that the greatest public discomfort about 
bodybuilders is that ‘all those muscles somehow come out of a bottle; that 
there is something as synthetic, unhealthy, useless and faintly sinful as plastic 
flowers about what they do and the way they look’ ((Gaines & Butler, 1981): 
76); that there is discomfort about ‘the impurity of the chemical body, the 
unnaturalness of the steroid body’ (Mansfield & McGinn, 1993, p. 59, cited 
in Monaghan  (2002), p. 2). 
The risks outlined with PED use are not only limited to the physical effects, 
which are broadly described and covered throughout scientific literature; other 
hazards include the adverse effects upon the psychological and social self of those 
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who use these substances (Monaghan, 2002).  These remain to be investigated 
further, from the perspective of those within a PED-using context.   
The next sections will provide an overview of the definition, prevalence and 
usage of PEDs available, with more specific information provided on the substances 
of focus in this thesis.  A broad historical context will be provided, as will an 
overview of gender identities, problematisation of PED use and the theoretical 
framework which underpins the empirical studies within this thesis.  
1.1. Performance Enhancing Drugs (PEDs) 
This section provides a general overview on PEDs to cover prevalence rates, 
methods of usage and a brief socio-historical context of PED use.  Specific 
information is provided on anabolic-androgenic steroids (AAS) and 2,4-
dinitrophenol (2,4-DNP) due to the focus on them within this thesis.  Certain parts of 
this section include verbatim information previously published by the author in the 
form of a book chapter (Ainsworth, Shelley, & Petróczi, 2018).   
1.1.1. What are PEDs? 
PED is an umbrella term encompassing a group of substances with 
performance-enhancing effects used in sport and exercise.1  PEDs comprise of 
dietary supplements and functional foods that enhance sports performance, over-the-
counter medications, herbal preparations, and controlled substances.  These 
substances are grouped into nine broad categories based on their primary functions 
(see table 1).  Notably, PEDs do not always fit neatly into one category.  In these 
 
 
1 This includes image-enhancement purposes; image-enhancement is as much 
performance-enhancement when we account for aesthetic-focused athletic disciplines such as 
bodybuilding.   
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cases, we categorised the substance according to the dominant use in sport and 
exercise.   
Table 1  
A list of substances used and their functional effects.  Adapted from Ainsworth, 
Shelley and Petróczi (2018) 
 
Substance Type Purpose 
Anabolic-androgenic steroids 
(AAS) 
Skeletal muscle hypertrophy, increased 
strength 
Selective androgen receptor 
modulators (SARMs) and 
PPARδ nuclear receptor agonists 
(cardarine) 
Effect similar to anabolic steroids on skeletal 
muscle but with fewer adverse effects 
traditionally associated with AAS 
Stimulants and neuroenhancers Increased energy and psychological focus  
Appetite suppressants, fat 
burners and clenbuterol 
Decreased appetite or increased caloric 
expenditure for weight loss 
Peptides: insulin, human growth 
hormone (hGH), melanotans, 
thyroid hormones 
Various, depending on the substance  
Erythropoietin (EPO) Increased red blood cell production, 
increased endurance 
Beta blockers / hypertension 
medications 
Lower heart rate and reduce tremor in times 
of high anxiety, thus improving accuracy 
Diuretics Rapid loss of fluid (known as “water weight” 
amongst the gym-going population).   
Dietary supplements and herbal 
preparations 





Within this thesis, two substances were focused on: Anabolic-Androgenic 
Steroids (AAS) and 2,4-dinitrophenol (2.4-DNP).2 
 
1.1.1.1.  Anabolic-Androgenic Steroids (AAS).   AAS are a group of 
synthetic derivatives of testosterone used for performance and aesthetic enhancement 
within the gym-going community.  Structural modifications are introduced to the 
testosterone molecule to maximise anabolic effects and minimise androgenic effects 
(Kicman, 2008).  Table 2 outlines commonly used AAS within the gym-going 
community.  
Table 2  
A non-exhaustive list of commonly-used AAS and the colloquial terms used for 
them within the community. Obtained from Ainsworth, Shelley and Petróczi (2018)  
Substance Type Commonly Known As 
Testosterone  Test, T 
Testosterone propionate (ester) Test prop 
Testosterone enanthate (ester) Test-E 
Testosterone undecanoate (ester)  
Testosterone suspension (ester)  
Oxandrolone  Var, Anavar 
Chlorodehydromethyltestosterone  Turinabol, T-bol 
Drostanolone  Masteron, Mast 
Mesterolone Proviron 
Methandione/methandrostenolone Dianabol, D-bol 
Methenolone/metenolone Primobolan, Primo 
Trenbolone  Tren 
Trenbolone acetate (ester) Tren Ace 
Trenbolone enanthate (ester) Tren E 
Trestolone Ment 
Nandrolone Deca-durabolin, Deca 
Nandrolone decanoate (ester) Deca 
Nandrolone propionate (ester) NPP 
Methyltestosterone m-tren 
Fluoxymesterone Halostin, halotestin, halo 
Stanazolol  Winstrol, winny  
Boldenone Equipoise, EQ 
 
 




Over the years, wide ranges of ergogenic and adverse effects have been 
catalogued for AAS.  Ergogenic effects of AAS are varied from increasing muscle 
mass to aiding recovery.  Adverse effects vary between individuals and are sex-
dependent.  Hoffman and Ratamess (2006) suggest that specific adverse effects are 





















Table 3   
A list of potential ergogenic and adverse effects from AAS use. Obtained from Ainsworth, 
Shelley and Petróczi (2018) 
System Ergogenic effects Adverse effects 
Circulatory Increase in erythropoiesis, 
haemoglobin, and haematocrit 
Lipid profile changes 
Elevated blood pressure, 
decreased myocardial function 
Digestive Increase in appetite Increased risk of liver tumours 
and liver damage 
Endocrine Increase in lipolysis 
Increase in glycogen storage 
Increase in protein synthesis 
Decreased sperm count 
(oligospermia or azoospermia) 
Menstrual irregularities 
Excretory None None 
Immune Some compounds have a slightly 
immunostimulatory effect 
Some compounds have a slightly 
immunosuppressive effect 
Integumentary None Acne 
Male pattern baldness 
Muscular Increase in lean body mass 
Increase in muscle cross-sectional 
area 
Increase muscle strength and power 
Increase in muscle endurance 
Reduction in muscle damage 
Decrease in body fat percentage 
Enhancement of recovery between 
workouts 
Enhancement of recovery from injury 
Intramuscular abscess (if using 
injectable compounds with 
unsafe injecting techniques) 
Respiratory None None 
Reproductive None  Decreased testicular size 






Skeletal Increase in bone mineral density Increased risk of tendon tears 
Premature epiphyseal plate 
closure 
Nervous Increase in neural transmission 







Users3 attempt to self-mitigate adverse effects from AAS use (Parkinson & 
Evans, 2006).  Such measures include using aromatase inhibitors (AIs) to mitigate 
hyperestrogenemia arising from androgen aromatisation, cabergoline for prolactin 
management, and diuretics to mitigate hypertension.  An AAS dosage depends on the 
individual’s sensitivity to compounds, the specific compounds used, and the sex of 
the user.  In Parkinson and Evans (2006), the range of self-administered self-reported 
dosages varied between 70 mg through to greater than 6,000 mg of testosterone or its 
equivalent per week.  To achieve mega doses, users practice polypharmacy, often 
“stacking” several other compounds considered appropriate for their goals. 
Notably, self-reported AAS dosages have shown a demonstrable increase 
over the past decade.  The upper limit of the self-reported weekly dosage has 
increased from 3,200mg to greater than 6,000 mg (Evans, 1997; Parkinson & Evans, 
2006).  The trend of ever-increasing doses is of concern to the extremity and 
possibility of adverse effects. 
1.1.1.1.1. Female-specific use.  Reports of female nonmedical self-
administered AAS use are uncommon—the virilizing side effects possibly deter 
potential users.  The female lifetime prevalence rate was suggested to be 1.6% 
(Sagoe, Andreassen, & Pallesen, 2014).  While the likelihood of encountering a 
 
 
3 The term “PED users”, “individuals who use PEDs”, “AAS-using patients” and 
other similar terms will be used interchangeably throughout this thesis.  However, I 
acknowledge that a “person-first” approach is fundamental for the purposes of this research.  
The term “PED-users” can be heavily stigmatising.  However, for the purposes of readability 
and brevity, I will employ the term “users” throughout.  
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female AAS user is low, it is imperative to understand the consequences which can 
arise from female AAS use. 
Female AAS use has a high potential for virilisation (Kicman, 2008; 
Nieschlag & Vorona, 2015).  Side effects can be dose and compound dependent, 
though individual-specific sensitivity should be considered.  Potential adverse effects 
include hirsutism, voice changes, clitoromegaly, fat redistribution, and psychological 
changes, including increased aggression.  Amenorrhoea is an often-reported side 
effect with female AAS use.  Chronic amenorrhoea is a potential adverse effect and 
is dependent upon the compounds used and the user’s natural menstrual cycle.  
Amenorrhoea can persist for up to 24 months (Nieschlag & Vorona, 2015).  The 
effects on female fertility are not fully understood.  Previous studies report that 
women will use the least androgenic compounds in order to mitigate potential 
virilisation (Abrahin, Souza, de Sousa, Santos, & Bahrke, 2017)—oxandrolone 
(“var” or “Anavar”) is a typical “beginner” compound, with dosages of 5–10 mg a 
day for four to six weeks being a standard cycle.  More androgenic compounds, such 
as trenbolone, could lead to an increased risk of virilisation.  
1.1.1.2.  2,4-dinitrophenol (2,4-DNP).   2,4-dinitrophenol (2,4-DNP) is an 
industrial compound used initially for munitions manufacturing in the early 20th 
century (Perkins, 1919).  Currently, the focus remains on its role as a fat burner.  2,4-
DNP is rarely taken for longer than two months (McVeigh, Germain, & Van Hout, 
2017) with daily dosages ranging from 250 mg daily through to 500 mg or more 
(Ainsworth, Vargo, & Petróczi, 2018; McVeigh et al., 2017; Petróczi et al., 2015).  
2,4-DNP can raise metabolism by 11% for every 100mg ingested (Grundlingh, 
Dargan, El-Zanfaly, & Wood, 2011).  This effect is possible through its role as an 
uncoupler of oxidative phosphorylation, leading to a significant increase in energy 
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expenditure through compensatory mechanisms (Grundlingh et al., 2011).  Adverse 
effects include tachycardia, nausea, yellow discolouration of bodily fluids and skin, 
rash, and uncontrolled hyperthermia.  As of now, no antidote is available for 2,4-
DNP overdose, although successful treatment of a single patient with Dantrolene has 
been reported (Barker, Seger, & Kumar, 2006).  Death occurs through irreversible 
hyperthermia. 
1.1.2. Prevalence of PED use among exercisers and gym-goers 
A recent survey among young exercisers in five European countries showed 
that although rates of self-reported lifetime use of controlled PEDs vary across 
countries, PEDs use is not limited to competitive sport; a considerable segment of 
PED users (19.6%) is present among 16- to 25-year-old regular exercisers (Lazuras 
et al., 2017).  In a US survey (n = 9,147, mean user age = 10.8 years), a wide variety 
of herbal and vitamin/mineral supplement use to improve sports performance by 
children was reported (Evans, Ndetan, Perko, Williams, & Walker, 2012).  Though 
most reported multivitamin and mineral combinations, fish oil/omega-3, creatine and 
fibre, developing a mindset that supplementation is needed to enhance performance 
at such an early age is concerning for later use of PEDs (Backhouse, Whitaker, & 
Petróczi, 2013).  Based on self-reported surveys, prevalence rates for PEDs use 
among gym users range between 0.4% and 35% (Abrahin, de Sousa, & Santos, 2014; 
Hitti, Melki, & Mufarrij, 2014; Khullar, Scull, Deeny, & Hamdan, 2016; Lazuras et 
al., 2017; Molero, Bakshi, & Gripenberg, 2017; Sagoe, Molde, Andreassen, 
Torsheim, & Pallesen, 2014; Simon, Striegel, Aust, Dietz, & Ulrich, 2006; Striegel et 
al., 2006; Stubbe, Chorus, Frank, de Hon, & van der Heijden, 2014).  In the absence 
of a standardised methodology, prevalence rates from individual studies are hard to 
compare.  Within this range, PEDs prevalence figures vary widely across substance 
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types, time frame, and methods used to establish prevalence, and, as is the case with 
all data from self-reports, the exact prevalence rate may be higher or lower than 
reported.  Within the UK, the 2016/2017 drug misuse crime survey (Broadfield, 
2017) found an increase in AAS use in the 16–24 age range compared to the 
2015/2016 report (0.1% to 0.4%).  The media have noticed this trend, as evidenced 
by the article titled ‘Up to a Million Britons Use Steroids for Looks Not Sport’ in the 
Guardian on 21st January 2018.  There is a notable upward trend in reported PED-
user numbers.  Of note is the trend with concurrent PED use through the form of 
stacking.  A greater qualitative understanding of their use can provide valuable 
information regarding perceptions of the compounds themselves.   
1.1.3. How are PEDs used? 
Generally, there are two components to PED use: cycling and ingestion, and 
the instrumentalised nature of their use.  A ‘cycle’ (or ‘cycling’) is a term used to 
describe the amount of time a substance is used for.  The length of use depends on 
the pharmacology of the substance and the purpose for which it is used.  Some cycles 
can be as short as one week (for example, diuretics) while others can last many 
months (certain AAS compounds).  Depending on the ester size and purpose of use, 
some compounds can be rapid-acting (i.e.  stimulants such as amphetamines or AAS 
such as halotestin (fluoxymesterone)).  Others can take longer for the effects to 
develop (such as testosterone undecanoate).  Substances can either be taken alone or 
with other compounds through “stacking”.  “Stacking” refers to using one or more 
substances concurrently for a synergistic effect.  These substances can be AAS only 
or include other PEDs.  Cycles can include AAS only, non-AAS PEDs only (such as 
stimulants) or include a combination of AAS and other PEDs (such as stimulants, 
diuretics and other compounds).  For example, someone who is “cutting weight” may 
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have an AAS cycle consisting of a testosterone base and trenbolone (both AAS) 
whilst stacking the thyroid hormone triiodothyronine (T3) alongside the stimulant 
clenbuterol for the purposes of metabolic management.  Ingestion methods vary 
depending on the substance being ingested.  Substances can be orally ingested as 
tablets, via sublingual or subbuccal ingestion or injected either intramuscularly or 
subcutaneously.  
1.1.4. Historical context 
Early records mention PED use within the first Olympic games, circa 766 to 393 BC 
(Bowers, 1998).  Some accounts describe athletes allegedly consuming sheep 
testicles to improve performance in sporting events (Knights & Mangoni, 2015).  
This use of PEDs was normalised and continued throughout into the 20th century 
(Waddington & Smith, 2000).  In the 20th century, PED use was an expected and 
normalised aspect of competitive sport (Coomber, 1999).  Even outside an athletic 
context, the use of substances such as 2,4-dinitrophenol (2,4-DNP) for image 
enhancement through fat-burning is evident from as early as 1933 (Tainter, Stockton, 
& Cutting, 1935).  Thus, the use of drugs in sport was not considered particularly 
controversial at this time.  Throughout the 20th century, despite the introduction of 
legislation governing certain recreational drugs (notably, cocaine and opium),  the 
use of PEDs was still seen generally as permissible and continued without restriction 
(Coomber, 1999; Waddington & Smith, 2000).  More recently, testosterone was 
synthesised in Germany in 1936 for the first time (Freeman, Bloom, & McGuire, 
2001).  From here, 1959 saw the development of the first AAS compound 
specifically to enhance athletic performance: methandrostenolone (also known as 
Dianabol) by Dr Ziegler (Waddington & Smith, 2000).  The period of the 1960s saw 
the first PED-related death; in 1960, the first reports of PED-related deaths sadly 
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arose in the form of two cyclists suspected to have died from amphetamine use: 
Danish cyclist Knud Jensen in 1960 and British cyclist Tommy Simpson in 1967 
(Waddington & Smith, 2000).  Shortly after, 1968 saw the first drug test at the 
Winter Olympics competition in Grenoble, the start of a decades-long prohibitionist 
approach to drug use in sports (Waddington & Smith, 2000).  While this period 
oversaw the first efforts to control drug use in elite competitive sport and society, 
PED use became more endemic.  From the 1950s, alongside the synthesis and 
introduction of Dianabol by Dr John Ziegler, numerous AAS compounds entered the 
market (Bateman, 2014).  Despite this public perceptual shift favouring the 
prohibition of drug use, PED use was still heavily endemic within sport (Waddington 
& Smith, 2000).  PEDs were commonly acknowledged as being essential for sport, 
with some athletic teams reporting as much as 30% of team members having used 
PEDs (Waddington & Smith, 2000).  The next two decades saw a surge in the use of 
PEDs through all levels of society, with reports that schoolchildren were using PEDs 
(Waddington & Smith, 2000).  This PED influx coincided with the first Mr Olympia 
bodybuilding competition in 1965.  This competition was (and still is) considered to 
be the most prestigious bodybuilding competition worldwide by crowning the 
“champion of champions” (Bateman & Žeželj, 2017).  Since then, numerous winners 
have come and gone; from the likes of Arnold Schwarzenegger displaying Greek 
statuesque proportions to more contemporary “mass-monsters” dominating today’s 
stages, characterised by a controversial amount of sheer muscular bulk. This overt 
portrayal of hypermasculine bodies warrants a brief consideration of gendered 
identities in the context of PED use.  
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1.1.4.1. Masculine and feminine identities and PED use  
It is widely acknowledged that the representation of the masculine aesthetic consists 
of male figures who are well-groomed and physically “well-built”, portrayed in a 
manner that correlates success with a masculine body (Walker & Eli Joubert, 2011). 
It would be simple to associate the use of PEDs, particularly AAS, with the desire to 
adhere to masculine identity. Indeed, this is the suggestion made by Kotzé and 
Antonopoulos (2019); the use of AAS is an attempt to “hyper-conform” with 
societally accepted norms of the masculine aesthetic, rather than as a deviation from 
these aesthetic norms or a move towards a disordered masculine identity. This point 
is further strengthened with the perception attached to specific side effects associated 
with AAS – for example, the development of gynaecomastia is considered a threat to 
the masculine aesthetic (Monaghan, 2002). In this context, this particular physical 
risk can have the additional risk of experiencing shame and stigma due to this side 
effect, on account of transgressing a gender boundary.  
However, is this expandable to the use of other PEDs? Consider the use of a 
substance such as 2,4-DNP. As outlined previously, this is a substance which is used 
to lose body fat and retain a more muscular aesthetic. On the one hand, it can be 
considered a tool to adhere to traditional masculine norms through showcasing an 
aesthetic which is low in body fat. On the other hand, the process of losing fat can be 
considered a feminine pursuit (Monaghan, 2002). Additionally, a distinction needs to 
be made regarding the perception of specific disciplines; 
Bodybuilding may be distinguished from weight-lifting since the former 
activity takes as its goal improvement of physical appearance (bodily 
display), whereas the latter pursuit is aimed at lifting a maximum weight 
(bodily performance). On an analytic note, this cultivation of strength for 
15 
 
displayed beauty (the bodybuilder’s muscles) is suspect for non-participants 
because it is latently feminine, whereas beauty in the service of strength or 
courage (as among boxers, for example) is, by contrast, solidly masculine 
(Jefferson 1998: 84). (Monaghan, 2002, pg. 29, citing Jefferson, 1998, pg. 
84).  
In summary, reducing the use of PEDs to simply developing and reinforcing a 
masculine identity is overly simplistic; PED use encompasses a range of substances 
for a range of purposes which extend beyond muscular hypertrophy.). Additionally, 
PEDs are used in a variety of sports of which the concept of masculinity is not 
necessarily straightforward. The development of the masculine identity is 
complicated among those who use PEDs, as are the resultant risks.  
In the context of female PED use, the literature understanding the context of female 
AAS use is clarified through understanding how these competitions came to be. A 
comprehensive overview is presented in Bunsell (2013).  
Female bodybuilding competitions initially started as beauty pageants or bikini 
competitions, held alongside male bodybuilding competitions (Andreasson & 
Johansson, 2020; Shilling & Bunsell, 2009). In the 1970s, with the advent of feminist 
movements alongside the relative success of female powerlifting, female 
bodybuilding in a more recognisable modern-day form was born (Bunsell, 2013). In 
these competitions, female bodybuilding was more akin to the pageants previously 
held; women had to wear bikinis and high heels (Bunsell, 2013). During the 1980s, 
female bodybuilding competitions were held in what was considered the “golden 
age” of female bodybuilding (Bunsell, 2013). From here, female bodybuilding 
developed into several categories, and muscularity increased over time to the 
aesthetics present in modern-day female bodybuilding.  
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It is also critical to discuss the impact that the East German doping scandal had 
regarding the attitudes towards female PED use – this provides more context which 
develops from the points made about “moral panics” mentioned earlier. For many 
years, beginning in the 1950s, over 10,000 male and female athletes were subject to 
mandatory doping, often without their consent (Loland, Skirstad, & Waddington, 
2006). These practices were kept secret until the dissolving of the USSR in 1989 
(Dimeo & Hunt, 2012). One particular work which uncovers the experiences of 
female athletes within this system is Faust’s Gold: Inside the East German Doping 
Machine by Steven Ungerleider. This is the only monograph that focuses on these 
particular experiences from that time; consequently, it was widely disseminated on 
an international scale (Dimeo and Hunt, 2012). The specific impact the uncovering of 
this doping scandal, if any, upon the perception of women who choose to use PEDs 
has not measured. Nevertheless, it is tentatively suggested there may have been an 
impact due to the wide dissemination of the sole monograph available in the English 
language (Dimeo and Hunt, 2012) alongside the impact outlined that the disclosure 
of these practices had on the perception of PED use outlined in Coomber (2014).   
The use of PEDs, notably AAS, by women is depicted as transgressing the boundary 
of societally accepted female aesthetic – by its very nature, the virilisation effects 
caused by AAS are considered a challenge to the traditional hegemonic masculinity 
(Andreasson & Johansson, 2020). Female bodybuilding is often considered a threat 
to traditional female identities due to this particular reason. Female bodybuilders 
who take steroids are considered “doubly deviant” – their pursuit for muscularity is 
already considered a move away from societally acceptable norms of femininity; the 
use of AAS, even more so (Bunsell, 2013).  However, limited empirical research 
exists which examines the female identity in the context of non-AAS substances, as 
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well as female AAS use outside a bodybuilding context. As mentioned earlier, the 
use of fat burners can be considered one that fulfils a goal traditionally considered 
“feminine” (Monaghan, 2002). Thus, somewhat similarly to male PED users, female 
identity construction and PED use is complicated.  
In short – the identities of female and male PED users are complex and can result in 
an array of particular risks and hazards. The risks associated with PED use can 
extend beyond the physical and psychological side effects – the effects of being 
perceived as a “gender outlaw” (termed by Shilling and Bunsell, 2009) can mean an 
increased amount of stigma associated with both female and male PED use, as 
outlined above.  
1.1.4.2.Problematisation and stigmatisation in non-PED and PED contexts  
Despite a burst in popularity, the discussion regarding PED use for both male and 
female users remains very limited and seldom discussed publicly. There was an 
overwhelming agreement that to reach these levels of competition, PEDs use is 
considered essential (Bateman & Žeželj, 2017).  This reluctance to publicly discuss 
PED use is related to the stigma associated with it. To understand this further, some 
context is required on the topic of stigmatisation and PED use. 
Coomber (2014) provides an in-depth review of discourses relating to non-PED use 
and their relation to discourses surrounding PED use. The aforementioned drug 
testing within sports from 1968 occurred concurrently with the “moral panics” 
associated with the use of amphetamines and other drugs (Coomber, 2014). Drug use 
was not only perceived to be physically harmful; its use was also associated with 
perceived social and spiritual harms (Coomber, 2014). Concerning the concepts of 
“healthism” discussed earlier, drug use was considered a “contamination” of the 
social fabric comprising of purity, thus representing a deviation from acceptable 
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societal norms (Coomber, 2014). The movement from drugs being acceptable to 
drugs being perceived negatively can be contextualised through the process of 
“problematisation”; discourses around drug use revolved around exaggeration of 
their effects and the negative perception placed upon the users of such substances 
through the propagation of particular myths associated with drugs and their users 
(Coomber, 2014). This problematising of drug use shaped the narratives surrounding 
the users of such substances and, consequently, shaped the ensuing demonisation and 
stigmatisation (Coomber, 2014). It is suggested that anti-drug discourses stemmed 
from the 1920s and gained traction during this tumultuous time of social and political 
strife in the 1960s (Coomber, 2014).  During this time, the messages being delivered 
about drug use in sport were shaped by a number of events occurring at the time; for 
example, drug use in sport fell outside of what was deemed acceptable in amateur 
sport and therefore considered deviant and immoral (Coomber, 2014).  Associations 
made between PED use and Nazi Germany, alongside Communist countries within 
the Cold War context further entrenched negative associations relating to PED use 
(Coomber, 2014).  Paradoxically, this increasingly negative perception of PED use 
did little to stem the usage rates.  It goes without saying that in the context of the 
early associations made from the start of anti-doping dialogues and prohibitionist 
drug policy, public perception of PED use is still heavily stigmatising and negative 
(Monaghan, 2013).  Risks are presented as inevitable and severe. This 
homogenisation of risks associated with PED use ignores the complex interactional 
factors which contribute to the risks associated with PED use – factors such as 
individual biology, gender, dosages, compounds used and how they are cycled. Such 
perceptions of the risks associated with PED use give way to generalisations and 
stereotypes, similar to narratives presented in other drug-use contexts. Stereotypes 
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relating to PED use include an overexaggerated mortality rate as well as discussions 
surrounding “symptoms” such as “roid rage” (Coomber, 2014). To give an example, 
one common side effect attributed to AAS use is that of “roid rage”. “Roid rage” is 
an alleged side effect of AAS, namely high levels of aggression and violence. Rather 
than acknowledging potential underlying tendencies for aggression, there is a 
perceived causal link between aggression and use of PEDs (Coomber, 2014). 
However, despite how widely acknowledged “roid rage” is, empirical data is 
inconclusive and not as clear cut as it may appear (Dobash, Monaghan, Dobash, & 
Bloor, 1999). Such stigmatisation and the feared effects from encountering it 
potentially contribute to the limited public discussion on PED use in bodybuilding 
and other strength sports from PED users. Yet stigmatisation is probably not the first 
risk that comes to mind when discussing the risks associated with PED use, except 
for those within the community. Risk perception within the community is more 
nuanced and complex than originally considered. To understand the risk perception 
associated with PED use, it is important to first understand how PED users perceive 
their use and the differentiation between functional and non-functional use.  
1.1.4.3.Identity construction and instrumentalised PED use  
To understand their perception of PED use, a brief overview of instrumentalised drug 
use is provided. One concept which underpins this approach to PED use is the drug 
instrumentalisation framework (DIF).  Outlined by Müller and Schumann (2011), 
DIF posits that the vast majority of non-addicted individuals take drugs to further 
their goals.  In short, drugs are instrumentalised to fulfil functional goals.  While the 
context is limited to psychoactive substances, this concept applies to non-
psychological goals. For example, the use of PEDs to facilitate weight loss, muscular 
hypertrophy or improve strength can be considered a form of drug 
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instrumentalisation.  Regardless of whether the individual is a competitive 
bodybuilder, powerlifter, or non-competitive gym-goer, the use of PEDs is first and 
foremost for the purposes of self-improvement (Monaghan, 2002). In this context, 
previous research outlines how bodybuilders’ perspectives of PED use qualify them 
as “ethnopharmacologists” (Bloor, Monaghan, Dobash, & Dobash, 1998; Korkia & 
Stimson, 1993). This term reflects the nature of the lay expertise associated with 
PED use within the community, such as the particular sub-cultural understandings 
associated with particular compounds to facilitate their use for their particular 
purposes (Bloor et al., 1998). Despite technically being “drug use”, the concepts of 
drug “use” and “abuse” are differentiated; their approach towards PED use is 
highlighted through a collective understanding of the “proper” way to use PEDs. 
Indeed, one respondent stated how, when using steroids, “…you have to be a 
scientist” (Bloor et al., 1998, p. 32). This term indicates the rationality and logic 
associated with the use of PEDs, thereby rejecting the notion that PED use is reckless 
and without a plan. In contrast, the “abuse” of PEDs is underlined by “…overuse, 
indiscriminate use and unplanned taking with an absence of control.” (Monaghan, 
2002, pp.  3). Notably, it was also suggested that using PEDs without a specific cycle 
or plan indicates a lack of discipline and not having a goal (Bloor et al., 1998).  
In short; the use of PEDs is perceived to be a careful and considered choice made for 
the functional purpose of self-improvement rather than recreation. In this context, 
user perceptions concerning the hazards associated with PED use are not as black 
and white as conventional understandings might portray. There is a notable debate 
which comes into play – the role of the PED-user as a “lay expert”, one who values 
experiential knowledge and understanding versus the exaggerated discourses 
surrounding risk espoused by the wider scientific community. To build upon this 
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gap, the studies within this thesis will be considered within the context of the Risk 
Society Model (RSM) theoretical framework.  
1.2.Theoretical Framework: Risk Society Model (RSM)  
For modern society, risk is an essential aspect to understanding everyday life 
(Giddens, 1999).  Indeed, the identification, management and risk assessment 
methods have encompassed many levels of modern society; from governmental and 
global levels through to the individualistic level (Duff, 2003).  Thanks to advanced 
technology and science, we are now equipped with more tools than ever before to 
help raise our awareness of risks and hazards ever-present to us, alongside giving us 
tools to evaluate the probabilities of a risk becoming a hazard (Duff, 2003).  
However, as outlined in Beck (1992), the very existence and progress of science and 
technology mean new risks and hazards arise, raising questions about how helpful 
these institutions are in terms of facilitating growth and improving society’s quality 
of life (Beck, 1992).  A risk society model (RSM) posits that the period of late 
modernity is a risk-oriented world whereupon identities and bodies are constructed 
reflexively amidst continuous warnings to danger (Monaghan, 2002).  There were 
two broad reasons why this particular framework was chosen to frame these results:  
Firstly, the aim of Beck’s (1999) RSM was to explain risk within 
sociocultural behavioural contexts and critique traditionally scientific and “objective” 
quantifications of risk assessment.  Building from this, lived experience is considered 
a key component often ignored by scientific accounts of risk within the RSM (Duff, 
2003; Lupton, 1999).  Particularly in the context of substance use, separating the 
user’s understanding of the associated risks from the context these substances are 
used in misses the aspects of risk navigation and perception from a lived experience 
perspective (Duff, 2003).  One of the aims of this thesis is to move away from 
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reductionist scientific descriptions of risks associated with PED use.  Instead, each 
qualitative chapter aims to build an understanding of the narratives and perceptions 
of individuals within a PED-using context from a first-hand perspective.  This 
importance placed on lived experience gives theoretical justification for the empirical 
works within this thesis.  This leads on to the second reason for the application of the 
RSM: a focus on the debate between “lay” and expert perspectives.   
1.2.1. Risk perception and PED use 
A fundamental tension between the “scientific” and “lay” groups outlines how both 
conceptualise risk.  The scientific understanding of risk is that of a “problem”: risk 
assessment is objective, rational and consists of a perhaps “cold” calculation of 
probabilities and hazards though “expert authority” (Beck, 1992). In this context, risk 
assessment can be considered to be a way to organise and perhaps dictate personal 
conduct and actions to improve personal wellbeing (Duff, 2003; Petersen & Lupton, 
2000).  In contrast, the lay perceptions of risk appear to be grounded in the direct 
understanding of risk; rather than avoiding risk, risk is a concept to be experienced, 
perceived, considered and managed; therefore, risk assessment is pragmatic and 
functional (Duff, 2003; Fox, 1999).  In response, a growing emergence of a different 
level of knowledge and risk assessment has arisen through the form of a lay 
understanding of risks.  This tension creates a conflict in the quest for obtaining 
legitimacy between the concept of “expert” versus “non-expert” (Duff, 2003);   
In restricting itself to the purportedly objective and rational 
dimensions of risk, the science of risk assessment discounts the subjective 
and situated experience of risk, despite the fact that risk is always 
encountered within specific social contexts.  Beck notes that this process has 
been compounded by the propensity for scientists to regard any opposition to 
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expert risk discourses as irrational and ignorant.  For scientists, the problem 
of risk is a problem of information and how it is disseminated; and so risks 
may be overcome through the more widespread dissemination of this expert 
information.  Lay actors, conversely are increasingly wont to dismiss this 
information as irrelevant, misguided or worse, ideologically motivated, 
because of the way it ignores changes in the ways risks are experienced in 
diverse cultural settings.  (Duff, 2003, p. 292).   
This notion is congruent with the context discussed earlier relating to the heavily 
negative stereotypes and perceptions of PED use and users. The two key 
justifications for contextualising the thesis through a RSM now enable an overview 
to be provided regarding the use of the RSM in a PED-use context.  
1.2.2.   Risk society and PED use context 
The applicability of the risk society lens to the PED using population has 
been covered in substantial depth through Monaghan (2002).  This was an 
ethnographic qualitative study to understand how PED-using bodybuilders in South 
Wales sustain their “risky” practices and how they construct and maintain their 
bodies and identities pursuing their choice of activity.  This is one of the few 
empirically grounded works which emphasises the importance of gaining and 
exploring the lived experience of these participants to better understand their choices.  
Here, the argument is made that chemical bodybuilding is a “technically 
sophisticated way of making muscular bodies.” (Monaghan, 2002).  The use of PEDs 
is seen as a controlled and carefully considered decision made for self-improvement.  
The processes of risk management are highly individualised and supported by 
dialogue relating to social responsibility and being competent technically.  Within 
this context, bodybuilder participants went to great lengths to limit the potential for 
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bodily and psychological harm which could arise from their use of PEDs. Narratives 
concerning the definition of harm and risk and how these risks are managed and 
experienced within this population require exploration in greater depth through 
understanding the lived experiences and narratives within a PED-use context.  
Through this understanding, user-oriented harm reduction initiatives can be 
developed through understanding their experiences and perspectives and remain 
congruent with the principles of co-production, which value the lived experience and 
perspectives of those within affected communities for the creation of meaningful 
interventions. 
1.3. Harm reduction 
Harm reduction is a public health philosophy initially developed for adults 
with substance use issues where abstinence was not feasible.  Sex education for 
adolescents in the context of sex education is an example of its success outside of a 
drug use context (Leslie, 2008).  The core objective is to reduce harms from 
potentially risky behaviours (Leslie, 2008).  This paradigm has two key underpinning 
concepts associated with it; firstly, the focus remains on the outcomes of substance 
use, rather than the use itself.  Secondly, the primary objective is to reduce the 
adverse outcomes associated with use, regardless of any reduction or non-reduction 
in use (EMCDDA, 2010).  Just as there are a plethora of associated harms with 
substance use, harm reduction is implemented in numerous ways (EMCDDA, 2010).  
For example, needle exchange services are perhaps the most familiar; through their 
implementation, annual decreases in HIV rates have been documented (Amundsen, 
2006).  In terms of effectiveness, the literature documents notable declines in 
morbidity and mortality associated with potentially risky behaviours through the 
implementation of harm reduction methods and principles  (Leslie, 2008).  
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Understanding the challenges and perceptions of those using PEDs and the 
surrounding societal groups can potentially inform harm reduction policies.  It is 
well-established that understanding “first-hand” the experiences from the 
perspectives of stigmatised groups is crucial to inform meaningful interventions 
(McKeown et al., 2014; Penny, Slay, & Stephens, 2012).  This is the concept of co-
production (Penny et al., 2012; Seymour, 2017). 
1.3.1. Co-production: Lived experience and intervention creation 
Co-production in healthcare settings is the active involvement of those with 
lived experience of a condition or behaviour in the design, delivery and monitoring 
of services (Seymour, 2017).  Co-production works upon the premise that individuals 
with lived experience of a particular condition or behaviour are best placed to advise 
what support and services will make a difference in their lives (Seymour, 2017).  The 
benefits from a service-user perspective include empowering those who require these 
services alongside improving the quality and efficiency of services (McKeown et al., 
2014; Penny et al., 2012).  One case study on a secure ward demonstrates how co-
production helped decrease the number of incidents on alongside reducing the 
average length of stay (McKeown et al., 2014). 
Additionally, co-production of services facilitates an improved relationship 
between service users and professionals by acknowledging the “expert-by-
experience” role service users bring, thus moving away from the assumption that 
only professionals can be experts (Penny et al., 2012).  one study describes a co-
production approach to designing harm reduction materials for injecting drug users 
(Hussey et al., 2019).  The process outlined emphasised the impact and importance 
of including individuals with lived experience throughout the design process.  The 
involvement of service users throughout the project helped decrease the likelihood of 
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stigmatisation and potential alienation, thereby improving engagement (Hussey et al., 
2019).   Co-productive principles assert that those with lived experience of PED-use, 
or in contact with PED-users, are often best equipped with the skills and knowledge 
to implement effective interventions (Hussey et al., 2019).  The results of this thesis 
can add to the knowledge base upon which pragmatic and feasible co-productive 
harm reduction initiatives can build.  Through outlining the experiences and 
perceptions of a group who are self-professed experts through experience, services 
can help implement harm reductive interventions and provisions.  To do this, we 
need to understand, beyond the conventionally acknowledged health-focused 
hazards, what risk and harm mean in a broader PED-using context. 
1.3.1.1. PED use and available interventions.  Currently, limited resources 
exist for harm reduction for experienced PED users (Bates, 2019).  Bates (2019) 
offers a comprehensive review of the limited number of interventions specific to 
PED use.  This review outlined 14 distinct interventions.  The majority of these 
interventions were preventative and predominantly aimed at young athletes.  Of all 
14 interventions outlined, only one was found to contain a significant number of 
individuals who used AAS (Jalilian, Allahverdipour, Moeini, & Moghimbeigi, 
2011).  Even within this study, only 20% of participants used AAS (Bates, 2019).  
This study used the theory of planned behaviour to create and disseminate an 
educational program for PED-users and non-PED users.  The aim was to reduce AAS 
use and, therefore, reduce potential harms associated with AAS use.  Of note are the 
findings of this interventional study; there was a notable decrease in individuals who 
used AAS within the interventional group compared to the control group (Jalilian et 
al., 2011).  Effectively, the end goal of the intervention was achieved.  However, it 
remains unclear whether participants who were using AAS at the time were 
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considering coming off beforehand.  Furthermore, it is unclear whether the 
intervention was co-produced with those who use PEDs or not.  This lack of specific 
interventions, combined with a lack of experiential narratives concerning PED use in 
the literature, indicate further research is required to create an experiential foundation 
upon which such interventions can develop  (Monaghan, 2013).   
1.4. Research question, aims and objectives 
Current literature extensively outlines the medical and psychological side 
effects arising from PED use, often from a heavily exaggerated and negative 
perspective (Coomber, 2014; Monaghan, 2009).  However, there is a shortage of 
lived experience accounts concerning what they perceive to be a risk, how they 
manage it, and how they navigate it.  This thesis sets out to answer the question: 
Through exploring lived experiences, how is risk perceived, navigated and 
experienced in the context of PED use?  Figure 1 demonstrates the studies in the 
context of the research question. 




Figure 1.  Diagram demonstrating each study in relation to the research question. AAS: 
Anabolic-Androgenic Steroids, 2,4-DNP: 2,4-Dinitrophenol. 
Each study aims to explore the navigation, experiences and perceptions of 
risk in the context of PED use.  The inclusion of different participant cohorts builds 
narratives of risk from different perspectives and in different settings.  Three 
different participant cohorts, backgrounds and perspectives give a more holistic 
overview regarding risk and PED use.   
1.4.1 Outline of empirical chapters and the gaps they address 
Each study was conceptualised inductively.  The aim was not to work within 
a pre-planned framework using testable hypotheses.  Rather, the goal was to 
organically develop a series of qualitative studies which aimed to explore specific 
facets of the PED-using experience within the framework of the research aims and 
objectives.  The ideas for each study came about from information within interviews 
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reflect chronological order.  It instead aims to provide a narrative moving from the 
idiographic and individualised approach to a more environmental and community-
based perspective.   
1.4.1.1.  Chapter 3 (Study 1).   
Chapter 3 is an empirical chapter which chronologically describes the female 
experience of AAS use.  This Interpretative Phenomenological Analysis (IPA) 
interview study outlines the challenges, experiences and perceptions of women who 
have, or currently use, AAS.  Women who use AAS are an understudied group 
within the context of PED-focused research.  For the first time, this study delves into 
aspects of AAS use that transcend the health implications; this study explores the 
impact upon the feminine identity throughout AAS use.   
1.4.1.2.  Chapter 4 (Study 2).  
 Chapter 4 is an article outlining the attitudes and perspectives of those who 
use 2,4-DNP.  This was the first time an interview study had been done with those 
who use 2,4-DNP.  The identified risks with 2,4-DNP use originate primarily from 
the lack of an antidote in the event of an overdose, combined with a relatively rapid 
build-up in the human body.  Exploring the attitudes and perceptions towards 2,4-
DNP uncovers essential aspects of disclosure and intra-community perspectives 
towards acceptable levels of risk and risk mitigation, building from the idiographic 
approach outlined in the first study in chapter 3.   
1.4.1.3.  Chapter 5 (Study 3).   
The last empirical chapter is a thematic analysis exploring the patient-doctor 
interaction between doctors and AAS-using patients within the UK.  This study is the 
first time both perspectives explored concurrently.  Through exploring both sides, 
risks and risk mitigation within the clinical interaction for each cohort can reflected 
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upon concurrently.  The risks present within this empirical chapter extend beyond 
those within the community itself; the perception and experiences of physicians give 
a different dimension to risk and offer a comparative point for risk from an out-group 






Chapter 2: Methodology 
This section will provide an overview on the qualitative theoretical 
frameworks used within each study.  Following this, information will be provided to 
explain in further detail the specific methods used within each study.   
2.1.  Qualitative theoretical framework 
Qualitative research offers the opportunity to explore and understand the 
perspectives and experiences of participants through their own words, particularly  
the perspectives of those who are often silenced (Creswell & Poth, 2016).  
Qualitative methods enable a deeper understanding of relatively unexplored 
phenomena and the contexts they occur in (Creswell & Poth, 2018).  Additionally, 
the author’s access to this hard to reach population enabled exploration of these 
novel narratives in greater depth.  Using qualitative methods facilitated these 
population cohorts to share their experiences and perspectives concerning risk and 
hazards in greater detail.   
2.1.1.  Ontological position 
The ontological position of this thesis is subjectivism.  The subjective 
paradigm posits that people experience their position within the world as a result of 
many factors (O’Gorman & MacIntosh, 2015).  Reality is comprised of the 
perceptions and interactions of individuals.  Two different individuals can experience 
the same event differently.  The papers within this thesis set out to outline the 
experiences and attitudes of both ingroup and outgroup participants of the PED-using 
community.  Participants were recruited from different gender groups, different parts 
of the world (and subsequently differing cultural groups), different athletic 
disciplines and professions, amongst other factors.  Though the majority of 
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participants used PEDs in the empirical chapters, experiences and perspectives differ 
amongst them.   
2.1.2.   Epistemological position 
This thesis is epistemologically situated within an interpretivist paradigm.  
Interpretivism differentiates knowledge-gathering between the human and natural 
sciences (O’Gorman and Macintosh, 2015).  The key difference is between 
explanation (for the natural sciences) and understanding (for human behaviour).  
Weber (1924) asserted that the causal-inference knowledge-gathering process in the 
natural sciences is unsuitable for the exploration of human experiences due to factors 
such as human free choice.  As such, the same version of events perceived through 
different eyes can be true at the same time (Rubin & Rubin, 2011).  Consequently, 
qualitative research methods help explore these different perspectives and 
experiences.  Research methods tend to be naturalistic and often involve in-depth 
interviews, participant observation and other data collection methods.  Due to the 
nature of qualitative inquiry, the researcher is the main component of data collection.  
Through the researcher, experiences, perspectives and other forms of data are 
interpreted and subsequently disseminated.   In accordance with this paradigm, a 
reflexivity and positionality statement is included below.   
2.1.3.  Reflexivity and positionality statement 
I am a married British-Asian female in her late twenties.  Until recently, I was 
a top-ten nationally ranked female powerlifter who has also competed in a 
bodybuilding event.  I have been involved in strength sports for almost a decade 
before my recent retirement.  I have competed alongside many people, including 
those who use PEDs and those who do not.   During this time, I have forged 
networks and friendships, which enabled me to gain access to participants in this 
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otherwise hard-to-reach group.  My position within the community also equipped me 
with necessary knowledge and understanding of the dynamics and taboos within this 
community. Of note were the numerous accounts surrounding PED use characterised 
by stigmatisation and fear of not being heard.  The accounts and perspectives of 
those who use PEDs influenced my research; I was keen to get their perspectives and 
experiences across and examine them in greater detail.  My initial observations led 
me to see how their perspectives were missing to those not within the community.  
Accounts and information relating to PED use were, more or less, contained within 
the community itself.  Dissemination outside the community was rare, due to the fear 
of stigma.  Meanwhile, the information about the risks and dangers of PED use from 
a non-PED context appeared overwhelmingly negative and stigmatised.  Media 
discussions focused almost entirely on deaths or doping when it came to PED use.  
The community is very close-knit and can be wary of “outsiders” – indeed, efforts to 
recruit initially by not stating my background were fruitless, as individuals thought I 
was a journalist looking to “badmouth” participants.  I noticed that to recruit and 
create rapport successfully, I needed to explain my background and competitive 
experience to create common ground and connections with potential participants.   
2.2.  Methods  
This section offers a broad overview of the methodological practices used 
across each study and offer insight into the use of different analytical methods.  
Detailed procedural information is available within each specific empirical chapter.   
2.2.1.  Ethical considerations 
Each study underwent the necessary ethical protocols before commencing 
any data collection (see appendices for the relevant ethical approvals).  The key 
underlying ethical aspect related to participants being in a stigmatised population and 
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dealing with sensitive stigmatised topics.  Throughout each study, measures were put 
in place to ensure that the anonymity of participants was preserved.  These 
methodological considerations are outlined below, as well as in each chapter.   
2.2.2.  Recruitment 
Recruiting participants from these population groups is challenging – the 
main problem arises from the stigma attached to the use of PEDs.  In this context, the 
topic is sensitive and needs careful navigation.  Research is sensitive if “…it requires 
disclosure of behaviours or attitudes which would normally be kept private and 
personal, which might result in offence or lead to social censure or disapproval, 
and/or which might cause the respondent discomfort to express.” (Wellings, 
Branigan, & Mitchell, 2000, p. 256).  In this context, PED use is a hotly contested 
and heavily stigmatised behaviour with many negative assumptions attached to it.  
Consequently, these participants can be hard to reach and challenging to recruit.  
Combined with occupational sensitivities, the associated legality of use (depending 
on the country of residence) and even within-community stigma and conflicts, 
disclosure of experiences and attitudes can be a barrier for research.  This element is 
not uncommon to participants of other hard-to-reach populations (Liamputtong, 
2015).  As such, researchers have to consider their recruitment methods carefully.   
Snowball sampling was used for each empirical study.  Snowball sampling 
enabled a chain reaction of recruitment.  My position within the community was one 
of familiarity; individuals knew me as a competitive powerlifter and researcher.  My 
position allowed me to gain access to those who might not have been so open to 
divulging their experience.  This familiarity helped build trust and rapport between 
myself and the community.  Often, I recruited virtually; this enabled access to a more 
diverse range of participants from around the world, thereby obtaining different 
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sociocultural perspectives without being limited to locality.  More specific online 
recruitment information is detailed within each chapter.   
2.2.2.1. Recruitment from different gym-going cohorts.  I made the 
decision to recruit from a wide range of athletic backgrounds.  My participants 
comprised of amateur and elite-level powerlifters and bodybuilders, coaches and 
recreational gym-goers.  This was deliberately done to explore the experiences and 
perceptions without limiting myself to one specific gym-going participant groups.  
Widening my participant cohort enabled me to incorporate a greater range of 
perspectives which might not have been possible if I had focused on a specific group.  
Additionally, I was able to explore both aesthetic and performance-based aspects of 
PED use, which can often overlap.    
2.2.2.2. AAS and 2,4-DNP focus.  As mentioned in Chapter 1, I chose to 
focus on two specific compounds: AAS and 2,4-DNP.  AAS have been  chosen as 
they are one of the most commonly used, if not the most commonly used PED within 
the gym-going community (Ainsworth, Shelley and Petróczi, 2018).  Notably, the 
legalities associated with personal possession of AAS in certain countries (such as 
the UK) mean they exist within a “grey area” of acceptability.  This, combined with a 
lack of understanding regarding female AAS use justify the focus remaining on AAS 
for two of the three empirical chapters within this thesis.  In the context of 2,4-DNP 
use, its use remains stigmatised and polarised even within this specific community.  
The “high risk, high reward” nature associated with its use, alongside  
the relatively little-understood potential physical implications arising from its use, 
make it extremely controversial within the community itself.  Very few PEDs have 
such a reputation associated with them.  Having two groups of substances provides 
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an opportunity to reflect on the similarities and differences in risk perception and 
navigation through exploring experiences of their use.   
2.2.3.  Data collection 
As per the previous section, naturalistic interviews are a commonly utilised 
method of data collection for qualitative studies.  Interviews enable a rich and 
detailed description of the topic or action in question through the use of an organic 
interview structure (Rubin and Rubin, 2012).  The term organic reflects how the 
questions are in no fixed order; instead, it is context and participant dependent.  
Particularly with these stigmatised populations, interviews give participants the 
ability to frame their attitudes and experiences in their own words (Liamputtong, 
2015).  The flexibility and fluidity afforded by qualitative interviewing methods 
enable participants to set the pace and schedule of the interview.  Empirical studies 
within this thesis used open questions to collect rich and detailed data that follow a 
fluid interview question schedule.  Interviews were audio-recorded and transcribed 
verbatim.  Study 2 was self-transcribed, whereas a professional transcription service 
was used in studies 1 and 3. Specific interview protocols are available within each 
empirical chapter and are attached as appendices.   
2.2.4.  Data analysis 
Two types of qualitative analysis were done throughout this study: Study 1 
used Interpretative Phenomenological Analysis (IPA) while study 2 and 3 used 
Thematic Analysis (TA).   
2.2.4.1. Interpretative Phenomenological Analysis.  IPA is a framework 
which provided shape and structure to the analysis of their experiences.  IPA was 
chosen in contrast to thematic analysis as the focus was on a specific phenomenon; 
namely, that of female AAS use.  The phenomenological emphasis on the 
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experiences and perceptions of the experiences also justified the use of IPA.  I 
wanted to focus on the experience of each woman and understand her own 
experiences on an individual level throughout her journey of AAS use.  IPA’s 
idiographic focus enabled me to do exactly this.  Thematic analysis for the other two 
chapters enabled a more “generalised” approach which enabled exploration of a 
broader range of factors and perspectives (such as outgroup and ingroup perceptions, 
the media and other aspects).   
2.2.4.2. Thematic Analysis.  Thematic analysis offers a flexible approach to 
qualitative data analysis without adhering to any specific theoretical framework 
(Braun, Clarke, Hayfield, & Terry, 2019).  Three core “schools” of thematic analysis 
exist as per Braun et al. (2019); coding reliability approaches, reflexive analysis and 
codebook thematic analysis.4  Study 2 utilised codebook thematic analysis.  A 
codebook approach is defined as being in between a more positivistic coding 
reliability approach and a more constructionist reflexive approach.  Two key reasons 
justify the use of this approach: Firstly, as this was my first qualitative study, a 
codebook approach was deemed the most suitable as it provided a more guided 
analysis for the interviews.  Secondly, codebook thematic analysis is a valid method 
for when more specific research questions want to be answered while undertaking a 
more structured reflexive analytical approach without undertaking more positivistic 
quantified reliability analytical approaches (Braun et al., 2019; Braun & Clarke, 
2006).  This study aimed to understand specific facets related to 2,4-DNP use.  The 
 
 
4 A coding reliability approach aims to provide a more “quantifiable” and 
generalisable  method of TA through the measurement of coding agreement across multiple 
coders.  See Braun, Clarke, Hayfield, & Terry (2019) for more information.   
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codebook served as a “roadmap” for the study, mapping out pre-determined “points 
of interest” in line with the research questions whilst thematic generation remained a 
fluid and flexible process.  My position within the community afforded me the 
opportunity to amend the codebook as necessary; I was able to take into 
consideration specific areas of discussion which could potentially be missed by those 
without this underlying knowledge or understanding.  Therefore, I was careful to 
ensure that the codebook reflected aspects of the participant’s reality.  This ensured 
the codebook retained the reflexive qualities valued by Braun et al (2019).    
Study 3 used an open-ended coding reflexive coding approach.  This study 
utilised two cohorts; one cohort of AAS-using patients and one cohort of physicians.  
This study benefitted from a more open reflexive approach due to the complexity and 
diversity of experiences and ideas presented within the data.  Having this reflexive 
approach enabled constant revisiting and reconceptualizing of concepts and codes 
throughout the study, thus enabling more iterative and fluid conceptualizations of the 
interview data.  This was important, as this was an exploratory study of a 




Chapter 3: The female experience of AAS use 
Preamble 
This chapter is formatted as a manuscript which is being prepared for 
submission to Qualitative Research in Sports, Exercise and Health.  This study is the 
first of the empirical chapters within this thesis as it moves from the more 
idiographic to the less idiographic.  All participant information within this 
manuscript was up to date at the time of interview.   
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Fragile femininity: An Interpretative Phenomenological Study exploring the lived 
experience of women who use AAS 
3.1.  Abstract  
Little research exists which explores the experiences of female AAS use from 
their perspective.  This study aims to explore the experiences, perceptions and 
perspectives of female AAS users qualitatively.  Snowball sampling resulted in four 
women volunteering their participation in the study.  Using Interpretative 
Phenomenological Analysis (IPA), four superordinate themes clarify the experiences 
and narratives detailed by the participants: preparation and anxiety (before AAS use), 
deviation from feminine identity (during AAS use), the turbulence of cessation (end 
of AAS use) and rediscovering femininity (post-AAS cessation reflections).  The 
results show the complicated reflection and framing of the feminine identity by 
participants throughout their AAS use.  Each participant anticipated negative side 
effects, but this did not stop negative emotional feelings arising from them.  This 
study is the first time an in-depth exploration of the AAS-using journey from a 
female perspective through illuminating the impact of AAS use on women, thus 
providing information which could prove beneficial for harm reduction purposes.    
3.2.  Introduction 
In the context of human enhancement, definitions of what is normal or 
deviant continuously evolve; consequently, we cannot use historical norms or values 
to define boundaries for human enhancement practitioners.  In modern times, the 
perception of the body has shifted from being an unmodifiable entity to an adaptable 
medium capable of fitting the desired look, function or experience and potentially 
surpassing ‘normality’ (Lipovetsky & Charles, 2005).  Exponential advances in 
medicine, pharmacology and technology have made pushing the boundaries through 
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human enhancement more accessible.   However, such practices raise questions 
about fairness and their impact on health and wellbeing.  Human enhancement 
impacts regulatory bodies and healthcare in caring for individuals using 
performance-enhancing drugs (PEDs) (Ainsworth, Vargo, & Petróczi, 2018; 
Brennan, Wells, & Van Hout, 2014; Hogle, 2005; McVeigh, Evans-Brown, & Bellis, 
2012; Menuz, Hurlimann, & Godard, 2013; Sagoe et al., 2015).  They can potentially 
impact individuals’ health and wellbeing and challenge governance within sport and 
society.  One widely used group of PEDs are anabolic-androgenic steroids (AAS) 
(Ainsworth, Shelley, & Petróczi, 2018).   
3.2.1.  AAS context 
AAS are synthetic substances which are structural modifications of the 
testosterone molecule (Ainsworth et al., 2018; Kanayama & Pope Jr, 2018).  These 
structural modifications maximise the anabolic or androgenic aspects of each 
compound (Kicman, 2008).  In particular, the gym-going community use AAS for 
their ergogenic effects (Ainsworth et al., 2018).  These include increased muscular 
hypertrophy, improved central nervous system neural transmission, and improved 
bone density (Hoffman & Ratamess, 2006).  However, there are also a plethora of 
potential adverse effects, including adverse cardiovascular effects (e.g., such as 
transient high blood pressure and adverse lipid profile changes), psychological 
aspects (e.g., mood changes), and sexual dysfunction (Hoffman & Ratamess, 2006).  
AAS are used in cycles.  In this context, a ‘cycle’ (or ‘cycling’) is a term which 
describes the duration of AAS use (Ainsworth et al.  2018).  Cycles can be as short as 
four weeks, through to lasting many years without a break.  Specifically, the cycle 
duration depends on the substances used, the purpose of the cycle and individuals’ 
personal choices relating to their AAS use (Ainsworth et al.  2018).   
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Literature evidence suggests prevalence usage rate of approximately 3.3% of 
the population, with a higher prevalence of 6.4% among males (Sagoe, Molde, et al., 
2014).   The general view of AAS use - despite the relatively low prevalence rate  – 
is that it is a growing public health concern (Kanayama, Hudson, & Pope Jr, 2008; 
Nicholls et al., 2017)  partly because it is often associated with potential health and 
psychological consequences (Sagoe, Molde, et al., 2014; Yesalis, 2001). 
3.2.1.1.  Female AAS use context.  Comparatively speaking, male AAS use 
and its effects are understood better than female AAS use (Monaghan, 2002).  A vast 
array of quantitative studies exists within the medical literature concerning male 
AAS use, primarily focusing on secondary male hypogonadism (Monaghan, 2002).  
This discrepancy possibly stems from the relatively low prevalence rate of female 
AAS use.  Sagoe et al.  (2014) quantify this at 1.6%, compared to the relatively 
higher rates (6.4%) of male AAS use.  For women, AAS use can additionally induce 
virilisation.  Virilisation is the development of masculine features in a female 
individual (Ainsworth et al.  2018).  Figure 2 is a diagram outlining some of the 
potential symptoms of virilisation.   
 
Figure 2.  Labelled diagram showing potential virilisation effects of AAS 
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Despite some understanding of female AAS use (Kanayama, Boynes, 
Hudson, Field, & Pope Jr, 2007), to date, little research has been conducted to 
understand the extent and nature of female AAS use further.  The small amount of 
existing literature tends to focus on the physiological aspects of female AAS use 
(Abrahin, Souza, de Sousa, Santos, & Bahrke, 2017; Kicman, 2008; Nieschlag & 
Vorona, 2015).  However, there is little to no direct detailed research exploring the 
phenomenon of female AAS use itself; the decision-making processes, the navigation 
of side effects, and the processes of starting and coming off AAS.  The stigma 
attached to female AAS use means very few women are willing to discuss their AAS 
use.  Some studies have outlined the challenges which face women who use AAS.  
For example, Monaghan (2002) highlighted how societal ideals of femininity are a 
constraining effect on female AAS use – muscularity and the development of 
secondary male characteristics is not deemed part of the feminine ‘norm’.  
Consequently, this could impact the prevalence rates and available accounts.  In a 2-
year long ethnographic study exploring the female bodybuilder as a ‘gender outlaw’, 
Shilling and Bunsell (2009) outline how guarded females were when talking about 
bodybuilding drug use: 
Female bodybuilders are, unsurprisingly, guarded when discussing 
drug consumption and this has been a difficult issue to deal with in this paper.  
The number of dedicated female bodybuilders in the UK is small and any 
details of drug use/experience would place them at a risk of identification.  
While not ignoring the issue, we have focused on other dimensions of the 
transgressions of these women… (p. 156).   
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3.2.1.1.1.  Research question, aims and objectives.  This omission of female 
experiences means a critical aspect of feminine identity and experience in this 
community is missing within the literature, alongside the impacts the use has on 
health and wellbeing for women.  The current study uses interpretive 
phenomenological analysis (IPA) to explore the lived experience of female AAS 
users and thereby fill this gap.  The primary research question is: how do female 
AAS users navigate and experience their AAS use through different phases of the 
journey?  The purpose of this study was to explore in-depth these experiences for 
each participant within their own words.   
3.3.  Materials and methods 
3.3.1.  Research approach: Interpretative Phenomenological Analysis (IPA) 
To best address the research questions, IPA was selected due to its ability to 
yield rich subjective accounts (Smith, Flowers, & Larkin, 2009).  IPA provided the 
methodological toolkit to explore each participants’ lived experience through case-
by-case systematic analysis preceding whole-case analysis (Smith et al., 2009; Smith 
& Shinebourne, 2012).  Three core concepts define IPA; firstly, the 
phenomenological component defines the detailed examination of a participants’ 
lived experience and social world (Smith et al., 2009).  Narratives are created 
descriptively (observing the lived experience without assigning meaning) and 
interpretatively (creating a narrative through revealing and interpreting the lived 
experience) without attempts to make them objective (Peat et al., 2019).  Secondly, 
the double hermeneutic component defines meaning-making via a fusion of 
participant and researcher perspectives (Peat et al., 2019; Smith et al., 2009).  The 
participant reflects and comprehends their world and experiences, and the researcher 
makes sense of these very reflections and sense-making accounts (Peat et al., 2019; 
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Smith et al., 2009).  The final element of IPA is its idiographic approach.  Each 
participant is examined as an individual case and thereby ‘bracketed off’ before 
moving to the next case (Peat et al., 2019; Shinebourne, 2011; Smith & Shinebourne, 
2012).   
3.3.2.  Recruitment and selection 
Recruitment commenced after obtaining ethical approval from the Faculty 
Research Ethics Committee (see appendix A).  Contact was made on social media 
groups using the lead authors’ established networks.  These networks were chosen as 
she had established rapport with this niche community (as in  Ainsworth et al., 2018) 
thus facilitating recruitment processes through pre-existing trust and familiarity 
(Liamputtong, 2007).  This method of opportunistic purposive sampling is in line 
with IPA’s philosophy; women with direct experience of AAS use could volunteer to 
share their lived AAS-use experience (Shinebourne, 2011; Smith et al., 2009).  The 
inclusion criteria consisted of being female, fluent in English, over 18 years of age 
and having experience with using and coming off AAS.  No specific cultural, ethnic, 
age or other demographic identifiers were used in order to understand experiences 
from different groups.   
3.3.2.1.  Participants.  Four women volunteered their participation.  Table 4 
provides a contextual synopsis of each participant.  Pseudonyms used throughout 
anonymise participants.  Each description consists of information given by the 
participant during the interview, including demographic information.  The 
information within these passages was current at the time of the interviews. 
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Table 4  
Participant synopses at the time of interviews 
Name Synopsis 
Anna 
Anna is an early forties white British female from England who 
currently works within a people-facing sales role. At the time of the 
interview, she was in a relationship. She is a competitive powerlifter, 
having started using AAS several years back to help recover from an 
injury. She did not take any breaks from AAS during this timeframe. At 
the time of the interview, she had been off-cycle for several months.  
Jenny 
Jenny is a married 30-year old Caucasian powerlifting coach who 
resides in the USA. She is a retired elite-level female competitive 
powerlifter. At the time of the interview, Jenny was pregnant with her 
first child. She has been using AAS on and off for several years,  before 
coming off AAS permanently earlier last year.  
Sandra 
Sandra is a single early fifties Caucasian woman living in the USA who 
works in a people facing sales role. She is also an amateur competitive 
female physique bodybuilder. Sandra has been competing in women’s 
physique for several years. Her AAS use has been on and off, depending 
on the goals of her training cycle. 
Alice 
Alice is a married late 20’s  Asian-American competitive amateur 
female bikini bodybuilding competitor residing within the USA. She has 
recently completed graduate school. She has been using AAS on and off 





3.3.2.2.  Data Collection: Semi-Structured Interviews.  The interview 
guide consisted of semi-structured questions (see appendix B for the interview 
guide).  The interview structure based on Bevan's (2014) interview structure 
provided a multi-faceted guide for the interviewer.  However, this acted as a general 
guide, keeping in line with the principle in IPA that interviews are flexible and 
guided primarily by the participant (Smith et al., 2009).  Throughout the interview, 
each participant answered the questions as per their individual focus and experiences 
in no particular order.  While each participant was asked similar questions due to the 
topic area (e.g., ‘How did you start using AAS?’), specific probing questions were 
asked to provide greater detail on their individual perspectives, reflections and 
experiences. 
Contextualisation questions were asked as per the Husserlian approach that 
experiences within a participant’s lifeworld stand out against a contextual backdrop 
(Husserl, 1970).  As stated in Seidman (2006), interviews need to develop via a point 
of providing context to give a focal point for these experiences.  Contextual 
questions focused on understanding their training history (e.g., ‘Tell me about how 
you got into training?’).  These gave crucial insights into their motivations for AAS 
use.  Other questions explicitly focused on their experiences of their AAS use.  These 
questions were open-ended and focused on the effects of AAS (‘What side effects 
did you get from AAS?’) as well as the effects of coming off AAS (‘Tell me about 
what coming off AAS was like for you?’).  These questions enabled each participant 
to focus on the particular aspects they perceived to be most pertinent for them, thus 
keeping in line with the idiographic approach of IPA.  Finally, imaginative questions 
added a more dynamic element to the interview (Bevan, 2014).  Bevan (2014) 
suggests implementing individualised imaginative questions to explore the stability 
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of the phenomenon in question.  Through visualising the same phenomenon in a 
different context, key insights were gathered, providing a unique perspective of their 
experiences (Bevan, 2014).  All interviews were conducted via video or phone calls 
due to participants’ locations.  Participants chose the interview format.  The mean 
interview length was 42 minutes.  After each interview, memos were made by the 
interviewer to note immediate reflections.   After data collection was completed, data 
analysis began.   
3.3.2.3.  Data Analysis: Interpretative Phenomenological Analysis.  
Following the process outlined by Smith et al.  (2009), each transcript was firstly 
read and reread multiple times.  This was followed by inductive and in-vivo line by 
line coding concurrent with initial analytical observation generation.  Iterative coding 
and analytical observations continued throughout this initial stage.  Secondly, after 
coding finished, the initial emergent thematic generation occurred.  Codes of 
conceptual similarity were thematically grouped and inter-code connections explored 
in greater detail.  Once codes were organised thematically, inter-theme connections 
were analysed alongside the researcher’s analytical observations.  Thirdly, once 
thematic analysis was complete, analysis of this participant was considered 
completed.  This case was subsequently bracketed and the next case was examined 
following the procedure outlined above.  Each case was individually analysed on its 
basis before the final step of between-case comparison occurred through 
superordinate theme generation.  The generation of superordinate themes facilitated 
pattern recognition and observing and reflecting upon any individual differences 
between participants.  Creating a narrative account including verbatim excerpts from 
participant’s transcripts, alongside the researcher’s analytical commentary, facilitated 
this stage.   
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3.3.2.4.  Rigour.  The guidelines for rigour outlined in  Smith et al. (2009) 
are Yardley's (2000).  Briefly, Yardley (2000) presented four broad principles which 
good rigorous qualitative research is comprised of sensitivity to context, rigour and 
commitment, transparency and coherence and lastly, impact and importance.  Figure 
3 outlines the application of these principles to the current study. 
 
Figure 3.  Diagrammatic summary of  qualitative validity criteria (defined by Yardley 
(2000)) applied to this study.  
Sensitivity to context
• Making note of the context of the phenomenon in 
question throughout the research process 
• Literature context: Acknowledging the gap of 
female-specific AAS-use accounts and working to 
fill the gap in experiential knowledge
• Social context: Acknowledging the hidden and 
niche nature of this community and using 
established networks and recruitment processes to 
recruit participants.
• Context in interviews: Understanding individual 
participants' contexts through the use of Bevan's 
(2014) interview guide for phenomenology studies.
Commitment and rigour
• Commitment: Prolonged engagement with topic, 
competence and skill in IPA and immersion in 
relevant data 
• Commitment to participant group: Using 
established networks forged over a period of years. 
• Immersion in relevant data: Reading and re-reading 
the transcripts, writing memos and reflecting on the 
content within the transcripts. 
• Rigour: Thoroughness of the study (Smith et al., 
2009)
• Recruiting participants from diverse backgrounds 
to ensure a more representative array of 
experiences and perspectives are obtained
• Following the methodological guidelines outlined 
in Smith et al. (2009) for methodological rigour.
Transparency and coherence
• Transparency: Clarity in presentation of the methods
• Step-by-step outline of the methodological process 
and justification of the relevant decisions made 
throughout this study
• Coherence: The fit of the research question with the 
philosophical perspective and investigative method
• IPA was considered the most appropriate method 
to answer the research question due to its focus on 
the idiographic in-depth analysis of individual 
experiences and perspectives of this phenomena. 
Impact and Importance
• Application and importance of the study
• The novel nature of this study will add to the 
literature concerning this niche and understudied 
group
• Offering an insight into the experiences of women 
who use AAS can inform meaningful harm 
reduction interventions to aid the health and 
wellbeing of this population. 






3.4.  Results   
This section presents four subordinate themes in chronological order of the 
AAS-use narrative.  The analysis resulted in four superordinate themes.  These are 
presented in Table 5 .   
 
 
Table 5  
 IPA superordinate themes and subordinate themes 
Superordinate themes Subordinate themes 
Preparation and anxiety 
(before AAS use) 
• Making the decision to use AAS 
• Anxiety regarding threats to femininity 
• Control and boundaries 
Deviation from 
feminine identity  
(during AAS use) 
• Gradual onset of side effects 
• Discomfort and pain of virilisation 
The turbulence of 
cessation (end of AAS 
use) 
• Making the decision to come off AAS 
• Emotional upheaval  




• Shifting of identities and new norms  
• Body image and function perceptions 




3.4.1.  Preparation and anxiety (before using AAS) 
This section uncovers the preparation undertaken and the anxieties 
experienced by the participants before beginning their AAS use.  These are 
categorised under the subordinate themes of making the decision to use AAS, the 
anxiety regarding threats to femininity and aspects surrounding control and 
boundaries.   
3.4.1.1. Making the decision to use AAS.  All participants began their 
training journeys without intending to use AAS.  Reasons for starting strength 
training varied.  For example, Alice explained the influence of social media in this 
decision-making process: 
…I’d always been kind of like active, I like ran… but I wasn’t like 
super happy with how I looked, I saw lots of images on my Pinterest and like 
Instagram about all these beautiful women, so I was like “okay, if I want to 
look like that, I need to train like that” and so that’s how I got into like 
bodybuilding.  (Alice) 
Alternatively, Anna outlines below how strength training was primarily healing and 
enabled her to recover from the debilitating effects of a car accident:   
…I can’t say disabled, because obviously I could walk etc., but quite a 
lot of pain all the time, to being completely pain-free and being able to train.  
So basically, the idea was to build up muscle to support the spine and take it 
from there…  (Anna) 
Similarly, each participant had different motivations for AAS use.  These reasons 
broadly fell under the umbrella of self-improvement.  For Anna, the main reason for 
her first cycle was “…purely not from a strength point of view initially, but was 
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because certain ones are known to help the joints, to help the discs, and that is why I 
started to use some Nandrolone in particular.”  (Anna).  For Sandra, the reason was 
predominantly aesthetic focused.  She describes how she “… didn’t like the way I 
looked, I wasn’t hard enough in my opinion, I didn’t think that I was, not that I 
wasn’t lean enough but I wasn’t, I didn’t feel like hard enough…”  (Sandra).  For 
Jenny, if it was a shortcut to getting certain results, she too wanted to take that 
shortcut:  
…I just kind of started hearing about it that other people were doing it 
and that other girls were doing it and I was like well yeah I want to do it too if 
it’s like a shortcut, that’s why I was doing it because it was like a shortcut 
[ok] and that’s why I started.  (Jenny).   
 
For Alice, her AAS use began when her coach informed her it would enable Alice to 
be competitive and reach the national-level competitions.  Alice acknowledged her 
competitiveness and wanting to be the best she can be:  
…he was like, you know, “if you want to get to the national level, 
most of the girls there are using something and you don’t have to but it’s 
going to be a much longer and much tougher road if you want to go that 
road.” So, I was like, well I mean I like being really competitive and doing 
well at whatever I do so I’m going to go for it.  (Alice). 
Participants’ motivations for commencing AAS use are heavily rooted in self-
improvement, akin to the reasons for beginning training.  For them, using AAS was 
seen as a step which was a ‘level up’ from training without using AAS.  Particularly 
when making the transition from just ‘working out’ to ‘training’ for a competitive 
goal, this resulted in a shift in participant’s motivations and contributed to the 
decision to use AAS. 
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3.4.1.2. Anxiety regarding threats to femininity.  Following the decision to 
use AAS, participants experienced feelings of anxiety primarily relating to potential 
side effects.  All participants acknowledged there would be side effects; however, 
anxiety remained regarding how they would individually react to the substances.  
The trepidation experienced by participants prior to starting AAS were related to 
perceived threats to femininity.  This was two-fold; as Sandra described, “…the big 
side effect is your face changing and looking more masculine and that I wasn’t 
willing to do so that was what I was worried about.”  (Sandra).  For Alice, the second 
aspect “…was like irreversibility versus, you know, fixability.”  (Alice).  This fear is 
expressed differently with Sandra through the amount of research she did before 
starting her AAS use: 
…even the Anavar, it took me, literally researched Anavar for a year 
before I even thought about taking it because you know, you're basically 
changing your hormones and it’s a scary thing.  (Sandra). 
The term “even the Anavar” is indicative of the commonly held perception 
that Anavar is a “weaker” compound; it is often recommended as a first cycle 
compound for female AAS users.  Despite its perceived “weakness”, Sandra still did 
considerable research before beginning her AAS use.  Researching the compound 
before using it is also indicative of the strong need to make an informed decision; the 
ability to take ownership through making a choice is important to participants.   
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3.4.1.3. Control and boundaries.  From the beginning, participants were 
determined to maintain control over their AAS-using decisions.  This was expressed 
by laying down boundaries about what is acceptable and what is not acceptable in the 
way of side effects.  Sandra did this through a  risk/benefit analysis relating to the use 
of AAS:  
 …until you decide that you want to take the risk and it is a risk, 
you're really not going to know how it’s going to affect you, when you come 
on or off.  You just don’t know, it’s the chance that you take. (Sandra) 
For Sandra, regardless of how much research she did, there was still a strong element 
of the unknown as she would not know how compounds affected her until she 
actually used them.  The level of individual variation meant predictability was not 
guaranteed.   
This decision-making capability is important primarily for mitigating the risk 
of developing unwanted side effects (either through dosages or compound choice).  
Whilst they cannot control their individual sensitivity to compounds, they can control 
the compounds they use, thus potentially lessening the risks of using AAS.  This 
decision-making capability related to both taking AAS and making compound 
choices;  
…and it’s my decision whether I want to do it or not.  Or what I want 
to do, cause there's certain things that I won’t do.  (Sandra) 
For example, when asked which compounds she would not do, Sandra discussed 
Trenbolone (a highly risk androgenic AAS compound): 
Tren, I won’t do it.  That’s one of the things a lot of women do in prep 
and I won’t do it, I don’t know why I won’t do it, I don’t know, it kind of 
scares me, I don’t know why.  (Sandra). 
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The word “scares” indicates the fear associated with using compounds on the other 
side of the spectrum; compounds used by very few women.  Essentially, the more 
potent the compound, the bigger the risk of developing side effects and beyond that, 
the bigger the risk of developing permanent side effects.  This concern is similar to 
those raised by Alice regarding the “irreversibility” of side effects.  Compound 
choices seemed heavily related to the goals in mind, alongside how “female-friendly” 
they are.  Sandra outlined this: 
… there will be certain anabolics that are weaker that are okay for 
women and then you start, and when you start getting into other ones like 
Tren, to me that’s just a little too much.  I’m not going to compete in the 
Olympia, I’m not going for my pro card, what am I doing? (Sandra).   
Note the word ‘weaker’, implying their perceived suitability for women.  
Exerting control over compound choices and the choice to use AAS is indicative of 
participants’ attempts to protect their femininity and mitigate side effects as much as 
possible.   
Control was also exhibited through regulating disclosure of use.  For Alice, 
she outlined how she “…like[s] honesty but…also like[s] information control…” 
(Alice).  For Alice, her requirement for information control outweighs the element of 
honesty relating to her AAS use.  This decision-making ability is important for 
stigma management; through information control, participants exert control over who 
is “allowed” to know about their use and who isn’t.  This is important for mitigating 
negative judgements, particularly in a community as stigmatised as female AAS 
users.   
56 
 
3.4.2.  Deviation from feminine identity (during AAS use) 
This section concerns sub-themes surrounding the time during AAS use.  The 
subordinate themes within this section explore the experience of the gradual onset of 
side effects and the discomfort and pain associated with virilisation.   
3.4.2.1. Gradual onset of side effects.  During their cycles,  participants 
commented on the gradual onset of side effects.  Jenny experienced it as:  
… a very gradual thing, it’s not like I just like woke up one day and 
had a beard or anything, it was super gradual and I’d have like a couple more 
hairs… and then one day I was like “oh I’m just going to shave them off” and 
I was like, “oh my face is so smooth, so maybe I’ll go and have one once 
every few weeks” and they kind of got maybe more frequent and then it 
ended up eventually after a couple of years or something, it was like every 
day… (Jenny). 
Notably, the differences in expectations and reality for both events indicate how, for 
Alice, it was not as drastic as she assumed it would be.  She compared the experience 
to “…losing your virginity for the first time, it’s like ‘sex is so scary, oh my god’ and 
then you do it and you're like, ‘oh I don’t have STD, I’m fine.’” (Alice).  This 
particular example indicates a fear of the unknown, particularly in the lack of direct 
experience.  What does it feel like? How will I be impacted? Secondly, this segment 
indicates a “deflowering” of sorts; a growing up, or maturation perhaps, in their 
training career and choices.  After all, using AAS was considered the “next step” in 
participants’ training lives.  The second facet of this quote indicates how the initial 
severe side effects she expected did not appear, and that, perhaps initially, her fears 
were unfounded.   
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3.4.2.2. Discomfort and pain of virilisation.  All participants reported 
experiencing side effects from AAS use.  However, the specific side effects which 
caused distress varied from individual to individual.  Anna explained how she “… 
started to notice…a lot of hair loss from my head which was quite 
devastating…”(Anna).  Jenny’s experience of hair loss was perhaps more sudden, as 
she describes how “…one day I was like really self-conscious about like putting my 
hair back because you could see like this hairline…” (Jenny).   
It was not only unusual hair growth or loss that they were uncomfortable 
with; Anna described her experience with hair growth: 
…[a] change of texture, so very wiry, very strange, curly hairs that I’d 
never had, growing in very strange places like my neck, my face started 
growing facial hair.  I was constantly shaving. (Anna).   
Hair quality and location are important aspects of femininity for these participants.  
The texture, location and amount of hair suggested a gradual shift towards 
masculinity; these women were describing excess body hair growth, alongside 
potential male pattern baldness.  Long hair on the head, alongside fine body hair is 
traditionally considered to be feminine features.  Losing these characteristics 
signifies a departure from the feminine norm and entering uncharted territory.  
Having to shave on a near-daily basis is a constant reminder of the push towards 
masculinity for the participants; the changes are in their face, and they cannot get 
away from these changes. 
Other side effects included voice changes: for Alice, her singing voice was a 
part of her core identity.  Being a soprano for many years, alongside being known for 
her singing voice, Alice describes the process of her losing her voice almost as if she 
is grieving its loss: 
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…like during the cycle I’d like always check to make sure it wasn’t 
dropping too low, and so I’d record myself singing and then at some point I 
was like, oh no, this is like really different.  And then there's like this app that 
helps you, you know, figure out if your voice frequency is like, it actually 
labels it, it’s like feminine, androgynous, masculine and you know, before it 
always fallen into very feminine, and then I landed in androgynous, I was 
like, oh no, people can tell.  And then at some point when I wasn’t paying 
attention… it like put me in masculine and I was like, oh my goodness, so 
that was a bit of a shock, you know… I think I cried, I’m pretty sure I cried 
multiple times over the last, you know, couple of months about this voice or 
the changes in my voice… my voice changed like pretty significantly… I was 
hoping that it would come back but I used to be a soprano and now I can’t 
reach any of the notes I used to, yeah.  But that’s been hard, I’m still trying to 
come to terms with it, you know, losing my integral part of my identity. 
(Alice).   
The pain from losing this integral part of Alice’s identity is palpable.  Her 
changes in her voice are, again, an indication of a deviation from the feminine 
towards the masculine.  This change in voice crossed a boundary that she had set in 
stone and was categorically uncomfortable doing so.  This is not only a threat to her 
identity as a feminine individual, but also a threat to her identity as a soprano and 
singer.  A lower voice is a change commonly associated with male puberty.  To add 
some context; Alice is a bikini competitor.  Traditionally speaking, the bikini class 
within bodybuilding is a hyperfeminine category for women (Tajrobehkar, 2016).  
Women are encouraged to be lean, but not too lean.  Bikinis are brightly adorned two 
pieces, with high heels and specific stage posing to exaggerate the female form.  
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With this in mind, this shift towards masculinity can be a considerable challenge to 
overcome psychologically.  Masculine traits are almost an antithesis for bikini 
competitors during competition.   
Ultimately, all  of the participants experienced virilising side effects.  For 
each one, they drew different boundaries on what was acceptable and what was not.  
Each participant determined what their levels of acceptability were, and each one 
came to terms with the onset in different ways.  However, there was a shared sense of 
discomfort and struggling to cope with the onset of these side effects.  The 
substantial impact these had on their body image and perception of selves was 
strongly related to how far their bodies deviated from their feminine norm.   
3.4.3.  The turbulence of cessation (end of AAS use) 
This section explores the experience of ending their AAS use.  The 
subordinate themes are making the decision to come off and the emotional upheaval 
of coming off.   
3.4.3.1. Making the decision to come off.  There are two pathways for AAS-
use cessation.  The first is coming off between cycles.  Alice and Sandra both 
describe coming off in these terms, saying coming off is not an option for either of 
them:  
I mean you know, I’ve taken eight-week breaks, I can take even 
longer, you have to ride it out because you can’t be on it constantly, you have 
to come off, you have to… (Sandra)  
Alice explains in further detail the connection between her goals and coming off.  
For her, coming off was related not only to her health, but also her goals: 
…the health risks of doing it, year-round are not worth like, you 
know, don’t match up with my goals...  I’m not trying to be a fitness model 
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and like look good year-round, I just want to look for like competition and 
that’s it, so yeah, it didn’t match up with my goals but I could see if someone 
was a fitness model and needed to look good all the time, then they would 
stay on cycle all the time… [Coming off] is what I need to do in order to 
reach my goals…as far as balancing health and goals. (Alice) 
As outlined, Alice reflects on how it might be considered “necessary” for 
those who make a livelihood from their appearance to stay on year-round, despite the 
associated health risks.  There is an inherent need to “look good year-round” which 
might supersede the health benefits of coming off.  Nevertheless, for these 
participants, coming off was considered mandatory.  This is indicative of the 
consideration participants had of the impact AAS use has on their health and 
wellbeing.  The terminology of a “break” shows how coming off AAS is considered 
a respite for the body.   
The second pathway is permanent AAS-use cessation, as with Anna and 
Jenny.  For Anna, this point was reached when she mentioned how distressing she 
found the physical changes when looking in the mirror: 
…every time I looked in the mirror, I didn’t see a woman, I saw a 
man, and I was like “I don’t like this anymore”. (Anna).   
Due to her personal discomfort with her aesthetic appearance, Anna decided to come 
off AAS permanently:  
…It was only as time went on that I started to think “you’re not really 
looking like a woman anymore.” and that’s when I started to really dislike it 
and decided that this isn’t for me anymore. (Anna) 
Jenny’s unplanned decision to come off coincided with her reaching her 
powerlifting goals:  
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…it was never really a planned thing though, it was never like, “ok 
I’m going to hit these numbers and like retire”, I just guess I felt fulfilled 
after those last couple of meets… (Jenny) 
3.4.3.2. Emotional upheaval.  The experience of coming off AAS differed 
across participants.  Sandra described feeling  
…Depressed… not severely depressed cause I don’t have depression 
issues, but you kind of feel, I guess there is a difference, you kind of feel sad 
I guess…it’s definitely more mental, that’s the harder part, than the physical 
part... (Sandra).  
 For Alice, coming off presented other challenges of coming off “cold turkey” such 
as adjusting to a loss in strength:  
…it was like cold turkey and I did have a lot of like strength loss, 
which I wasn’t expecting.  Yeah, that was, I almost think part of it was like 
psychological too… when I’m on cycle I’m able to push a lot more weight, 
and I feel a lot more confident in doing stuff, whereas when I’m off cycle, 
I’m a lot more conservative…just like really focusing on like form and things 
like that… (Alice) 
Sandra experienced similar challenges when coming off AAS.  She describes the loss 
in strength as akin to having a “bad day” in the gym:  
…I mean everybody has a bad day, you know when you PR [personal 
record], you know, and then all of a sudden, two weeks later, you can’t even 
lift what you did before you PR’d, it’s like, you know, it’s upsetting but that’s 
just the way it goes, you're just not going to be as strong… (Sandra). 
Sandra also described the negative impacts associated with experiencing physical 
joint pain whilst coming off;  
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…plus also, you know, it also helps with joint, you know, your joints, 
lubricating of joints, your joint recovery and then when your joints start 
hurting too that didn’t hurt before, that also messes you up, you might not be 
able to work out as long, you might, you know, you hurt a little more, that 
might hurt you, your legs, if it’s a leg day, you might not be able to walk, 
instead of one day, three days, you know, stuff like that, so it helps with 
recovery and joint lubrication and everything like that. (Sandra). 
These accounts demonstrate the emotional upheaval associated with coming 
off AAS.  It is a multifaceted experience, extending beyond the reported depression; 
it is also inclusive of the emotional turbulence and difficulties in adjusting to their 
body’s capabilities.   
3.4.3.3. Dissipation of virilisation.  For each participant, most side effects 
dissipated over time.  For example, the receded hairline did recover for Jenny:  
…then one day I was like really self-conscious about like putting my 
hair back because you could see like this hairline, that did get a lot better, like 
it’s not, I have not thought about that in a long, long time you know, it’s like 
normal now so I guess that it did go back. (Jenny). 
The words “I guess” show some uncertainty concerning whether it has “truly” 
returned to normal.  Nevertheless, the realisation she has not thought about it for a 
“long long time” shows how thoughts concerning her hairline have not arisen for a 
considerable length of time.  Jenny also described feeling lucky as she did not expect 
anything to return to normal;  
I wasn’t anticipating that anything would grow back, I thought that’s 
the way it was going to be… I really feel super lucky because I feel like other 
women they don’t get as lucky… (Jenny).   
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The term “feeling lucky” perhaps indicates “getting away” with her use of AAS; 
particularly for Jenny, her use of AAS was experimental, with harsher compounds 
being used compared to more cautious compound use of other participants.  Though 
she accepted the possibility of side effects becoming permanent, she was 
nevertheless relieved when they gradually dissipated after coming off permanently.   
Another aspect of virilisation dissipation is related to age.  Anna discusses 
how youth can have an impact on the side effects due to the hormonal differences,  
…because if a woman’s younger and she comes off she’s got quite a 
lot of oestrogen still, so she may have less side effects because she’s got 
higher levels of oestrogen. (Anna).   
The role of oestrogen here is almost perceived as a “protective” substance against the 
androgenic side effects.  Traditionally considered a “feminine” hormone, it is often 
decreased in women who experience menopause.  For Anna, her age means she has 
less oestrogen than someone younger.  Therefore she does not have as much 
protection from oestrogen as someone younger. 
3.4.4.  Rediscovering femininity (post-AAS cessation reflections) 
This section covers the reflections and experiences of the participants’ post-
AAS cessation period.  The subordinate themes within this section explore the 
shifting of identities and new norms, body image and function alongside coming off, 
health and fertility.   
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3.4.4.1. Shifting of identities and new norms.  Multiple participants 
expressed a shift in their core identities – whether this was through a return to what 
they perceived as feminine for themselves (as in Anna’s case), or whether this is 
adjusting to the effects permanent side effects can have (such as for Alice).  For 
example, not all side effects dissipated.  Alice had to adjust to permanent voice 
changes:  
…my voice changed like pretty significantly… I was hoping that it 
would come back but I used to be a soprano and now I can’t reach any of the 
notes I used to, yeah.  But that’s been hard, I’m still trying to come to terms 
with it, you know, losing my integral part of my identity…I’ve kind of 
accepted my voice as it is now, or I’m like, well you know, I can live with it 
and this is just part of growing up, not growing up but like you know, people 
will have changes in their identity and this is just one of them, it will be fine. 
(Alice) 
The adjustment to this permanent side effect is a notably painful but, inevitably 
necessary, process.  The hope mentioned by Alice indicates a desire for a return to 
normal, perhaps to be one of the ‘lucky’ ones as described by Jenny.  However, the 
journey to acceptance of this new norm (in this case, the new normal pitch and tone 
of her voice) is seen as a process of maturation and “growing up”.  When side effects 
have become permanent, a level of acceptance is necessary in order to come to terms 
with new norms.  Alice described how she has had to shift her self-perceived 
aesthetic gender identity from being traditionally feminine to being considered more 
androgynous.  Alice describes how she feels “…okay with [looking] androgynous, 
because you know, I have short hair, like I can do the whole sporty look, 
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whatever…”(Alice).  Acceptance for Alice is the core part of moving on from the 
initial pain of encountering permanent side effects.   
For Anna, stopping her AAS use has given her an improved quality of life 
and is indicative of a shift to new focal norms.  The cessation of AAS indicates a 
shift in identity as a competitor, with a different mindset, priorities and goals;  
…I feel more confident about how I look, I feel good, I never care if I 
miss a lift, if I miss a lift, I miss a lift… to me, being a woman is more 
important, so I want to look good, I want to feel nice.  If strength’s gone 
down, it’s gone down.  I don’t really care.  I’d rather look like a woman, feel 
like a woman, feel attractive, feel good about myself, and still go to the gym 
and still lift, and still compete but understand that it’s not going to be at the 
same level. (Anna)  
“Feeling like a woman” is considerably more important for Anna – the return to 
femininity brought a multitude of positive aspects.  For example, Anna associated 
being off-cycle with reconnecting with others in her social circle alongside feeling 
balanced, healthy and, more importantly for her, feminine and confident.  The 
sacrifice in strength and getting to her powerlifting goals is worth it for her improved 
quality of life.   
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3.4.4.2. Body image and function.  Off-cycle was associated with multiple 
physical changes.  For example, Jenny discusses how her “…face has gotten so much 
softer in the last two years…I would get like cellulite on the back of my legs and on 
my butt, I was like less hard”.  (Jenny).  The terminology “less hard” and “softer” 
demonstrate a gradual return to more feminine characteristics.  “Hardness”, as 
described by Sandra, is another term for lower body fat percentage.  The shift to a 
higher body fat percentage is an indicator of femininity.  For Anna, she felt 
comfortable with her higher body fat percentage: 
I’ve got fat, I’m not too kind of lean, but I feel so, so much better 
when I look in the mirror.  I feel so much better when I look in a mirror, how 
I feel, how I look and that’s important to me. (Anna) 
For Anna, regardless of her increased body fat percentage, her self-esteem and 
perception of her body were significantly higher than before.  Her improved self-
confidence and self-esteem are worth the “cost” of losing leanness and gaining body 
fat.  Her femininity is established through the return of a higher body fat percentage.   
3.4.4.3. Coming off, health and fertility.  Jenny, like other participants, used 
the return of her menstrual periods as an indicator of health.  She explains how, upon 
return of her periods after AAS cessation, “…it’s like ‘ok like everything’s fine’, I 
think that’s how I felt like, ok my body still works…”  (Jenny).  The verbiage “my 
body still works” demonstrates how important fertility is for female users.  At the 
time of the interview, Jenny was pregnant in her third trimester.  She remarked 
feeling “…like I had a good run and I mean I’m healthy now and like I can make 
babies now and so everything happened for a reason or that was just like my path.” 
(Jenny).  Childbearing and health seem to be intrinsically linked for Jenny.  The 
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return of periods is an indicator of both health and femininity.  Thus, the relief is 
understandable when they returned for Jenny.   
The ability to bear children was also considered paramount for Sandra and 
Anna.  Both are older females who are post-menopausal.  They both remarked they 
would not use AAS if they were younger.  For Sandra, this was rooted in the impact 
on fertility specifically using testosterone would have:  
…if I was in my twenties or thirties, I would never, just wouldn’t, it 
could affect your fertility, why would you do that, you don’t know, even if 
you're thinking you never want a kid, in your twenties or thirties, how would 
you know, you just don’t know what's going to happen, why would you mess 
with that, it’s not worth it, for what, for muscle, it’s stupid, to me, that’s just 
my opinion. (Sandra).   
The focus on testosterone might stem from its perception as a predominantly “male” 
hormone; perhaps a boundary which should not be crossed until certain conditions 
are adhered to.  The heavily masculine aspect of testosterone might be seen as a 
significant threat to female fertility for Sandra, thereby deeming it unsuitable for 
younger female users.  Anna expressed a similar notion related to fertility, saying 
younger women “…should just be very careful so if they’re young, and in particular, 
you know they might want a family one day, well, that could be harder.” (Anna).   
Fertility and childbearing abilities are considered critical to retain.  Notably, 
this mindset appears more pronounced for both of the older participants, Sandra and 
Anna.  Perhaps it results from a post-menopausal mindset, reflecting on the changes 
to fertility and the associated impact on the feminine identity that comes with the 
menopause.  Being in the unique, contradictory position of undergoing a uniquely 
female phenomenon, while encountering the loss of uniquely female experiences 
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(such as the menstrual cycle) might impact the personal importance these participants 
attach to female fertility.   
3.5.  Discussion 
For the first time, this study provides a fresh understanding through the 
application of  IPA to four individuals’ narratives.  The findings corroborate other 
accounts of female identity navigation in sports and non-sports settings, with the 
added novel complex interplay between gender identity and AAS use.   
3.5.1.  Preparation and anxiety 
Participants approached their AAS use in different ways.  For example, 
Sandra conducted extensive research and sought to understand the potential side 
effects.  Others, such as Jenny, had a more unconstrained approach to AAS use.  
These differences in perception can be contextualised within a risk management 
framework.   
A post-modern risk approach to risk and hazard perception outlines that 
hazards are socially constructed through the lens of culture (Fox, 1999).  In this 
context, AAS themselves are not considered a hazard.  Hazards for these participants 
include potentially permanent virilisation, specific virilisation side effects and the 
impacts of these aspects.  AAS.  Risk is outlined as the possibility of permanent 
deviation from the societal definition of feminine norms.  As Fox (1999) outlines 
using an example of ecstasy, ecstasy becomes a hazard when the potential risks 
outweigh the potential benefits.  For our participants, the risk associated with AAS 
use was mitigated through compound choice, dosages used, cycle lengths, time off-
cycle and researching a variety of avenues.  However, all participants were aware 
that the associated risks of virilisation and health impacts would never be completely 
mitigated.  Thus, the benefits of AAS use (e.g., physical strength, muscular 
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hypertrophy, wellbeing and other effects) outweighed the risks through risk 
mitigation conducted by the participants on an individual level.    
3.5.2.  Deviation and feminine characteristics 
Participants within our studies described the gradual onset of side effects.  
However, they also describe the psychological discomfort associated with the 
development of side effects.  In line with other studies, this is potentially due to the 
blurring of boundaries between masculine and feminine, a highly individualised 
boundary which was experienced by all participants in different ways.  The journey 
of what it is to be feminine and how the participants navigated feminine identity 
threats is concurrent with other accounts of femininity and muscularity within sports.  
Other studies within this niche community have focused on the navigation of the 
feminine identity for female bodybuilders (Shilling & Bunsell, 2009; Wesely, 2001).  
These studies cast a more holistic eye over the construction, navigation and 
continuum of the feminine identity within the context of a female bodybuilders’ 
lifestyle.  The emphasis is on posing and clothing, weight training programs and 
other aspects of competitive female bodybuilding.  One study on female 
bodybuilders focuses on the impact of weight training and nutritional regimes upon 
the feminine gender identity (Boyle, 2005).  Within this study, the pressure placed 
upon female bodybuilders demonstrates ‘appropriate norms’ for feminine standards 
within society.  Participants in this study took control of their training and nutritional 
regimes in order to balance the fine line between performance and femininity.  This 
control is not dissimilar to the boundaries and controls imposed by the participants 
within the present study – decision-making processes determine what compounds 
they will use, how they will use them, when they come off cycle and other aspects of 
AAS use.  In line with the female bodybuilders, participants often decided to 
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maintain control over their aspects of femininity.  However, within the Boyle (2005) 
study, it seems that boundaries are initially self-imposed through individual decision-
making processes.  Upon further examination, it appears that the standards they must 
conform to regarding femininity are dictated by a primarily white, heterosexual 
masculine audience or judging panel.  The ideas of femininity are flexible within the 
present study; participants enforced their boundaries and ideas of what they 
considered acceptable deviations from femininity.  To some extent, these aspects of 
‘acceptability’ still fall within the remit of societal feminine norms, similar to the 
standards outlined in Boyle (2005).  Notably, while the study above have women 
who discuss becoming ‘too big’ as negative and excessive deviation from the 
feminine, this was not mentioned as an issue by the participants within the present 
study.  Muscularity was considered a positive aspect, and not necessarily incongruent 
with their ideas of femininity.   
3.5.3.  The turbulence of cessation 
In line with male studies on AAS cessation (Griffiths, Henshaw, McKay, & 
Dunn, 2017), participants emphasised the importance of coming off for health 
reasons.  However, for female participants, there is an additional effect of mitigating 
unwanted virilisation side effects, something which does not affect male AAS-users.  
Similar to the participants in Griffiths et al.  (2017), some female participants 
reported turbulent withdrawal periods and psychological upheaval while coming off 
AAS.  For some individuals, it was more pronounced than with others.  These 
differences suggest that, to some degree, individual susceptibility is responsible for 
the severity of psychological upheaval and coming off cycle.  However, the cycle 
duration and taking breaks between cycles are potentially important determinants of 
AAS cessation difficulties.  Further research can elaborate on this possibility.   
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3.5.4.  Rediscovering femininity  
Rediscovering their femininity was a complex, yet welcomed process.  Every 
participant had to adjust to new personal norms of femininity.  Thus the term 
‘rediscovering femininity’ was used.  These identity reconstructions after AAS 
cessation are analogous to the processes of biographical disruption (Bury, 1982) or 
biographical flow (Faircloth, Boylstein, Rittman, Young, & Gubrium, 2004).  While 
these two concepts are discussed extensively in critical illness contexts, similarities 
exist between those experiencing chronic or acute illness events and participants’ 
perceptions of their changing bodies from AAS use.  Categorising it as one or 
another is challenging due to how our participants reframe and view their bodies 
after coming off.  For example, Alice’s experience with her permanent voice change 
is biographically disruptive; her identity and physical feminine features were brought 
to the forefront of her mind when beforehand they were taken for granted through 
being an “absent present” (Malcolm and Pullen 2018).  Secondly, her questioning of 
her self-identity from a gendered context is Alice questioning her self, another 
component of biographical disruption; am I still feminine? Am I losing my 
femininity? Thirdly, the impact of socialisation activities had a negative impact in 
terms of her psychological wellbeing.  However, in time, she accepted and reframed 
her new identity, shifting from feminine through to androgynous.  This shift is 
contextualised within ongoing AAS use with regular breaks in usage. 
Similarly, Anna reframed her post-AAS body in a novel way; here, we notice 
a biographical “flow” narrative (Faircloth et al., 2004).  She acknowledges the 
readjustments she has to make.  However, they are taken in a positive context and 
considered part of an ongoing life narrative.  Particularly regarding her own gender 
identity and the meanings she ascribes to being feminine, the impact her AAS use 
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has had has been part of a narrative, and not considered particularly disruptive.  A 
similar experience can be noted by Jenny, who considers her process of AAS use and 
cessation to be part of an organic flow of her feminine narrative.  With Sandra, 
despite struggling with body image issues and temporary psychological setbacks, she 
has acknowledged these changes are, again, a part of an ongoing narrative which do 
not define her core identity.  For these women, there were aspects of biographical 
disruption present in the threats to their feminine identity and questioning their 
selves.  However, they have also adjusted their perceptions of their post-cycle 
feminine identities and accepted personal new norms.   
Another notable aspect was the importance placed on fertility.  Literature 
relating to female fertility and femininity, the closeness of femininity, fertility and 
health have been corroborated extensively (Komatsu et al., 2014).  For our 
participants, health and fertility were closely related concepts.  The idea of losing 
one’s fertility, as in the Komatsu et al.  (2014) study, is determined to be a severe 
deviation from one’s feminine identity.  Perhaps, as mentioned in Komatsu et al.  
(2014), the idea of losing childbearing abilities is indicative of a threat to the 
feminine identity.  In this study, potentially losing one’s fertility was an unacceptable 
side effect for some participants while for others, it was considered an acceptable risk 
with some participants even accepting the “worst-case scenario” of female sub-
fertility.  It remains unclear whether it is a generational aspect relating to the ideas of 
femininity and fertility, as it was the older participants who considered female 
fertility to be precious and attached higher importance to this aspect, compared to the 
younger participants.   
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3.5.5.  Strengths 
This study offers a novel insight into the female experience of AAS use; The 
established rapport built with this community by the first-author gives a unique 
insight into this population that is otherwise difficult to reach.  Participants were 
from different countries, ethnic backgrounds, age groups and competitive 
backgrounds.  This cohort diversity enabled the exploration of a variety of 
experiences and perspectives in greater detail.   
3.5.6.  Limitations 
In line with IPA, the sample size is small, and the cases cannot be 
generalised.  Nevertheless, the in-depth interviews and analysis enable the addition 
of a more detailed account of the female AAS-using experience to the existing 
literature.   
3.6.  Conclusion: Further study and recommendations 
This study offers a novel insight into PED use rarely seen within the existing 
literature.  For the first time, through these narratives, a greater understanding is 
offered regarding the patterns of usage amongst women who use AAS.  While some 
similarities are present between female and male AAS use, these results shed light on 
the vastly different challenges surrounding women.  Understanding the experiences, 
motivations, perceptions and physical and psychological side effects of AAS use in 
women can meaningfully inform harm reduction policy.  Harm reduction workers, 
medical professionals and those who work with women who may use AAS can use 
the information within to further their understanding of this community.  The 
recruitment methods outlined within this study can perhaps help inform future 
research initiatives by implementing the recruitment practices.  Further research can 
look in more depth at the impact cycle length, compound choice and dosages have 
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for the experiences of AAS cessation in women.  Building upon these findings can 
help develop meaningful harm reduction interventions specific for women who use 
AAS. 
What this study adds 
This paper focused heavily on the individual lived experiences of risk 
navigation, risk perception and mitigation through a gendered lens.  The narratives 
uncovered throughout this paper uncover the journey of female AAS use in greater 
depth than before.  Accounts of control and ownership over decisions were prevalent 
throughout.  This was relevant not only in the context of dosage, cycle length and 
compound choice, but also related to disclosure.  Chapter 4 (study 2) will build from 
these findings as it aims to uncover, in greater detail, the perceptions surrounding 
control and risk perception with a different compound: 2,4-dinitrophenol (2,4-DNP).  
Of note will be the differences in side effects, the onset of potential side effects and 
the associated risks, as well as a focal broadening from the idiographic through to the 




Chapter 4: Control and the use of 2,4-Dinitrophenol 
Preamble 
This is a manuscript which was published in the International Journal of Drug 
Policy in 2018 (Ainsworth, N. P., Vargo, E. J., & Petróczi, A. (2018). Being in 
control? A thematic content analysis of 14 in-depth interviews with 2, 4-
dinitrophenol users. International Journal of Drug Policy, 52, 106–114.).  This 
version of the manuscript is stylistically amended in terms of formatting to remain 
consistent with the layout of the rest of the thesis.  However, the content remains 
unchanged from the published version.   
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Being in Control?  A Thematic Content Analysis of Interviews with 2,4-
Dinitrophenol Users 
4.1.  Abstract 
Background: 2,4-Dinitrophenol (2,4-DNP) is a compound with multiple 
industrial purposes.  Currently unlicensed for human consumption, it is used by the 
gym-going population for drastic, short-term body fat loss.  Nonetheless, 
physiological mechanisms can lead to potentially fatal hyperthermia.  Reported fatal 
incidents have caused concern and highlighted the need for intervention.  
Understanding decision-making leading to 2,4-DNP use alongside the perceived 
outgroup attitudes is vital to forming effective harm minimisation policies targeting 
current and potential users.  First-hand accounts from this elusive population are 
scarce. 
Methods: Fourteen novel and experienced users (13 male, 1 female) were 
recruited via “snowballing” techniques.  Semi-structured interviews were conducted, 
comprising 28 questions.  Thematic content analysis was conducted using 37 codes. 
Results: Four characteristic themes emerged: 1.  Users considered the Internet 
to be a crucial multifunctional resource directly impacting their 2,4-DNP use.  2.  
Users “respected” 2,4-DNP, proactively taking harm reduction measures.  3.  
Attitudinal polarisation towards 2,4-DNP within the gym-going community was 
consistent in all accounts.  4.  Users perceived outgroup populations to have 
inherently negative attitudes towards their use.  These themes fell under the all-
encompassing theme of “being in control”. 
Conclusion: For the first time, this study offers a rich detail of attitudes 
toward 2,4-DNP use by giving a collective voice to users.  The element of control 
over every aspect of the users’ life appears to be a significant contributor to the 
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successful risk-management of 2,4-DNP use.  In the absence of an established safe 
upper limit and effective regulatory control, education is critical to harm 
minimisation. 
4.2.  Introduction 
The use of performance-enhancing drugs (PEDs) among bodybuilders around 
the world has been abundantly discussed in literature (Abrahin et al., 2014; Nakhaee, 
Pakravan, & Nakhaee, 2013; Perry, Lund, Deninger, Kutscher, & Schneider, 2005; 
Sagoe, Andreassen, & Pallesen, 2014; Sepehri, Fard, & Sepehri, 2009).  Based on 
self-reported surveys, prevalence rates for PED use among gym users ranges between 
0.4% to 35% (Abrahin et al., 2014; Hitti et al., 2014; Khullar et al., 2016; Lazuras et 
al., 2017; Molero et al., 2017; Sagoe, Molde, et al., 2014; Simon et al., 2006; Striegel 
et al., 2006; Stubbe et al., 2014).  Within this range, PEDs prevalence figures vary 
widely across substance types, timeframe and methods used to establish prevalence.  
Specifically, much focus has been on anabolic steroid use.  Direct questioning 
methods typically yield a lower and more likely prevalence rate compared to indirect 
methods. 
Uncertainty about the true prevalence rate aside, information concerning use 
patterns in this community is still limited, due to the attached societal stigma.  The 
bodybuilding community appears to hide their substance use, and distorted 
perceptions are predominant in the general population (Evans, 2004; 
Gonzalez  Francis Keaney, Alejandro, 2001).  PEDs known to be generally used by 
bodybuilders are anabolic-androgenic steroids (AAS) (Kicman, 2008; Reardon & 
Creado, 2014; Sagoe, Molde, et al., 2014) and peptides such as human growth 
hormone (Meinhardt et al., 2010).  Fat burners are also used, to create a larger caloric 
deficit for fat loss (Jeukendrup & Randell, 2011), either through appetite 
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suppression, direct effects upon users’ metabolism, or both.  However, one 
compound that has flitted in and out of use is 2,4-dinitrophenol (2,4-DNP). 
4.2.1.  Overview of the compound 
2,4-DNP is a member of the dinitrophenol chemical family.  These chemicals 
have a wide variety of industrial applications (Harris & Corcoran, 1995).  2,4-DNP 
raised interest upon discovering that ingestion caused significant weight loss (Harris 
& Corcoran, 1995) and consequently, the compound was prescribed as a weight loss 
aid (Hardgrove & Stem, 1938; Harris & Corcoran, 1995; Horner, 1942; 
Parascandola, 1974).  Between 1933 and 1935, an estimated 100,000 patients were 
given 2,4-DNP (Tainter et al., 1935).  Studies concerning human oral exposure 
comprise primarily of case reports and clinical studies dating between 1932 and 1938 
(Harris & Cocoran, 1995).  These studies frequently had limitations as human trials 
did not include participant matched control groups (Harris & Cocoran, 1995).  This 
has created difficulty in separating side effects caused by 2,4-DNP to potential pre-
existing conditions of participants.  Reliable accounts of 2,4-DNP’s effects on 
humans thus lack in current literature. 
2,4-DNP works through a variety of dose-dependent physiological 
mechanisms.  Alongside being an uncoupler of oxidative phosphorylation, 2,4-DNP 
is also a chemical ionophore (Grundlingh et al., 2011).  The resulting proton 
electrochemical gradient shift from this process means this potential energy 
dissipates as excess heat, rather than ATP conversion (Grundlingh et al., 2011; 
Wallace & Starkov, 2000).  At high doses, ingesting the compound results in an 
elevated body temperature alongside increased caloric expenditure, leading to fat 
loss.  Possible side effects also include hyperthermia, tachycardia, skin 
discolouration or rash (if allergic), nausea or vomiting, abdominal pain, agitation and 
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headache, excessive sweating potentially resulting in electrolyte imbalances (Kamour 
et al., 2015).  Some studies have suggested long term risks relating to peripheral 
neuropathy (Phillips & Singer, 2013).  Moreover, others have suggested the 
possibility of cataract formation from prolonged exposure (Allen & Benson, 1935; 
Boardman, 1935; Kniskern, 1935; Lazar, 1935).  However, mechanisms remain 
unclear and potential harms – apart from media reports of fatalities - are relatively 
unknown. 
In addition to the level of acute health risks, there is a distinct differentiation 
between 2,4-DNP and AAS regarding effort.  Because of its mechanism of action, 
2,4-DNP use may appear as a shortcut for weight loss compared to dietary 
adherence.  Notably, 2,4-DNP use has acute effect on lifestyle and wellbeing.  
Despite this, it is still considered less effort to use 2,4-DNP compared to AAS.  This 
will be discussed in further detail later on. 
Currently, 2,4-DNP is not licensed for human consumption globally.  No 
therapeutic dosage and duration, or safe upper limit, is established.  Despite this, 
users are not dissuaded from using 2,4-DNP for fat burning purposes, and can easily 
access it from online sources. 
4.2.2.  Method of use 
The route of administration of 2,4-DNP is oral, taken either as tablets or 
capsules, once or twice a day.  Based on users’ online accounts and self-reports, 2,4-
DNP appears to be commonly used in cycles (McVeigh et al., 2016; Petróczi et al., 
2015).  Most 2,4-DNP cycles are brief − lasting anywhere from one to four weeks, 
but rarely longer (McVeigh et al., 2016).  Typically, 2,4-DNP cycles are variable and 
dependent on a number of factors, both internal (i.e., bodyweight) and external (i.e., 
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weather conditions).  Users will often determine the ideal dosage solely through their 
bodyweight, not factoring in external determinants.   
4.3.2.1.  Accessibility and Motives for Use.  Sale of 2,4-DNP for human 
consumption is presently illegal in the UK due to health concerns ('Warnings issued 
over deadly DNP "diet drug"', 2013; "New warnings issued over deadly DNP 'diet 
drug'", 2014; 'FSA action over 'fat burner substances', 2013).  Consequently, users 
now take advantage of its easy accessibility via the Internet (McVeigh et al., 2016; 
Petróczi et al., 2015).  An additional challenge is the ease with which 2,4-DNP can 
be obtained; as long as it is advertised “not to be used for human consumption”, 2,4-
DNP can be sold without limitations (Petróczi et al., 2015).  Compounding the issue 
are discussion boards, which users utilise to seek guidance and share experiences 
(Barratt, 2011).  These factors counterbalance efforts of regulatory bodies to prevent 
access and use of 2,4-DNP. 
2,4-DNP appears to be utilised by the gym-going population owing to its 
unique muscle-sparing properties (Goldgof et al., 2014).  The existing limited 
literature suggests that motives for using 2,4-DNP are primarily tied to the short-term 
aesthetic goal of losing considerable amounts of body fat (McVeigh et al., 2016; 
Petróczi et al., 2015).  Similar motives were found amongst young non-exerciser 
adults in hypothetical situations; those who wished to rapidly lose a considerable 
amount of weight were the most willing to take the risk with 2,4-DNP (Hoxha & 
Petróczi, 2015).   
Studies exploring prevalence and the experiences of users with regards to 
motives, reasons and risk perceptions associated with 2,4-DNP use are inadequate or 
non-existent.  To date, research has evidenced that 2,4-DNP users make self-
perceived conscious and informed decisions about 2,4-DNP and are well-prepared 
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for the side effects (McVeigh et al., 2016; Petróczi et al., 2015;).  Willingness to take 
risks with 2,4-DNP has been linked to body image and magnitude of the desired 
weight or fat loss (Hoxha & Petróczi, 2015; Petróczi et al., 2015).  However, studies 
investigating this matter are limited.  There appears to be a clear gap in knowledge 
and disconnect between 2,4-DNP users and the scientific community researching 
voluntary 2,4-DNP use. 
4.3.2.2.  Aims and Objectives.  Whilst prevention via warnings about the 
danger of 2,4-DNP could be an effective strategy for the naïve potential users, this 
approach is unlikely to deter those who are knowledgeable and experienced PED 
users.  Prevention via controlling the supply has deemed difficult because of the 
widespread availability of the drug through the Internet.  Where deterrence and 
control fail, there is room and need for strategies that primarily aims at harm-
reduction.  In order to explore 2,4-DNP use and implement harm reduction measures 
for this population, further evidence-based information is required.  Though some 
understanding of the physiological effects of 2,4-DNP are evidenced through case 
reports and animal model experiments, very little is uncovered regarding 
psychological factors.  Due to 2,4-DNP use being considered high risk and 
potentially dangerous behaviour even within the gym-going population, users tend to 
be very cautious when disclosing their 2,4-DNP use.  As such, they are a hard-to-
reach population, resulting in studies harvesting data from the Internet forums and 
discussion boards (e.g., McVeigh et al., 2016). 
A better understanding of this population can be reached by examining 
attitudes and subjective experiences with 2,4-DNP of the users.  This study, for the 
first time, set out to provide a more thorough and comprehensive qualitative 
overview of users’ experiences through thematic content analysis of semi-structured 
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interviews.  In particular, we aimed to explore 2,4-DNP users’ attitudes towards the 
Internet as a tool, perceived attitudes of in-groups and out-groups towards their 2,4-
DNP use, as well as exploring 2,4-DNP use through participants’ attitudes towards 
the compound.  This, in turn, can inform practically relevant and meaningful harm-
reduction policies which are accepted by this population. 
4.2. Methods 
4.2.1.  Participant recruitment 
Recruitment consisted of a purposive sampling strategy carried out online.  
“Snowballing”, the recruitment of participants from a hidden population through peer 
referral (Biernacki & Waldorf, 1981) procedures were utilised.  This involved 
making initial contact with “gatekeepers” of various bodybuilding forums discussing 
2,4-DNP use to gain better access to potential participants.  The researcher was 
active in these forums and familiarised with their administrators.  Discussing the 
study with gatekeepers helped  credibility and made recruitment far easier than 
having approached individuals directly.  Online recruiting from this population was 
challenging; the main reasons being the sensitive nature of discussing such 
compounds and a perceived lack of anonymity. 
Specific exclusion/inclusion criteria for participants were being over 18 years 
of age and having previously done, or were currently doing, a 2,4-DNP cycle.  
Credibility of participants’ accounts was individually judged by the level and 
accuracy of the specific details and information by which they described their 
experiences with 2,4-DNP (Gergen & Gergen, 2000). 
Utmost care was taken to ensure participants’ confidentiality, and this was 
emphasised when discussing the details of the study.  Self-assigned alphanumerical 
codes were used for transcription and data analysis to maintain confidentiality and 
83 
 
anonymity.  Ethical approval was granted for the project by the Research Ethics 
Committee of the Faculty of Science, Engineering and Computing, Kingston 
University (see appendix C).  Informed consent, voluntary participation, 
confidentiality and right to withdraw at any time from the study were all discussed 
with participants pre-interview, alongside any other queries. 
4.2.2.  Measures: semi-structured interviews 
Semi-structured interviews were employed.  The interview consisted of 28 
questions (see appendix D for the interview questions and appendix E for the 
demographics questions), which were created by the research team and explored 
motivations, reasons, expectations, side effects, use of other drugs, knowledge of 2,4-
DNP, peers and purchase.  Interviews were designed to facilitate adequate dialogue 
between the interviewer and participant.  Capitalising on the researcher having an in-
depth understanding of the environment and surrounding culture, open questions 
were used as much as possible.  Where possible, the interviewer asked the participant 
to expand upon answers in order to gather more information.   
All interviews were conducted via Skype (v.  7.21.0.100 through to 
v.7.27.0.101) as participants resided in different parts of the world.  Audio-only calls 
were used to ensure anonymity.  Due to the stigmatisation of the compound even 
within gym communities, and its worldwide illegality concerning human 
consumption, we considered it prudent to utilise audio-only interviews.  The 
locations of participants around the world meant that in person interviews were not 
possible.  Interviews were recorded using a recording app (Audio Recorder, Android 




4.2.3.  Data analysis  
Transcription was conducted by the researcher (NPA) with the aid of an 
online transcription application (https://transcribe.wreally.com/).  All identifying 
information was redacted from transcripts. 
A thematic content analysis approach was employed to analyse the data 
(Braun & Clarke, 2006).  Due to the nature of the study, a deductive approach was 
used.  This approach fit the methodology best to form themes driven by our 
theoretical interests in the area.  A closed coding scheme was utilised; codes were 
determined pre-hoc and revised with the research team during analysis.  Coding was 
conducted individually, then compared with the group of researchers to ensure 
consistency (Weber, 1990).  The finalised codebook consisted of 37 codes (see 
appendix F).  Clearly defined definitions of each code were constructed, and every 
effort was made to ensure consistency during the coding process.  Atlas.ti (v.7.1.50) 
software was used for coding and analysis.   
The process of theme formation was conducted by aggregating codes which 
we considered semantically similar, or which revolved around a similar facet present 
within the data.   Thematic formation was conducted through a number of ways; 
firstly, frequency counts were analysed to determine if any codes had a large count 
(grounded), or were connected to other codes.   Additionally, codes were pre-
grouped into sub-themes before coding commenced.    These sub-themes were 
further organised into over-arching themes, which could be applied to our dataset as 
a whole (Braun & Clarke, 2006).    
The process of thematic analysis (Braun & Clarke, 2006) was organised in a 
clear framework that assisted researchers during the analytical step of this study.   
Throughout the process, in order to maintain the flexibility afforded by this 
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methodology, codes were revised where necessary.   This included post-hoc 
codification of text segments.   Constantly checking over data, and recoding and 
rechecking the transcripts enabled the researchers to increase reliability of the 
codebook.    
4.3.  Results 
4.3.1.  Participant sample demographics 
The final sample for the semi-structured interviews consisted of 14 
participants (13 males and 1 female).  The median age was 22 years old (age range of 
19–39 years old).  All but one participant were aged below 30 years old, with the 
remaining participant being over 30 years old.  Self-reported ethnic origin 
breakdowns were as follows: 10 were White/Caucasian, one was Asian (Oriental), 
one was Asian (Indian, Pakistani, or Bangladeshi), one was Hispanic or Latino and 
one was mixed.  With regards to locality, 11 resided in the USA, one in Canada, one 
in Germany and one in the Netherlands.  All participants considered themselves 
regular gym goers. 
Thirteen participants had used some form of PED or were currently using 
PEDs, with the remaining participant having no history of other PED use.  Most 
participants had used recreational drugs previously (such as alcohol or marijuana).  
During their 2,4-DNP cycles, only one drank alcohol and two used marijuana.  The 
rest did not use recreational drugs on cycle.  Nine participants concurrently used 
other PEDs on their 2,4-DNP cycles.  Participants’ accounts regarding side effects 
and dosages were consistent with other reports of 2,4-DNP use.   
4.3.2 Emerging themes 
Thematic analysis revealed four core themes: (1) attitudes towards the 
Internet as a tool (“The world at your fingertips”), (2) non-participant societal and 
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close peer group attitudes towards 2,4-DNP use (“What they would know about the 
horror stories”), (3) attitudes of the gym-going community (“There’s two 
extremes…”) and (4) participant attitudes towards 2,4-DNP (“I have to respect the 
hell out of this supplement”).  These four core themes are related to each other 
through varying degrees, encapsulated in the overarching theme of “being in control” 
(as shown in figure 4) and are vital in understanding 2,4-DNP users’ experiences.   
 
 
The following sections are organised into the aforementioned overarching themes 
and further described through key concepts which emerged from analysis. 
 
Figure 4.  Visual presentation of emergent themes within this study 
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4.3.2.1.  Attitudes towards the internet as a tool (“The world at your 
fingertips…”).  For our group of participants, the Internet was a vital tool.  Not only 
did our participants have access to the vast array of information related to 2,4-DNP, 
they were also able to share experiences with other peers using the drug.  By 
bringing such a variety of shared experiences and knowledge sources, one participant 
described it as “the world at your fingertips” (Male, the Netherlands).   
The secrecy within these communities can make it difficult to obtain 
information and even 2,4-DNP sources.  However, some participants had doubts 
regarding advice given over the Internet: 
…you're getting all this information not from a medical doctor, you 
know, from a bunch of dudes on the internet.  And as much as it sounded like 
enough people have used it and put in the time and collectively pooled their 
experiences and stories that gave me a good base, it's still always a thought in 
the back of my mind because you know, I don't know how my body 
personally will respond to this, even though I'm just taking the one dose, I 
have no idea… (Male, USA). 
This excerpt hints at the risk present not only through ingesting 2,4-DNP, but also 
through taking advice from this online community.  The wide accessibility of the 
Internet meant anyone could potentially offer advice, whether it is correct and safe or 
not.  Some participants consequently had to be careful sifting the “broscience” 
(commonly accepted term in the community for non-scientifically based information) 
from the science; 
One thing I had to learn to do not just with DNP but with uh, steroids 
as well is to filter the information and take everything with a grain of salt to 
learn what is considered I guess you can say broscience or you know, things 
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that people discuss and not really have scientific backing for? Versus reliable 
anecdotal evidence just because there isn't too much scientific evidence on a 
lot of these products that we're using.  So lots and lots of research and lots 
and lots of digging through mud I guess you could say, to make sure that the 
information I had was more or less reliable. (Male, Canada). 
In short, our participants acknowledged the power of the Internet as a rich 
source of information.  There was awareness that getting information from 
anonymous sources on the Internet was risky, and consequently participants were 
cautious when using it.  Peer experiences were considered vital, despite the need for 
careful interpretation. 
4.3.2.2.  Perceptions of societal and close peer group attitudes towards 
2,4-DNP use (“What they would know about the horror stories”).  Within this 
section, participants’ perceptions of society, friends and family’s attitudes towards 
2,4-DNP use are discussed separately.  An important distinction between personal 
attitudes and outgroup’s attitudes emerged strongly from the interviews.  Both 
society’s and social groups’ attitudes towards 2,4-DNP were thought to be shaped by 
media reports of fatal cases.  A further differentiation within friends dependent on 
their inclusion or exclusion from the gym-going community was also evident.   
4.3.2.2.1. Perceived perceptions of society towards 2,4-DNP use.  In 2015, 
there was notable international media attention for the death of a young woman from 
a 2,4-DNP overdose (Morris, 2015, July 23rd).  Many participants thought it to have 
had a significant impact on 2,4-DNP use perception by non-PED using outgroups; 
I imagine the average person we'd run into on the street, if they 
knew about DNP at all, what they would know about is the horror 
stories that, you know, come on the new… And, you know, their 
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judgement of me using DNP would then be based on that, you know, 
very, very biased, very case-specific um, information. (Male, the 
Netherlands). 
The use of the word “biased” implies that the public has a one-sided opinion, 
and this was a viewpoint shared by the whole cohort.  When explaining why 
outgroups would consider 2,4-DNP negatively, participants commented on 
“laypeople” relying on news reports and superficial information; 
…you know, people fear what they don't understand and you 
know, perhaps rightfully so.  But if people would do a little bit of 
research, before they give their opinions, I think we wouldn't have as 
much of an issue with it… I think the lack of education about DNP 
um, and all the other PEDs just causes issues you know.  If people 
know how it worked, there wouldn't be a huge issue with it.  It would 
just be, “let's make sure you do it safely”.  But you know, that's not 
how it is right now. (Male, USA). 
Interestingly enough, some participants thought this negative viewpoint to be 
beneficial; “the last thing we need is more people that have no idea what they're 
doing, getting a hold of it and killing themselves with it.  It's a dangerous compound, 
you know.” (Male, USA).  Several participants drew parallels between 2,4-DNP use 
and AAS use, saying 2,4-DNP use has a “very similar vibe as steroids have, where 
you hear about only the bad things that can happen and you never look at all the 
benefits.” (Male, USA).  AAS use is often associated with an aesthetic extreme of 
large amounts of muscle mass and consequently seen as an aesthetic outlier. 
When discussing whether this attitude would change in the future, one 
participant was optimistic regarding future perceptions of 2,4-DNP: “I think at least, 
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based on America, [laughs], everyone here is looking for that magic skinny pill that 
helps you lose weight…” (Male, USA).  Weight loss is a relatable goal for the 
majority of the general public, as it fits with the “traditional” societal norms of 
beauty, particularly in Western societies.   
The idea of an uninformed public is clear through these excerpts; the public is 
perceived as having “no idea” regarding what they are doing, alongside making hasty 
judgements based on a prominent media story.  An ingroup/outgroup divide emerges 
from the data.  This could account for the secrecy which surrounds the community, 
and could impact help-seeking behaviours. 
4.3.2.2.2. Perceived attitudes of friends and protecting self-image.  In general, 
participants were hesitant to inform their social networks of their 2,4-DNP cycles.  It 
was perceived that naïve individuals held biased views towards this practice and only 
ingroup members could have an informed and valid opinion. 
Participants sometimes divided their friend groups into “bodybuilding 
friends” and “non-bodybuilding friends”.  This was crucial in their eyes; related to 
the earlier concept of the “layperson’s” lack of education and misconceptions.  One 
participant said they  
…didn't want them to uh, think that I was some crazy drug addict 
either because if my friends outside the bodybuilding community heard that I 
was using this performance enhancing drug, I think their initial reaction 
would be “oh my gosh you are doing drugs, that's bad” and I did not want 
them to think that at all. (Female, USA).   
Fundamentally, participants viewed only ingroup gym-goers as trustworthy in 
relation to the accuracy of their opinions of 2,4-DNP.  They were very concerned of 
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outgroup’s prejudices and negative opinions of drug use, and how they could 
potentially be damaged by negative stereotypes. 
4.3.2.2.3.  Protecting the family.  The decision whether to tell friends and 
family about drug use can be difficult.  Our cohort feared closure and non-
acceptance, particularly with family.  Those who kept their use away from family 
had various justifications for not informing them of their 2,4-DNP use, with one 
stating “what they don't know won't hurt them.” (Female, USA).  One participant 
elaborates on his decision to tell some of his friends and family: 
I'm pretty open about my PED use so it was something that, 
um, most of my friends were kind of interested in when they found 
out.  You know, I have done a good job of explaining stuff to people 
so um, I didn't have any problem telling most of them.  I kept it on the 
down low for the most part cos of… my parents, cos they weren't 
huge fans of it.  But everyone else I was pretty open with.  And, um, 
you know, it was a good experience from that too, I had other people 
that'd, you know, if something were to go wrong, they would know 
about it at least…it wouldn't be a whole bunch of people wondering 
what happened. (Male, USA). 
This particular individual’s reasoning for informing his friends and family stemmed 
partly from a safety perspective.  The usage of the word “at least” indicates that this 
was a minimum requirement for them, made on a personal level.  Informing a small 
group of people for safety reasons was suggested as good practice. 
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4.3.2.3.  Perceived attitudes of the gym-going community (“There’s two 
extremes…”).  Participants almost universally acknowledged that there was growing 
interest within the gym-going community for 2,4-DNP use; some individuals were 
more “open” to its use, whilst others considered it to be wholly dangerous and 
unnecessary to any fat-loss goals individuals might have: 
… as with many things, there's two extremes: people who are 
very much for it you know, who supported using and people who you 
know, call it “The Devil” and say no, you should never use it.  And 
there's people in between… (Male, the Netherlands). 
Some participants offered potential reasons why some individuals in the gym-going 
population might disapprove of 2,4-DNP use; “…a lot of people don't like that there 
is this pill that you can take which causes you to lose fat” (Male, Canada).  These 
people believe that there is an extremely high possibility of abuse.  2,4-DNP is 
viewed negatively because it is seen as a “no effort” pathway to reaching weight loss 
goals.  2,4-DNP is considered different to other PEDs: with other PEDs, the general 
understanding is that you still have to work hard and be consistent, whereas with 2,4-
DNP, “you take it and it works” (Male, Canada), implying training and diet are not 
needed. 
4.3.2.4.  Participant attitudes towards 2,4-DNP (“I have to respect the 
hell out of this supplement”).   Our participants were almost overwhelmingly 
positive about their use of 2,4-DNP, although they emphasised the need to “respect” 
the compound due to the potential adverse effects, alongside its lethality at certain 
doses; 
Right, my opinion is that it can be used very safely, and very 
effectively, to get great results, in a short period of time.  But, the other side 
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of the coin that, the other side of the coin is, you know, this is a fact, is that it 
is lethal at a certain dosage you know.  There is all these adverse effects you 
know, such as the cataracts, it messing with you, with your thyroids, your 
metabolism, all these different things.  It can adversely affect you that way.  I 
think if you know what you're doing, and you do it properly, it can be used 
very safely and very effectively. (Male, the Netherlands). 
For other participants, similar themes of respect and “doing it properly” were 
notable.  it is crucial that underlying attitudes towards 2,4-DNP are “… based on the 
foundation of ‘I have to respect the hell out of this supplement’ and I can't ever get 
out of turning into this mindset of getting impatient or taking more is better.” (Male, 
USA). 
According to another participant, the “wrong way” can lead to consequences 
“as severe as, you know, death.  Or you know, having to deal with PN [peripheral 
neuropathy] symptoms for a long time or developing cataracts” if you do it the 
“wrong way”.  (Male, USA) 
Most acknowledged that high doses were dangerous and condemned 
individuals taking high risks; 
…they're running a gram a day and I think that's reckless and 
asking for something to go terribly wrong.  I believe the half-life is 
somewhere around 36 h, so I mean there's no way to get it out of your 
body other than waiting.  And if you gotta wait 36 h for half of it to 
get metabolised, there's nothing you're gonna be able to do to keep 
yourself alive and your body just starts cooking… (Male, USA). 
Upon further elaboration, when asked if they would ever push the boundaries 
with dosages, almost every participant said no.  One went so far as to state that “it'd 
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be a… one time experience thing [laughs]…” (Male, USA).  Another stated “Not in a 
million years.  For me…there's really no need, why risk messing up my body, you 
know.  It's a marathon, not a sprint.” (Male, USA). 
In contrast, our participants strongly advocated for harm reduction measures 
as being the “right way” to approach using 2,4-DNP.  One participant stated the 
importance of implementing “…due diligence and background, getting the blood 
work you need, taking the supplements and cycle support you need.” (Male, USA). 
When asked if they would recommend 2,4-DNP to anyone else, there was a 
definite polarisation.  Some stated they would recommend it, provided certain 
conditions were met, 
I would definitely recommend DNP to people given that I have 
sufficient background with them.  Erm, for someone for example online as I 
do most of my discussions online, I would not recommend it freely just 
because, I would give my opinion on it but I wouldn't actually tell them 
whether or not they should do it. (Male, Canada). 
However, others went so far in the other direction; 
I would not recommend DNP to my worst enemy.  It is, in my mind, it 
is a poison as well, I take it because I want the results.  I do, if somebody told 
me they were taking it, as long as they've done their research, I will 
wholeheartedly support them.  But I would never recommend it to somebody.  
I'd rather them find out about it on their own, do their own research and fully 
understand and grasp what DNP can do, what potential side effects are, what 
you can really gain from it before attempting it.  And I would never, I would 
never supply it to anybody, I would never recommend it. (Male, USA). 
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Our cohort considered themselves to have a strong respect for the 
compounds, grown out of the research they had conducted before using 2,4-DNP.  
Most participants strongly advocated for individual research before embarking on a 
2,4-DNP cycle and implementation of harm reduction measures.  Polarised attitudes 
towards recommending 2,4-DNP could be, in part, due to its lethality and severity of 
potential adverse effects. 
4.4.  Discussion 
Our results give a number of novel insights regarding how 2,4-DNP users 
approach their use, as well as how perceived public perceptions influence their 
behaviour.  It is clear that the majority of users get their information almost 
exclusively from the Internet.  Users consider themselves well-educated on the risks 
and effects of 2,4-DNP, with most having done what they considered to be extensive 
research before embarking upon a cycle. 
The four themes can be viewed through the overarching thematic lens of 
control, present to some degree in all the sub-themes discussed.  It was clear how 
important the Internet was with regards to users’ 2,4-DNP experiences.  Users turned 
to the Internet for a number of purposes; from sourcing 2,4-DNP, to researching the 
compound and cycle details, as well as peer-to-peer experience sharing.  In this 
sense, it was considered a powerful tool that allowed the sample to exert control over 
this risky practice.  In particular, the Internet enabled users to exhibit greater control 
over their 2,4-DNP experiences in the following ways: 
Firstly, the anonymity the Internet can provide was considered a valuable 
asset.  Users can choose to be as anonymous or identifiable as they wished.  There 
are a number of methods used to research and obtain 2,4-DNP which leave no trace.  
With regards to PEDs in general and the stigma attached to them, anonymity is 
96 
 
extremely important for users.  Many stated they did not want friends or family to 
know, due to the surrounding negative attitudes. 
Secondly, the wide variety of PED-related information available via the 
Internet makes it a powerful tool for research.  For example, several participants 
were able to find research papers about 2,4-DNP use effects on humans, increasing 
their knowledge on the compound’s effects.  Additionally, users could get anecdotal 
information from specific forums.  Users were able to control which of these sources 
of information they utilised, based on their level of knowledge and trust in the 
information source. 
Thirdly, participants had a wide variety of suppliers and vendors from which 
to choose.  Different suppliers provide different dosages per capsule, types of 2,4-
DNP (whether it was crystal or powder form), and even possibly supply other PEDs 
for participants. 
Users’ attitudes towards public perception of 2,4-DNP influenced who they 
told about their use.  Many users made the conscious decision to not divulge their 
drug use to their family (and often friends).  Some made the distinction between 
“gym going” friends and “non gym-going friends”.  The stigma attached to 2,4-DNP 
use has many similarities to stereotypes associated to the use of PEDs in general.  
Some participants likened it to the overwhelmingly negative attitudes prevalent in 
society towards AAS use.  Notably, some participants perceived this negative stigma 
as a benefit, in order to prevent any “laypeople” encountering and ingesting the drug.  
Most participants in this sample had experience with previous PED use, therefore 
considering themselves well-versed in harm reduction in similar contexts.  In 
contrast, the general population was not as well educated or knowledgeable about the 
necessary harm reduction measures necessary with any PED.  Participants made it 
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clear they were different from the general public due to their knowledge and 
experience with PEDs, as well as training and diet. 
An additional point to consider is the distinction even within the gym-going 
community between 2,4-DNP and other PEDs regarding effort.  The use of 2,4-DNP 
has been reported to increase basal metabolic rate by 11% for every 100 mg ingested 
(Grundlingh et al., 2011).  The gym-going community considers 2,4-DNP a “short 
cut” compared to other methods of losing weight, since a rigid diet is not necessary 
for the drug to be effective.  Conversely, AAS use is associated with pushing beyond 
genetic “natural” limits, a perceived necessity for certain disciplines such as 
bodybuilding. 
Finally, the control theme underpins all aspects pertaining actual 2,4-DNP 
use.  Participants controlled their lifestyle and other substance use while on 2,4-DNP 
and all but one benefitted from having experience with other PEDs.  Users in this 
study also carefully controlled what, when and how much they revealed about their 
high-risk behaviour to their social groups and differentiated based on how well-
informed they believed they were.  Users also considered their social image when 
choosing not to tell friends about 2,4-DNP use.  This high degree of control, coupled 
with respect for this very potent but highly toxic chemical suggests very clearly that 
users do not haphazardly take risks with 2,4-DNP.  Rather, users search for 
information, educate themselves about the drugs and side effects, keeping a 
controlled lifestyle and not exceeding the amount they felt was “safe”. 
Participants were well aware of the risks associated to 2,4-DNP use.  Many 
participants had a “threshold” dose which they would not bypass due to their concern 
about unwanted side effects.  In particular, participants were concerned about death.  
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Whilst participants seemed keen to take the risk of ingesting 2,4-DNP, the risk 
appears to be a “calculated” one, rather than an impulsive decision. 
What is clear from the interviews is that participants would take as many 
measures as they felt were necessary to mitigate negative effects and yield only 
positive outcomes from 2,4-DNP use.  According to the sample, negative societal 
effects (by not informing certain social groups of their use and maintaining 
anonymity) and negative physical effects (through the use of supplements or drugs, 
as well as through self-experimentation) could be contained and controlled.  For 
participants, controlling and mitigating negative effects was crucial and each 
participant exercised their control by making certain choices within their goals and 
possibilities. 
It can be suggested that the control element found in our cohort’s narrations 
reflects commonalities with eating disorder symptomatology (Marzano-Parisoli, 
2001).  A distinction between “practical” control (in this context, controlling as many 
elements as possible to reduce harm from the compound) and “pathological” control 
(control which stems from a pathological root) is nonetheless necessary.  Media 
reports indicate that in those suffering from eating disorders or some other 
pathological conditions (e.g., exercise addiction) and use 2,4-DNP, often fatally (e.g., 
Moore, 2017, July 27th; Philby, 2013, April 23), death or serious health conditions 
were related to overdosing with 2,4-DNP.  It remains unknown whether overdosing 
were due to impurity; the lack of knowledge and understanding or loss of control 
over the measures taken for weight loss.  Further research is warranted to compare 
and contrast elements of “practical” control, necessary when using a highly lethal 
compound such as 2,4-DNP and the “pathological” control characteristic of eating 
disorders or exercise addiction. 
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4.4.1.  Comparisons with past research   
In part due to difficulties in recruiting from this population group, studies on 
attitudes of 2,4-DNP users have been scarce.  Qualitative studies which include 
thematic analysis are even rarer.  Petróczi et al.  (2015) administered a semi-
qualitative, self-reported survey to 35 2,4-DNP users.  Similar to our results, the 
Internet was a major source for obtaining information on 2,4-DNP as well as for 
acquiring the actual substance.  Users were aware of the health risks and made an 
informed choice to use the compound regardless. 
A netnographic study was undertaken by McVeigh et al.  (2016).  This study 
examined online community comments from 2,4-DNP users, using thematic analysis.  
The results uncovered novel descriptive information focused on purchasing, dosages, 
outcomes, side effects and cycles.  Individuals’ attitudes towards 2,4-DNP partly 
mirrored our results; user groups utilised scientific studies and discussed use from a 
physiological perspective.  Whilst McVeigh et al.  (2016) compared 2,4-DNP users 
to novel psychoactive substance (NPS) users, we identified differences between 2,4-
DNP users and AAS users. 
(Gottardi & Fimognari, 2010) suggested a spectrum of two extremes of AAS 
users; the ‘first extreme profile’ is an individual who has a high hazard knowledge 
and correct risk perception − though the perceived high reward is worth the risk in 
their eyes.  The second user is the ‘second extreme profile’, an individual who 
perceives a moderate amount of reward, yet risk and hazard perception related to 
AAS are limited.(Gottardi & Fimognari, 2010) suggested most users will fall 
between these two extremes.  It is possible to extend this scale to 2,4-DNP users − 
the majority of our participants acknowledge the high risk and numerous potential 
hazards associated with using the substance.  However, the high reward (high 
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amount of fat loss in a short amount of time) is worth the calculated decision they 
made.  Thus it is possible they would fall under the “first extreme profile”. 
This is also reflected in the amount of 2,4-DNP users ingest.  In our and 
similar studies, 2,4-DNP users appear to be significantly more conservative with 
their doses when compared to AAS users.  Parkinson & Evans (2006) found that the 
average dose of AAS used has increased from 1997 (where the reported dosage was 
500 mg) to 2006 (where dosages of 1000 mg and more were reported in the study).  
Whilst no studies exist to determine typical 2,4-DNP dosage, informal suggestions 
range between 200 and 600 mg, with potential users being advised to start off at the 
lower end and gradually taper up if they can do so (Petróczi et al., 2015).  AAS users 
are mostly concerned about long term effects (Parkinson & Evans, 2006), and side 
effect increases with increasing doses and number of AAS taken concurrently 
(Bolding, Sherr, & Elford, 2002).  Long term risks versus short term risks could 
potentially influence the risk and hazard perception of each user group, and this 
perception of acute harm could impact the dosages and methods of use in AAS 
compared to 2,4-DNP. 
4.4.2.  Limitations and future directions  
Procedural limitations were present within this study.  One of the main 
limitations was sample size.  Despite the interviewer being an “insider” for the 
community, recruitment was still challenging due to the high level of suspicion 
among community members.  Additionally, recruitment was conducted in a short 
period of time (approximately four weeks).  It is possible that a larger sample could 
be recruited over a longer period.  However, it should be noted that a sufficient level 
of data saturation (Fusch & Ness, 2015) was reached with our sample; similar themes 
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were appearing repeatedly, and a point had been reached where no novel information 
was appearing. 
Self-selection bias is an element present within this study.  Many of the users 
in our sample were open about their drug use, as well as educated on it to some 
degree.  However, providing representative information of 2,4-DNP users was not 
our intent.  We aimed to provide an in-depth description of the 2,4-DNP decision-
making processes.  Future studies could perhaps recruit from gyms as well as other 
online avenues to diversify study populations, thereby opening up a new pool of 
participants who could discuss a different array of attitudes and experiences. 
Whilst we attempted to recruit from a diverse range of participants, it is clear 
most participants were white Caucasian males.  This might be due to the 
stigmatisation of female PED use; female drug use in general appears more 
stigmatised than male drug use (Hecksher & Hesse, 2009; Van Olphen, Eliason, 
Freudenberg, & Barnes, 2009).  Fewer women are willing to be open about their 
PED use compared to males.  Scientific understanding of female PED use is much 
more limited compared to male PED use.  Future research could potentially 
investigate female-specific 2,4-DNP use and decision-making. 
4.4.3.  Recommendations for prevention and harm reduction policies 
It has been previously suggested in the context of AAS use that deterring 
people via exaggerated scare tactics and only emphasising negative effects has 
limited effectiveness (Petróczi, Dodge, Backhouse, & Adesanwo, 2014).  Rather, an 
evidence-based harm reduction approach appears to be more effective in reducing 
health costs (Goldberg, Bents, Bosworth, Trevisan, & Elliot, 1991).  Another 
potential direction for future research would be gathering more participants from a 
wider cultural pool.  Currently there is little research to determine whether cultural 
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background influences how individuals approach PED use (in particular, fat burners 
such as 2,4-DNP).  This could be accomplished via cross-country research. 
Prevention of use by presenting evidence-based information could be 
effective for non-users interested in initiating 2,4-DNP use.  However, additional 
approaches should be considered for experienced 2,4-DNP users, who might not be 
so easily dissuaded from use.  Additionally, the easy availability of the substance 
through the Internet makes “harm-minimising” by controlling substance access 
challenging.  It has been suggested that harm reduction in this context should focus 
on decreasing drug-related harm, as opposed to reducing drug use (Hunt et al., 2003).  
In the context of other PED users, this is a well-established concept, for example 
through the use of needle and syringe service providers (NSPs).  Notably, NSP 
programmes also provide information on maximising the effects obtained from AAS 
in order to minimise the amount used (Kimergård & McVeigh, 2014). 
In the past, AAS users have been reluctant to take advice from doctors as they 
feel they are more educated on AAS and other PEDs than health professionals (Pope, 
Kanayama, Ionescu-Pioggia, & Hudson, 2004).  Future research could examine if 
similar processes occur in a representative 2,4-DNP user cohort, determining whether 
similar perceptions towards medical professionals are present.  Considering the 
findings of this study, 2,4-DNP users are pro-actively engaged in avoiding potential 
harms but engage in preventative measures in an isolated manner.  This protective 
factor can be reinforced and supported by acting on possible negative attitudes 
towards health professionals. 
Health professionals and other groups of people in contact with 2,4-DNP 
users should also understand that this population considers itself well informed about 
the risks involved.  Our cohort utilised scientific studies (where possible) in order to 
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determine dosages and educate themselves on side effects.  It must also be 
remembered that this user group bases decision-making on other users’ experiences, 
and realises that experimenting with such a substance without adequate medical 
supervision is inherently extremely risky. 
Findings also highlight the importance of creating and maintaining 
community relations with the target population; the depth and richness of 
information gathered during our qualitative interviews brought forth many valid 
harm reduction recommendations from our cohort, for example informing a close 
friend when starting a 2,4-DNP cycle.  Additionally, it can be empowering for the 
community to be part of policy creation.  It is imperative to forge a connection with 
the PED-using community, and actively involve them in policy creation as much as 
possible.  Considering the submersed nature of the PED using population and the 
high risks involved in using 2,4-DNP, developing effective communication strategies 
that better inform research, policy and preventative measures is vital.  Harm 
reduction is an important standpoint in promoting a non-judgemental attitude and 
improving communication with the PED using population (DeCorte, 2001). 
In a community where peer experiences are highly valued, peer-to-peer 
education schemes, presenting information in a non-judgemental light, and 
advocating the benefits of moderation in consumption whilst cautioning against 
excess could have beneficial outcomes for the gym-going population.  Considering 
the dose-dependent danger associated with 2,4-DNP, this moderation-based approach 
would be far more effective than withholding information to prevent use.  Taking all 
of this into account, policy creation could potentially occur through well-conducted 
participant action research (PARs) initiatives (Baum, MacDougall, & Smith, 2006).   
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4.4.4.  Conclusion 
Participants concluded that if used with caution, 2,4-DNP is highly effective 
and efficient as a fat loss agent.  However, many also remarked upon its dangers.  
The main concern, in addition to adverse physical effects, was the risk of death.  
Most considered “respect” for the compound to be important and pivotal to reduce 
adversities.  Internet has a powerful role and interactions with peer groups online 
shaped perceptions towards 2,4-DNP and other PEDs.  Attitudes towards 2,4-DNP 
use are particularly polarised and complex within in-groups. 
Further research on 2,4-DNP use within gym-goers is warranted.  
Understanding users’ motives and decision-making processes is crucial to develop 
better interventions and policies.  It is also a priority to adopt a non-judgemental 
approach and avoid further marginalisation of 2,4-DNP users.  Instead, using their 
experiences to devise prevention, education and valid harm-reduction strategies 
could be beneficial to public health initiatives. 
What this study adds 
This paper uncovered some key insights into risk management, perception 
and mitigation relating to 2,4-DNP use.  From chapter 2, some notable similarities 
exist concerning risk perception and mitigation.  For example, though the potential 
side effects were different for each cohort, controlling dosages and cycle lengths 
were key elements of controlling for unwanted side effects.  Additionally, disclosure 
in both cohorts stemmed from the perception of stigmatisation.  This was mitigated 
through controlling disclosure.  This element of disclosure, alongside the gap in the 
literature concerning the patient-doctor relationship form the basis for the next study; 
a thematic analysis work investigating influential factors into the patient-doctor 
relationship with AAS-users.  Through study 4 (chapter 5), a greater understanding 
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can be built concerning the perception and navigation of risks within a different 
context; that of the clinical interaction.  Additionally,  the next study will bring “out 
of community” perspectives of risk relating to PED use through the exploration of 




Chapter 5: Outgroup perceptions of PED-related risk through the exploration of the 
patient-doctor relationship with AAS-using patients 
Preamble 
This chapter leads on from the last in two ways: firstly, by moving from the 
idiographic (chapter 2) through to the in-community perspectives through to this 
chapter which includes out-group perspectives.  Secondly, this aims to build upon the 
risk perception, experience and navigation outlined in the previous two chapters by 
exploring the risk of stigma and anticipating stigma in greater detail.  This also aims 
to explore what risk means to those likely to come into contact with PED users.   
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Two sides of the same coin: A qualitative exploration of experiential and perceptual 
factors influencing the clinical interaction between doctors and Anabolic-Androgenic 
Steroid using patients 
5.1.  Abstract 
Background: Modern patient-doctor interactions involve complex interplays between 
patient and doctor autonomy.  This complexity is intensified in stigmatised populations, 
such as anabolic-androgenic steroid (AAS) users.   Regardless of their class C 
classification, possession for personal use is legal.  Despite this, previous research 
indicates that medical providers express negative perceptions and poor knowledge of 
AAS and AAS-using patients, and AAS-using patients perceive doctors negatively.  
Exploring this unique clinical interaction in greater detail could provide a holistic 
understanding of the underlying dynamics and help foster a more cohesive 
collaboration.  For the first time, this study qualitatively examines the influential 
factors upon the clinical interaction as identified by both cohorts. 
Methods and Findings: This is an exploratory two-cohort qualitative study.  
Participants were recruited via purposive snowball sampling in the UK.  In line with 
the interpretivist paradigm, an interview-based qualitative study design using an 
inductive thematic analysis method was used to elicit detailed experiential data.  
Individual in-depth interviews were audio-recorded and transcribed verbatim.  Data 
were analysed utilising iterative inductive thematic analysis. 
Twelve participants (six AAS-using patients, six medical doctors) were individually 
interviewed.  Six themes were identified: four themes for AAS-using patients 
(perceived riskiness of disclosure, low expectations of clinician knowledge and skill, 
perceived power imbalance and identity as an AAS-using patient and anticipation of 
mislabelling) and two for doctors (professional and contextual barriers and 
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professional role quandary).  The overall picture suggests that the primary factors 
impacting this clinical interaction involve stigma management techniques among 
AAS-using patients and dealing and coping with clinical uncertainty for doctors.   
Conclusions: Blurred lines regarding enabling versus management create a problem 
impacting both patient and doctor.  Further discussion remains regarding the role of 
doctor and patient autonomy.  Greater clarity is required regarding what constitutes as 
appropriate management.  Improving access to healthcare services and guided AAS 
cessation, if necessary, are vital for effective harm-reduction.   
5.2.  Introduction 
Modern medical interactions can be a delicate balancing act.  Ostensibly, both 
patient and doctor share the same objective of better health outcomes for the patient.  
However, what exactly defines a “better” health outcome can differ significantly 
between both sides. 
Shared-decision-making models of medicine create debates concerning the 
clash between patient and doctor autonomy (Millenson, 2017; M.  Parascandola, 
Hawkins, & Danis, 2002; Sandman, Granger, Ekman, & Munthe, 2012).  Continually 
growing patient autonomy expectations and greater accessibility of information mean 
the role of the patient and doctor remains unclear, and professional role boundaries 
become ill-defined (Yagil & Medler-Liraz, 2015).  These lines are further blurred 
when working with individuals exercising their rights to push limits through using 
morally charged performance-enhancing substances, such as Anabolic-Androgenic 
Steroids (AAS). 
AAS are synthetic substances used for performance and aesthetic 
enhancement within the gym-going community (Ainsworth et al., 2018).  Despite its 
Class C classification in the United Kingdom (UK), possession for personal use is 
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not illegal (Ainsworth et al., 2018).  A significant increase in AAS use within the 16-
24 age range has been documented in the UK (Broadfield, 2017).  In lieu of precise 
prevalence rates, actual rates of use are suspected to be considerably higher than 
reported rates of use (Ainsworth et al., 2018).  AAS use results in several potential 
ergogenic effects; these include muscular hypertrophy and strength increases 
(Ainsworth et al., 2018).  However, several possible adverse effects can arise from 
AAS use; these include hypogonadism, cardiovascular aberrations, mood changes, 
and other effects (Ainsworth et al., 2018).  It is these side effects that cause medical 
concern.  For doctors, mitigating these side effects is thereby of clinical importance.  
Within a harm-reduction context, the patient-doctor interaction is considered a 
critical factor in preventing drug abuse (Hawk et al., 2017).  Therefore, ensuring 
adequate medical engagement through addressing a cohort’s needs is paramount to 
mitigating potential harms.   
In a harm reduction context, poor patient-doctor interactions can be rife with 
mistrust and unclear expectations (Yagil & Medler-Liraz, 2015), leading to needs not 
being met (Backhouse & McKenna, 2011; Yu, Hildebrandt, & Lanzieri, 2015).  The 
resultant poor care engagement contributes to worsening health outcomes, a process 
seen in other stigmatised populations (Backhouse & McKenna, 2011; Yu et al., 
2015).  Additionally, healthcare avoidance can lead to missing the diagnosis and 
treatment of other risky behaviours in some AAS using patients, including 
recreational drug use (Yu et al., 2015). 
While there is limited research examining the clinical interaction within an 
AAS use context, a systematic review exploring pan-European doctors’ attitudes 
towards doping practices showed a limited amount of AAS knowledge despite 
exhibiting mostly negative attitudes towards doping (Backhouse & McKenna, 2011).  
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Moreover, studies uncovered healthcare providers expressing more negative attitudes 
towards AAS using patients and eating disorder sufferers than towards cocaine users 
and healthy adults (Yu et al., 2015).   
Despite a shared goal, the literature highlights an incongruency in what 
optimal health outcomes mean for each cohort.  The paradox between shared goals 
and a disharmonious interaction warrant in-depth investigation.  To this end, 
uncovering the contributory factors would provide an improved understanding of this 
clinical interaction. 
5.2.1.  Aims and objectives 
This study aims to explore what contributing factors influence the patient-
doctor interaction qualitatively.  More specifically, it investigates how they influence 
the interaction through exploring the perceptions and attitudes of each cohort.   
5.3.  Method 
5.3.1.  Design and Setting 
This exploratory qualitative study is conducted within an interpretivist 
philosophical paradigm.  This qualitative study design was chosen due to our focus 
on the lived experiences of participants using naturalistic data collection methods.   
5.3.1.1.  What is interpretivism?  Interpretivism, also known as social 
constructionism (Creswell & Poth, 2018), is the philosophical position which asserts 
that reality is fluid (it changes with context) and subjective (different individuals 
perceive a shared event or experience differently).  Factors such as values or pre-
existing experiences can shape these realities (Gibson, 2016).  The primary research 
aim of interpretivist paradigms is to understand the lived experiences of others and 
explore how factors such as values, culture and pre-existing experiences shape their 
perceptions of their experiences (Creswell & Poth, 2018; Gibson, 2016).   
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5.3.2.  Recruitment and Sampling 
After obtaining institutional ethical approval (see appendix G), recruitment 
commenced.  We aimed to purposively recruit information-rich participants who 
could provide insight on the topic in question (Patton, 2015).  Inclusion and 
exclusion criterion guided this purposive sampling process.  The inclusion criteria for 
each participant in both cohorts were a minimum age of 18 years old and residence 
within the UK.  For AAS using patients, either being current users of AAS or having 
a prior history of AAS use were the only cohort-specific eligibility criteria.  AAS 
using patients did not have to have seen a doctor for AAS-specific issues; this was to 
explore their perceptions relating to disclosure of use when visiting the doctor for a 
separate issue.  For the medical doctor cohort, cohort-specific criteria enabled either 
retired or currently working doctors to participate.  No specialism restrictions were 
imposed.   There was no requirement for doctors to have had clinical experience with 
AAS using patients; this is to understand how they perceive their role as practitioners 
instead of direct clinical experience and their perspectives on AAS-using patients.   
Both online and in-person recruitment methods were used to obtain more 
diverse data throughout the UK.  Sampling strategies are outlined below:  
5.3.2.1. Doctors.  The first author used online groups and preliminary 
connections to find participants (snowball sampling).  A range of specialities, age, 
sex and clinical experience with drug use and AAS using patients were recruited to 
obtain a diverse range of perceptions and experiences.   
5.3.2.2. AAS using patients.   Due to the self-contained and niche nature of 
the communities, the first author recruited AAS-using participants through her gym-
going community networks.  After identifying online community gatekeepers, they 
were given a prepared statement to disseminate the research brief (snowball 
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sampling) (Bengry, 2018).  Gatekeepers disseminated this brief on their online 
communities.  Individuals expressing interest in participating were contacted via one-
to-one messaging or email by the first author. 
5.3.3.  Data collection 
5.3.3.1.  Interview questions.  In line with the interpretivist paradigm, semi-
structured interviews were used.  The flexible, non-directive nature of semi-
structured interview empowers the participant to organically explore experiences or 
viewpoints they feel are most pertinent.  Simultaneously, semi-structured interviews 
ensure information relevant to the research question is collected due to the question 
guide (Roulston & Choi, 2018).  Question creation was a collaborative, iterative 
process in conjunction with the co-authors and peers in both participant cohorts 
(Chamberlain & Hodgetts, 2018; Liamputtong, 2007b; Roulston & Choi, 2018).  
Interview questions were created based on the exploratory aims of this study.  We first 
outlined broad topic areas we considered potentially relevant to the research question 
(Roulston & Choi, 2018).  Questions were formulated to elicit particular experiences or 
perspectives of each participant.   A “mirror” format enabled similar questions were 
used for both cohorts; this helped obtain their perspectives on this shared experience 
(see appendix H for the full interview schedule and appendix I for the demographics 
questionnaires).  The final question protocol consisted of five primary areas with 
questions grouped under each category: perceptions of PEDs, including problems 
and management (e.g.  “how do you feel about AAS use?”),  impact of prior 
experiences with doctors or patients (e.g.  “how does it feel to obtain medical care as 
an AAS user”/”what experiences have you had of working with AAS using 
patients?”), perceptions of the community (e.g.  “how do you feel the AAS-using 
community feel about doctors in general?”/”how do your colleagues feel about AAS 
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use or users?”), attitudes on disclosing use (e.g.  “how do you feel about disclosing 
use to your doctor”/”how do you think patients feel about disclosing AAS use?”) and 
expectations and/or medical knowledge related to AAS use (e.g.  “how do you feel 
about your current knowledge on AAS?”/”how do you feel about your current 
medical knowledge of AAS as a clinician?”).   
Questions acted more as a general guide for the interviewer rather than a rigid 
schedule; participants could choose to elaborate on any points they deemed critical, 
as well as retain a more natural flow of dialogue (Chamberlain & Hodgetts, 2018; 
Liamputtong, 2007b).  In stigmatised populations or those with time constraints and 
other restrictions, the use of collaborative, flexible interview approaches between 
researcher and participant are warranted (Chamberlain & Hodgetts, 2018; 
Liamputtong, 2007b), in line with the co-creative facet of the interpretivist paradigm. 
5.3.3.2. Procedure.  One-to-one one-off semi-structured audio-recorded 
interviews were done in person, over the telephone or online video calls (i.e.  Skype).  
Individual interviews were used to explore participants’ personal experiences and 
beliefs in a private setting; this was important considering the stigma associated in 
this context (Chamberlain & Hodgetts, 2018; Liamputtong, 2007b).    
Interviews were not conducted in work settings.  Each participant was 
interviewed in a location of their choosing.  The first author conducted all the 
interviews.  Each interview began without recording to build rapport with the 
participant (Roulston & Choi, 2018).  Verbal consent was obtained from each 
interview at the beginning of recording through the reading and agreement to a 
consent paragraph (Roulston & Choi, 2018).  Anonymised paper forms and online 
responses were used to collect demographic information.  Each participant was 
assigned an alphanumerical identifier to preserve anonymity.  Participants were 
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offered the opportunity to review their transcript, but all declined the offer.  
Interviews and recruitment continued until data saturation (O’Reilly & Parker, 2013) 
had been reached, as deemed by the first author in agreement with the co-authors.  
Data saturation occurred when no new emergent patterns were evident, and data was 
repeating itself (O’Reilly & Parker, 2013).   
Each audio-recorded interview was between 37 minutes and 79 minutes in 
length (mean interview length = 55 minutes).  In total, 663 recorded minutes of 
interviews were conducted for both groups, generating 298 pages of interview data 
for analysis.   
5.3.4.  Data analysis 
NVivo.10 software was used to analyse the data.  Data analysis was 
conducted using an inductive, iterative thematic analysis from Braun and Clarke’s 
(Braun & Clarke, 2006; Braun et al., 2019) method by NPA.  This approach was 
used to reinforce the inductive, naturalistic approach used within interpretivist 
paradigms.  Figure 5 outlines the analytical process in brief.   
Figure 5.  Image showing the process of thematic analysis as per Braun and Clarke's (2006) 
method. 
• Reading and rereading transcripts
First step: Transcript familiarisation
• E.g. "It boils my blood"
Second step: Generating detailed initial codes using in vivo first cycle coding
• Generating first order themes from in vivo codes (e.g. "it boils my blood" grouped under the first order 
theme of "feelings associated with being mislabelled"
• Clustering first order themes into second order themes (e.g. "Feelings associated with being mislabelled" is 
a sub-theme for the theme titled "Identity as an AAS-using patient and anticipation of mislabelling"
Third step: Searching for themes (using second cycle holistic coding)
• Thematic map production to facilitate thematic review process
Fourth step: Reviewing the themes
• Finalising and refining themes
Fifth step: Defining and naming themes
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Firstly, transcripts were read and re-read multiple times by the first author for 
familiarisation.  Interviewing and analysis were concurrent.  Secondly, initial code 
generation occurred through in vivo coding.  First-cycle coding consisted of in vivo 
coding for each transcript to retain the participants’ perspectives by using their own 
words (Saldaña, 2016).  Detailed line by line coding was used for the first two 
participants of each cohort, after which in vivo coding was done on a sentence by 
sentence approach for each participant.  After extensive immersion with the 
transcripts and in vivo coding completion, the third step of thematic analysis 
(searching for themes) commenced.  This process was facilitated using a second-
cycle holistic coding strategy; this clarified intergroup conceptual commonalities 
throughout transcripts through initial cross-transcript clustering of coded segments 
according to conceptual similarity (Saldaña, 2016).  This process identified first-
order themes through grouping in vivo codes into conceptually similar thematic 
groups.  These first-order themes were clustered further into broader second-order 
themes, which were more applicable to each cohort.  Continual production of in-
depth memos from the first interview facilitated this step of thematic analysis.  
Utilising memos enabled continual analysis and reflection upon the data in greater 
detail, contextualising concepts and experiences (Lempert, 2012).  The fourth step of 
thematic analysis, thematic review, consisted of producing several preliminary 
thematic maps throughout on paper to visualise and refine conceptual connections, as 
per Braun and Clarke (Braun & Clarke, 2006; Braun et al., 2019).  The fifth step of 
defining and naming the finalised themes reflect a pattern of shared meaning-making 
across participants, inclusive of divergent attitudes and experiences (Braun et al., 
2019).  Thematic refining occurred in conjunction with the co-authors.  The 
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analytical process was non-linear throughout and involved revisiting transcripts 
regularly to ensure applicability. 
5.3.4.1. Quality criteria.  Due to the paradigm used within this paper, 
alongside the thematic analysis method, the quality checklist outlined in Braun and 
Clarke (Braun & Clarke, 2006) ensured adherence to a consistent, robust approach to 
thematic analysis while keeping in line with the flexibility thematic analysis offers.  
COREQ guidelines were also used to adhere to qualitative quality control standards 
in health science publications. 
5.4.  Results 
5.4.1.  Participants 
Six doctors and six AAS using patients were recruited (n = 12).  Table 6 outlines 
relevant demographic information.  Each participant has a culturally appropriate 
pseudonym for readability purposes.  All doctor participants were currently practising 
in the National Health Service (NHS).  All AAS using patients are gym-goers, with 












Table 6   
Participant demographic information (AAS-using patients and doctors) 
 
Pseudonym Category Gender Age 
range 
Education level Ethnicity 













































































Note. A&E, accident and emergency; AAS, anabolic-androgenic steroids; A-levels, 
advanced level qualifications (UK school leaving qualifications); Dr, doctor; GP, 
general practitioner; ITU, intensive care unit; SEM, sports and exercise medicine 
 




5.4.2.  Themes 
Within this section, themes are organised in group perspectives: AAS using patients 
and doctor themes. 
5.4.2.1.  AAS using patient themes.  Table 7 outlines the AAS using patient 
specific themes and subthemes. 
 
 
Four themes were present, each with subsequent sub-themes: perceived 
riskiness of disclosure, low expectations of clinician knowledge and skill, perceived 
power imbalance and identity as an AAS-using patient and anticipation of 
mislabelling.   
Table 7   
AAS-using patients’ themes and sub-themes   
Themes Sub-themes 
Perceived riskiness of disclosure Making the decision to disclose  
The disclosure-honesty relationship 
Low expectations of clinician 
knowledge and skill  
Poor level of clinician knowledge 
Expectation of poor clinical style  
Perceived power imbalance  
“Us versus them” 
Inability to relate to clinicians 
Doctors as gatekeepers 
Identity as an AAS-using patient and 
anticipation of mislabelling    
Self-perceived differences between 
AAS and ARD use 
Feelings associated being 
mislabelled 
Note.  AAS, anabolic-androgenic steroids 
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5.4.2.1.1.  Perceived riskiness of disclosure.  Perceived riskiness of disclosure 
was characterised by the decision-making process behind disclosure and a 
relationship between disclosure and honesty.   
5.4.2.1.1.1. Making the decision to disclose.   The process to disclose AAS 
use in a clinical interaction is an informed and calculated decision-making process.  
As will be clear in the accounts below, the actual decision-making process before 
disclosing is more complicated than it may appear.  Several individual factors are 
taken into consideration.  For example, one reason why an individual may not 
disclose is due to the experience of stigmatisation.  Nathan elaborates on the negative 
feelings associated with disclosing his use, showing how disclosing can be risky by 
creating discomfort and embarrassment through experiencing stigmatisation:  
…it’s a general question… do you use performance enhancing drugs?  
At the doctor’s you might say, no… I have held things back and I’ve been 
embarrassed with it, you know, going in and saying to people, going to seeing 
doctors about my use because of how you're judged on it.  – Nathan, M, 
AAS-using patient 
Disclosing and being fully honest seemed particularly pertinent when a threat 
to life was established.  One user stated that if major organs were affected, it was 
essential to divulge all information to get appropriate and essential care; 
NPA: So when you say if I thought it would help them what situations 
would you consider the information to be important?  
Frank: Problems with your heart or problems with your liver or 
kidneys, anything like that, you’ve got to tell them, it helps them work out 
what’s wrong with you, if you don’t tell them they’re not getting all the 
120 
 
pieces of the jigsaw so they can’t do anything to help you so you’ve got to 
give them all the information you can.  - Frank, M, AAS user 
These accounts suggest that there is a threshold between anticipating 
judgment and getting appropriate treatment.  For Nathan, it was more important he 
received the correct medical care for a serious abscess than avoiding stigmatisation 
through disclosure.  What this quote demonstrates is how disclosure appears to be a 
choice up to a certain point.  When it is a life or death situation, as perceived by the 
individual, disclosure is not a choice, but a necessity: 
I mean it’s more important to be honest than, to make sure that I was 
okay because when I got to hospital, if I left it, it could have got into my 
blood and it could have been game over and when I got in hospital, my leg 
got even worse by the night time, I couldn’t walk cause of my leg so if I’d 
left it and I hadn’t been honest, it could have been, I could have been in a 
really bad way so I had to do it for my own health.  - Nathan, M, AAS user 
5.4.2.1.1.2. The disclosure-honesty relationship.  Participants described a 
paradoxical relationship between disclosure and honesty, depending on the context of 
the disclosure.  For example, Peter describes how if he was honest with his doctor, he 
would not have obtained what he considered to be appropriate treatment.  Here, his 
understanding of the medical problem at hand becomes a factor in his decision to 
disclose his AAS use.  Below is an interaction detailing receiving medication for 
acne: 
NPA: What do you think would’ve happened if you were honest with 
him? 
Peter: I probably wouldn’t have got the help I needed.  I probably 
wouldn’t have got the medication that I wanted. 
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NPA: Why would that have been? 
Peter: Because they seem to think that because I was taking them out 
of my own choice that I shouldn’t be allowed to have the medication to treat 
certain side effects that come with it.  - Peter, M, AAS user 
In summary: for AAS-using patients, disclosure was perceived as a risky 
process in a multitude of ways.  Participants reacted accordingly by carefully 
considering the decision to disclose.  In particular, risks are balanced between 
encountering stigmatisation, judgement, and experiencing adverse health outcomes.  
Combined with the perceived relevance of their AAS use to the medical problem and 
their self-perceived grading of the medical problem itself all feed into the perceived 
risk associated with disclosing their use.  Based on the risk associated with being 
honest, participants would carefully control which information they would give to 
the doctor.  This withholding of information and control of disclosure appears to be 
an attempted redistribution of power, as they aim to retain agency throughout the 
medical interaction. 
5.4.2.1.2 Low expectations of clinician knowledge and skills.    Participants 
not only perceived disclosure as being risky; they also often described their low 
expectations of clinician skill, understanding and knowledge.   
5.4.2.1.2.1. Poor level of clinician knowledge.  For some participants, it was a 
lack of clinician knowledge which impacted the interaction.  This is considered 
pertinent when working with a patient cohort who have, at the very least, a basic level 
of understanding.  This clash in perceived knowledge levels can create problems within 
the medical interaction.  The impact of this upon the clinical interaction is plain to see; 
participants will be less likely to engage in medical interactions if they anticipate 
doctors having little to no knowledge about the topic.  Matthew outlined how AAS-
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using patients will “shut off” when encountering scaremongering and incorrect 
information about AAS from clinicians:  
…the average user does know the basics and though you still get 
those idiots that don’t have an absolute clue what they’re doing there’s a lot 
of information out there.   And when a professional… when they give advice 
that is either dated or proven to be incorrect, they [the patients] used to shut 
off.   “You don’t know what you’re talking about; I’m not going to listen to 
you anymore”.   And it’s very damaging for them in their engagement…But 
when they come out with ridiculous stuff like, “Everything you’ve got wrong 
with you is down to steroids”, and, “Yeah, that’s because of steroids”.   “Oh, 
your heart’s going to explode, or this is going to happen.   This might…”, 
come on.   You know, you’re just shutting people off.  – Matthew, M, AAS-
using patient.   
5.4.2.1.2.2. Expectation of poor clinical style.  For others, it was not 
necessarily the level of knowledge, but the expectation of a poor clinical style rife 
with judgement that negatively impacts the clinical interaction.  Frank describes how 
the subtle negative nature of an interaction makes him feel:  
… it’s a general whole, it’s hard to put into words here, they just look 
at the original problem, that was bad for you, you shouldn’t have done that, 
well that’s not helping the case, we all know there are side effects, we know 
that when we start taking them, I’m just here for a wee bit of help… - Frank, 
M, AAS-using patient.    
Frank went into the interaction with a particular desired outcome in his head 
(“a wee bit of help”).   Yet, this subtle judgemental interaction invalidates his 
informed decision to use AAS.   This element of the interaction is unwanted and 
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demonstrates the clash in goals for the clinical interaction.  Other negative 
interactions also demonstrate subtle interactions, evoking feelings of being 
patronised and negative judgements: 
I can’t remember what they were saying but you know when 
someone’s being patronising to you, and then, its more, little comments or 
how they say things and also how they look at you, you know, they give me 
that look, disappointing look at you...  - Nathan, M, AAS user 
Of note is how participants perceived the underlying judgement and negative 
perception within these interactions.  A stigmatizing or negative clinical manner is 
perceptible, no matter how subtle.  For some participants, first-hand experiences of a 
more overt stigmatizing clinical manner came to mind;   
And I’ve got a few cases of first-hand experience where I’ve received 
prejudice and I’ve seen dismissal.  I was once admitted to hospital with a 
suspected brain aneurysm….  So a consultant came round and they said, 
“Well we can see that your liver enzymes are elevated”.  “Yeah”.  “And I 
know that, you know, have you used steroids?” I said, “In the past, yes”.  
“Oh, well that’s what it will be then and that’s what’s causing the problem in 
your head”.  And I went, “Woah, woah, woah, woah, woah”.  I said, “If you 
look at my records you’ll see I was in here some months ago, unrelated issue.  
Full set of bloods done”, “Yeah”, “and you’ll see that my liver enzymes are 
fine and normal”.  “Yeah”.  “I’ve not used in seven-month period.  So your 
assumption is wrong”.  I’ve said, “The fact is I’m currently on antibiotics but 
you never bothered asking that, did you?” This resulted in the consultant 
walking off in a huff and 12 hours later I discharged myself from hospital 
having received no further medical treatment.  - Matthew, M, AAS user 
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For Matthew, his knowledge of his body and his results enabled him to “stand up” 
for himself in this interaction.  Matthew’s example showcases how being at the end 
of this clinician’s swift assumptions can feel.  The interaction seems steeped in 
hostility, without any collaboration.  His self-advocacy appears to be a protective 
factor in clinical interactions, in anticipation of poor clinical manner.   
The excerpt below demonstrates how a poor clinical interaction characterised 
by poor clinician manner can be disappointing.  Peter describes feeling let down and 
as if the doctor did not care about their wellbeing.  Feelings of disrespect and 
frustration are evident in this experience:  
…it kind of made me feel like he didn’t care what happened to me, 
he didn’t care.  Like as a doctor they should know things you know, like 
they’re medical professionals, they should know enough to know that there 
are good things and bad things about them… And the fact that you can go 
and, if you’ve got a heroin addiction, you go to the doctors and they’ll help 
you, you know.  If you’re on steroids everyone looks at you like you’ve just 
walked into a church and pissed on the floor, like they hate it.  So I think let 
down may be the right term because why should I be treated any different 
because of the things that I do, you know?  It’s completely legal within the 
eyes of the law to take them, so why should a doctor not be willing to help 
you, you know?  Fat people get help if they’re eating, like if they’ve got an 
addiction to food if you like, so why shouldn’t I have the same you know, 
the same rights.  – Peter, M, AAS-using patient.   
“Feeling let down” shows how certain expectations are had regarding the 
clinical interaction and role of doctors.  This is similar to Frank when he stated how 
he wanted a “wee bit of help”.  For Peter, getting medical help was a “right”, on par 
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with other similarly stigmatised patient cohorts.  Clearly, there is a clash between 
patient and doctor expectations from the patient’s perspective.  Not obtaining the 
help they required demonstrates the expectation of poor clinical manner.  The 
prevalence of this interactive style is summarised when Peter mentions how 
“surprised” he felt when, rather than being combative, he had a non-judgemental and 
collaborative interaction with the clinician; 
 I was relieved [laughter].  But also shocked, he was more 
helpful than I was expecting…with him, I was really comfortable, like I felt 
like I could literally tell him everything and there was no judgment.  He 
wasn’t judgemental at all, he was actually there wanting to help me rather 
than judging me and trying to educate me and force opinions down my throat.  
– Peter, M, AAS-using patient 
It is important to note that other positive doctor experiences were 
characterised by feelings of collaboration, non-judgemental approaches and acceptance 
within clinical interactions: 
It was one GP I had experience with who was non-judgemental of my 
choice to use and though he trod the line of management but not enablement 
very well, and he understood why and he understood the goals but he also 
understood the dangers.  And so obviously his primary was to try and 
minimise my risk and hopefully prevent me from using but he accepted that it 
was my choice and if I was going to choose to use then he guided me on what 
areas I needed to be aware of and what to look out for.  - Matthew, M, AAS 
user 
In short; AAS users want to feel like they have a more active role in managing 
the risks from their AAS use.  Positive experiences are an important factor in helping 
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create stronger interactions through enabling the patient to feel respected and 
comfortable.  Currently, participants anticipate low levels of clinician skill and 
knowledge in relation to AAS-use, thus negatively impacting the interaction through 
poor engagement. 
5.4.2.1.3.  Perceived power imbalance.  Within the AAS users’ interviews, 
there was a perception of a power imbalance which manifested as an “us versus 
them” belief.  Additionally, participants mentioned struggling to relate to their 
clinicians within interactions.  This struggle, in turn, has a strong negative effect 
upon engagement within the clinical interaction.   
5.4.2.1.3.1. “Us versus them”.  This perception serves as a reminder for the 
AAS using patient regarding their role in the clinical interaction as being passive and 
as a “lower status” compared to the doctor: 
So when you go and see a high-end endocrinologist or a high-end 
cardiac specialist or a high-end plastic surgeon, doesn’t matter what 
specialism they’re in, straight away you feel very subservient.  You feel like 
you’re in a room with someone who’s really important and really special and 
that you need to be a little bit, you know, beneath them.  - Matthew, M, AAS 
user 
The term “subservient” is a powerful word which demonstrates Matthew’s 
perception.  Feeling subservient indicates how the interaction does not feel equal, nor 
collaborative; rather, it indicates elements of paternalism and control.  Matthew then 
expands on this notion through discussing the “ivory tower” element.  An “ivory 




GPs very much have the sort of ivory tower persona attached to them, 
not them deliberately doing it themselves but they’re viewed in this, you 
know, lifestyle of purity and never done anything wrong and aren’t unhealthy 
in any way, shape or form and so therefore you’re going to judge me, and to a 
degree that’s backed up quite often that they do.  - Matthew, M, AAS user 
5.4.2.1.3.2. Inability to relate to clinicians.  Living in an ivory tower is 
indicative of the perceived power discrepancy between AAS-using patients and 
doctors.  One core defining component related to the ivory tower factor was the 
inability to relate to clinicians.  The importance of lived experience and relatability is 
outlined in this excerpt.  It demonstrates how important understanding and 
acceptance are for AAS-using patients seeking help for problems related to their 
AAS use, and the impact the lack of relatability has on patient engagement:   
Matthew:  Prime example… I’m going to stick the Head of 
REDACTED Endocrinology Department on a stand and I’m going to stick 
(Male bodybuilder  name REDACTED) on a stand.   I’m going to fill the 
room with steroid users.   I’m going to tell them who the two people are and 
I’m going to ask them to pick who they’re going to go to for advice.   Do you 
know where they’re going?   
NPA: Where do you think they would go? 
Matthew: They’re got to (Male bodybuilder name REDACTED).   
Course they’d go to (Male bodybuilder name REDACTED) because he looks 
like he knows what he’s talking about. 
NPA: Yeah.   Of course. 
Matthew: He’s lived it because he had real-world experience.   The 
Head of REDACTED Endocrinology has never lived it, he’s just read about 
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it, so he can’t tell you what it’s like to wake up at three o’clock in the 
morning…covered in sweat.  He can’t tell you what it’s like to be having sex 
with your partner when you’re on tren [trenbolone] and actually getting the 
urge to harm them.  He can’t tell you what it’s like to sit there when you’re 
doing 100mg of tren and crying into your porridge because you’re watching 
Lassie and you can’t cope.  He’s never been there.    
NPA: Of course, yeah. 
Matthew: So who would you talk to?  Who would you go to?  You’d 
go to the person that’s relatable.  – Matthew, M, AAS-using patient 
5.4.2.1.3.3. Doctors as gatekeepers  The perception of a hierarchical dynamic 
and the consequent lack of relatability serve to widen the communication gap 
between patient and doctor.  Related to this hierarchical dynamic is the perception 
that doctors are service gatekeepers.  This can lead to the perception of doctors as 
service gatekeepers, rather than being collaborative.  This factor is defined by a 
clear perspective of what the doctors’ role is with regards to this cohort.  AAS 
users discussed the concept of a general practitioner (GP) having a “duty of care” and 
defined their duty of care as giving them opportunities to monitor their health, and 
not act as an authoritative, judgemental figure:  
But I don’t think it’s a good idea blankly to refuse people to look at 
their own health markers due to the GP disagreeing with their own ethical 
considerations, I don’t think that’s their position at all.  As a GP they have 
duty of care.  I can’t imagine them turning away many heroin addicts, when I 
think about it, saying, no you’ve done it to yourself go and deal with it.  To 
me a GP is there to care and look after you and trust you and they break that 
trust and they talk to you like an authoritative figure in that state, when 
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they’re not.  They’re there to care for you, not to tell you what you should 
and shouldn’t be doing, essentially.  - Oscar, M, AAS user 
In line with this viewpoint is their desire for doctors to accept their AAS use as an 
informed decision.  One participant’s use of the word “a grown man” indicates the 
desire to acknowledge their decision to use AAS as a mature, informed choice.  This 
participant outlines how they want their decision to be respected, rather than being 
told what to do:  
Like I’m a grown man, like I know what I’m about to do, I know what 
I have been doing and okay, it may not be the smartest thing I’ve ever done in 
my life, but I’ve weighed up the pros and cons.  I’m not asking you to tell me 
what I should do, I’m asking you to help me make it the best version I can, 
you know.  - Peter, M, AAS user 
Participants clearly outline the desire for their choices to be respected, and the 
desire for a more collaborative approach.  However, a perceived power imbalance 
feeds into the categorisation of doctors residing in an “ivory tower” and living a 
“lifestyle of purity”.  The subsequent feelings of subservience and hierarchical 
differences make it a challenge for AAS-using patients to relate to clinicians, thus 
negatively impacting the clinical interaction.  In addition, the roles of doctors as 
being authoritative “gatekeepers” feeds into participant perceptions that their needs 
are not being addressed on their terms and create a struggle to obtain their desired 
outcomes.   
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5.4.2.1.4.  Identity as an AAS-using patient and anticipation of mislabelling.    
Of note is the impact AAS-user’s self-identities and labels had upon the medical 
interaction.  This, combined with their perceptions towards alcohol and recreational 
drug (ARD) users, impacted how they felt when they were being grouped together 
with these individuals.  This identity threat has a notable effect on the interaction by 
resulting in negative emotional feelings, in turn facilitating poorer engagement.   
5.4.2.1.4.1. Self-perceived differences between AAS and ARD use.  Notably, 
there were quite significant differences in the self-perception regarding AAS use and 
ARD use.  For example, AAS use is associated with a strong sense of being a 
responsible individual contributing to society;  
NPA: What differences are there between steroid users and 
recreational users? 
Frank: That’s a hard one, I really don’t know how to put it into words, well 
for me personally steroid use helps me, because of my age the engine in the 
body doesn’t run as smoothly as what it used to and I get a lot of aches and 
pains in my knees and my joints...but you see a lot of the recreational drug 
users that go out at the weekend, going on a bender, some of them in a spot, 
getting into mega debt because they have missed work so I’ve never done that, 
I have never had to miss a day’s work due to it so I think this is totally 
different.  - Frank, M, AAS user 
…But I’m not causing a nuisance to people, I don’t go out stealing to 
be able to afford my steroids, I don’t you know, hide away and sit in a bloody 
alleyway somewhere leaving dirty needles on the floor.  You know, I pay for 
my steroids out of money that I’ve earned from a job that I work.  I’m not on 
the dole.  .  .  If you’re claiming Jobseekers and doing stuff like that, then 
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you’re an idiot in my opinion because you should be focusing on food and 
living.  .  .  I’m safe, I clean everything, I dispose of everything in the sharps 
bin.  The sharps bin goes to the doctors to get disposed of or to a tattooist and 
then they dispose of it for me.  All my empty vials go in a bag, in a 
Tupperware pot, then in the bin.  .  .  I don’t leave needles around for a five-
year-old kid to pick up and jab themselves with.  - Peter, M, AAS user. 
5.4.2.1.4.2. Feelings associated with being mislabelled.  Considering  these 
differences, there is notable anger at being labelled by doctors as a “drug user” due to 
the associations with ARD users: 
Let’s just it boils my blood, there is no way you can put me on par with 
a heroin user or a cocaine user or anything like that, it’s totally different, it’s 
not even in the same ballpark really so it does, let’s just say, boil my blood.  - 
Frank, M, AAS user 
Clearly, participants fiercely value their identity as a functional and responsible 
member of society; their drug use is instrumental and functional.  The purposes are 
for self-improvement.  This is a stark contrast to the perception of ARD users, who 
are perceived as reckless and irresponsible.  Thereby, the consequences of being 
miscategorised as an ARD user, particularly by a medical professional, can be 
unsettling.  For Adam, the additional risk of miscategorisation as a street drug user 
from disclosure led to compartmentalisation and feeling stigmatised after disclosing 
his AAS use.  Adam describes how he feels “dirty” when being categorised 
alongside recreational drug users and “junkies”: 
…It kind of makes you think, “I just feel dirty now.  I just feel I’ve 
been put in that bracket again.”  I suppose, you have your Hollywood image 
132 
 
of your junkie and you’ve just been put in that box.   – Adam, M, AAS-using 
patient 
These accounts show the power of words; how important their self-identity 
and self-perception is.  AAS users wanted their use differentiated from alcohol and 
recreational drug (ARD) use.  These differences appear to be related to how 
contained their AAS use is and the impact on the environment and community (in 
terms of functionality versus non-functionality, resources utilised, and other related 
aspects).  For example, the effects of their AAS use on their society and community 
is different and perceived as comparatively low risk.  However, the negative 
perceptions associated with ARD use (high risk for community and environment and 
using a large number of societal resources) mean there is frustration at being 
associated with ARD users.  Participants felt their AAS use was as a controlled, 
conscious decision made for self-improvement purposes.  In contrast, ARD use was 
considered reckless and non-functional and associated with negative experiences 
such as being in debt or being jobless.  The impact of these perceptions upon the 
interaction are clear, as participants outline feelings of anger and frustration at this 
mislabelling.  These passages highlight the importance of understanding the labels 
this cohort attach to themselves, alongside the differentiation between “functional” 
versus “recreational” use and utilising this within the clinical interaction.   
5.4.2.2.  Doctor themes.  Table 8 outlines two core themes identified  by the 
doctor participants: professional and contextual barriers and the professional role 






Table 8  
Doctor themes and subthemes 
Theme Sub-themes 
Professional and contextual barriers Impact of experience and resources  
Lack of guidelines  
 
Professional role quandary  
Note.  AAS, anabolic-androgenic steroids; ARD, alcohol-recreational drugs  
 
5.4.2.2.1.Professional and contextual barriers.  There was a distinct 
relationship between experience and resources.  Experience was shaped by clinical 
exposure, which in turn also shaped resource allocation for certain clinicians.  A lack 
of either led to uncertainty and difficulty in clinical interactions, or perceived 
difficulty in lieu of direct contact.  This was further compounded by a lack of 
guidelines, which created further difficulties in the clinical interaction by not 
providing organizational safeguards or specialist pathways to seek information and 
help from.  
5.4.2.2.1.1. Impact of experience and resources.  Doctors often commented 
on how rare AAS users were within their typical patient cohorts, alongside the 
limited amount of training provided on substance misuse in general throughout their 
medical career: 
Well it’s not something that, I mean we may have covered it briefly in 
medical school.  I think we had one, our medical training was very much kind 
of case base, so you’d have a case.  I think I recall having one case where it 
was mentioned.  But it’s not covered, and perhaps that’s because it’s not that 
common.  But yeah, it’s a gap in my knowledge, I imagine it’s a gap in quite 
few kind of my equivalent people, my peers.  (Laura, F, ITU). 
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For some clinicians, this low clinical exposure presents problems differently.  
Lorna explains the structured nature of resource allocation and the challenge 
associated with assigning resources to issues which do not appear to be prevalent.  
The problem with a low clinical prevalence rate means limited resources get 
allocated for that particular cohort, in favour of more immediate healthcare concerns.  
As a result, resources are not allocated to cohorts for which a large demand does not 
exist.  Consequently, there can be risks associated with “stepping outside” the set 
targets;  
Sometimes the dilemma is that if you don’t meet your targets you will 
suffer financial penalties.  So, if I put a lot of resources into something which 
no one’s shouting at me as a problem [yeah], I run the risk of missing other 
targets and then losing my service.  So, [I see, yeah] it’s actually, there are 
very strong disincentives these days to actually step outside of what you’re 
commissioned to do… – Lorna, F, Dr (Psychiatrist) 
For Anita, she reflects on the hypothetical prospect of how a lack of knowledge and 
resource availability can impact her role as a clinician during an interaction with an 
AAS-using patient.  Her perceived lack of knowledge and the lack of resources mean 
the clinical consultation would be “tricky”.  Her concerns revolve primarily around 
not meeting the patient’s outcomes:  
Certainly me as a doctor being able to educate the patient that I’m 
doing the right thing giving him the information that I don’t know much 
about it, but also telling him the facts that the resources are very limited.   I 
know I may not be helpful here to him, at that present time, but certainly to 
see people I would be struggling so I get a mixed feeling that the consultation 
should maybe be a bit tricky to what the patient’s expectation may not be 
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fulfilled there and then which I hope he or she will understand why it is. 
(Anita, F, GP).  
The potential impacts of limited exposure were clear; a lack of exposure facilitated 
feelings of uncertainty, and participants reflected on how uncomfortable this lack of 
knowledge made them feel within their patient-physician interactions.  But what 
about improved exposure?  One doctor explained the importance of increased patient 
clinical exposure in improving doctors’ abilities to deal with specific cohorts through 
improved confidence: 
.  .  .  The more you see something the more confident and familiar 
you are just managing off that but the less you see something, the more you 
have to kind of go back to the guidelines and make sure that you know what 
you’re doing.  - Laura, F, Dr (ITU) 
Aman outlines the impact of increased exposure.  Aman, who encounters 
AAS users in a non-clinical gym context as a gym-goer as well as clinically, strongly 
differentiates between AAS users and ARD users and speaks positively of AAS-
using patients: 
We can’t compare these people with the street drug users, abusive of 
over the counter drugs, or the cocaine users or the morphine users or any 
other ketamine users, we compare them no, absolutely not.  .  .  If you are 
talking only about the steroid patients, they’re nice, they’re very gentle, they 
talk to you very nicely and they will tell you the truth that they’re lifting this 
weight and it ruptures or they come up with depression.  .  .  they are 
educated, well mannered, well behaved and they listen to us, they will do 
exactly what we ask them to do as well.  And we do treatment no problem, 
and they’re well mannered, they’re not aggressive.  .  .  And because I’ve got a 
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constant people around me that use steroids, so my vision towards those guys 
has changed a lot.  .  . – Aman, M, Dr (A&E) 
This excerpt highlights how, through regular contact with this cohort in a 
non-clinical context, the increased familiarity has facilitated a more positive shift in 
perspective and confidence when treating this patient cohort.     
5.4.2.2.1.2. Lack of guidelines.  Another key facet was a lack of guidelines 
available to manage AAS-using patients.  A distinct lack of organisational referral 
pathways or clinical guidelines can negatively impact the clinical interaction.  Preeti 
outlines the challenges of working with a niche clinical cohort without accessible 
pathways into secondary care by using the example of gender reassignment patients 
and care pathways.  Here, the feelings of uncertainty are palpable, and the example 
shows clearly how a lack of organizational pathways negatively impacts a clinician’s 
confidence if they are unsure:  
.  .  .  very different [situation], gender reassignment.  It’s 
niche, it presents actually more than it has ever before but managing 
that is incredibly specialist, managing the hormone treatment, 
prescribing the hormone treatment, knowing where to start the regime, 
that is incredibly niche but actually that is falling in primary care but 
under the guidance of secondary care with a clinic for men, 
consultants have got the remit, they’ve got the protocols that they 
want to use for that.  So if I have a patient who comes to me who 
would like to transition, he needs to, I don’t know where to start with 
that so I need to find out how to manage it so that means looking at 
local service, who do I refer him to, so if I have a patient who comes 
to see me who has got a question that I can’t answer I will go and find 
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out the answer, it may not be managing it but it may well be going 
well actually you need to see this person in the sports clinic and it 
might be private.  So that’s the clinical needs, if I’ve got a person ask 
me a question I might not be able to answer it there and then, I might 
not even manage it because it might not be me, it might need to be 
somebody who deals with it day-to-day who is safe, who has the 
experience, who has the credentials to manage potential side effects, 
adverse outcomes, somebody not reacting in the predicted manner to 
their regime, I have no idea where to start with anabolic steroids and 
coming off them, I don’t even know where to start taking them so I 
can’t give you that advice and so therefore I would need to outsource 
that… - Preeti, F, Dr (GP) 
For Preeti, a lack of pathways or guidelines create a serious problem.  
Without that organizational framework and associated backup, Preeti describes 
feelings of anxiety and uncertainty.  And yet the existence of guidelines and 
protocols does not supersede the importance of experience.  For Preeti, even if there 
were appropriate guidelines and resources, Anita describes how a lack of exposure to 
these patients would mean she did not feel comfortable administering care: 
As a GP, I can do many things but should I and that’s where it comes 
down to, that even if I’ve got guidelines and protocols about how to manage 
somebody having issues with anabolic steroids I’m not necessarily going to 
because I won’t have the experience of dealing with it on a repeated basis.  .  . 
- Preeti, F, Dr (GP) 
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5.4.2.2.2.  Professional role quandary.  All participants agreed that 
information and helping with decision making was within their clinical remit.  
However, there was a notable clash regarding management: it was unclear whether 
management was within the remit of GPs or not.  Outsourcing to more 
knowledgeable services or units appears to be a method of professional risk 
management.  Some doctors stated they saw themselves as providing information or 
being an interpreter of information.  The assumption is that there is a large amount of 
information out there, and AAS users might not necessarily possess the tools to 
interpret it accordingly: 
But I guess it’s about providing the high-quality stuff.  And about 
finding a way to direct people to these resources, say for example, if you get a 
steroid user, I might be able to say to them, well, if you’re going to, go to 
here because you know you’ve got safety information, you’ve got a bit more 
about how to use it in a controlled manner obviously I recommend you don’t 
but if you’re going to do it as best you can sort of thing. - Laura, F, Dr (ITU) 
However, this is a paradoxical perspective, as one GP acknowledged wanting 
to give more information but simultaneously lacking the knowledge to do so: 
Certainly me as a doctor being able to educate the patient that I’m 
doing the right thing giving him the information that I don’t know much 
about it, but also telling him the facts that the resources are very limited.  I 
know I may not be helpful here to him, at that present time, but certainly.  .  .  
I would be struggling... - Anita, F, Dr (GP) 
The harm-reduction psychiatrist stated their role would be very similar to 




Well, I guess I would argue that if someone’s got a problem 
controlling their use of a substance, there’s going to be a huge amount of 
overlap.  A lot of the addictive behaviour’s going to be the same.  The 
difference might be in what you do about it, your understanding of what the 
impact might be.  No, a lot of the stuff we do isn’t actually getting people off 
drugs, it’s reducing harm or helping them make changes, making things a bit 
safer, a bit less unpleasant.  So yeah, I mean I would always expect that I 
would be utilising a lot of my skills in say behavioural change, motivational 
interviewing.  I think these things would all be the same, but there are 
specifics that I should know about steroids that I know that I had someone 
else turn up I would have to go and look it up again.  - Lorna, F, Dr 
(Psychiatrist) 
Some saw themselves as an advocate for their patient.  This sport and 
exercise medicine (SEM) doctor perceived their role to be one of risk management 
and patient protection, particularly in an environment where numerous power 
dynamics might be at play: 
If I was the doctor for an amateur rugby club and somebody said “the 
coach has been giving me injections” or “asking me to take X, Y and Z” then 
my responsibility would be to the player who’d been my patient to educate 
them on the risks of what they were doing, the health risks in particular.  If it 
was clear that it was coming from the coach then I’d have to find a way to get 
more evidence, also if it wasn’t clear I’d have to get more evidence, if it was 
clear or if there are others who are saying the same things then I’d have to find 
a way to talk to the coach about it.  .  .  I would talk to the coach about the 
risks of the medication that they were recommending, explain that they were 
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illegal, that there were significant health risks in doing so and also that they 
are in a position of authority and power over the players and therefore that 
would be potentially an abuse of that position if they were requiring them to 
take them. - Philip, M, Dr (SEM) 
These accounts provide a clear clash in expectations and perceptions 
regarding the management of AAS users.  There seems to be a clash in what 
constitutes a doctors’ duty of care, with no clear line of referral or external support.  
Multiple roles exist within the doctors’ sphere of clinical practice; and yet, the role 
when treating AAS users is not well-defined and left to a subjective assessment of 
the practitioner.  This factor can create uncertainty, anxiety and the perception of not 
meeting desired health outcomes on either side of this interaction.  Ultimately, these 
clash in goals between their desired goals (health outcomes) versus the goals of the 
AAS users (performance-related) are summarised in this quote: 
Acknowledgement, yes there is always acknowledgement, yes it 
causes this, yes it causes this but there is always a refusal to do what we want 
them to do.  Because their focus is different and our focus is extremely 
different.  - Aman, M, Dr (A&E) 
Doctors in this cohort expressed uncertainties about their role with AAS-using 
patients.  Self-perceived roles tended to range from an educator role through to 
gatekeeper roles and patient advocate roles.  These difference in perception of roles 
mean there is little structure in what the doctors’ role is within these medical 
interactions.  This lack of clarity facilitates feelings of uncertainty, thereby 
potentially clashing with AAS-using patients desired clinical outcomes and 
negatively impacting the patient-doctor interaction.   
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5.5.  Discussion 
To date, this is the first qualitative study investigating this interaction from 
these two specific perspectives simultaneously.   The concurrent cross-group analysis 
provides a more holistic and in-depth understanding than previously available.  This 
study provides clinically valuable insights into this interaction upon which 
interventions and guidelines can develop.   
The findings from this study emphasise the importance of clinical contact in 
building clinician confidence, particularly with hard-to-reach patient cohorts.  
Professional role identities are fragmented and unclear, leading to inconsistent care 
and clinician uncertainty compounded by the lack of guidelines and resources. 
AAS users often withhold disclosure of their AAS use as a stigma-reduction 
mechanism.  Throughout their accounts, an underlying perception of a power 
imbalance is present, with stigma management methods attempting to mitigate this 
through retaining control.  Roles and expectations of doctor and patient are ill-
defined, leading to an incongruent and inconsistent interaction. 
5.5.1.  Comparisons with other studies 
Due to the novelty of this study with these cohorts in this context, qualitative 
studies do not exist to provide a direct comparison.  However, similar accounts are 
present in different healthcare contexts (for example, in transgender patients; (Poteat, 
German, & Kerrigan, 2013).  The following sections outline comparisons with 
stigma management for AAS users in other stigmatised identity contexts, and 
comparisons with studies investigating clinical uncertainty and exposure for doctors. 
5.5.1.1.  AAS user-specific perspectives.  A comparative survey study 
conducted within the USA by Pope and colleagues (Pope et al., 2004) indicates AAS 
users distrusting doctors and holding inherently negative attitudes towards doctors 
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compared to non-AAS users.  AAS users rated physician AAS knowledge 
significantly lower than non-AAS users, and the majority of participants (56%, 27 
out of 44 AAS users) did not disclose their use to their doctors  (Pope et al., 2004). 
In this study, selective disclosure of AAS use is a carefully controlled process 
treated as a calculated risk-management method.  Through selective disclosure, 
participants focused on prioritising health versus avoiding stigmatisation.  Selective 
disclosure also aims to retain control over medical care obtained, through the self-
perceived relevance of AAS use to a medical problem.  Participants were also wary 
of disclosing due to the anticipation of mislabelling as an ARD user– this led to 
feelings of anger at being miscategorised with ARD users.  This process of selective 
disclosure was also perpetuated by an “us versus them” mentality amongst 
participants; an inability to relate to doctors, alongside prior negative experiences 
deepened the chasm between these groups. 
AAS use is a concealable stigmatised identity as per the definition in Quinn 
(2017); concealable stigmatised identities are “.  .  .  culturally defined as distinct 
from the nonstigmatized, negative stereotypes exist about their character, and poorer 
outcomes exist at the group level.”.  It is well-established that AAS use is associated 
with negative perceptions from the general public (Griffiths, Murray, & Mond, 2016) 
and healthcare professionals (Backhouse & McKenna, 2011; Yu et al., 2015).  
Concealability occurs through various pathways, including withholding disclosure 
(Chaudoir & Fisher, 2010).  We can, therefore, contextualise these experiences 
through a stigma framework.  The effects of enacted stigma (direct negative 
experiences) and perceived stigma (societal and clinical cultural stigma) significantly 
impact medical engagement amongst stigmatised cohorts (Quinn, 2017).  The 
decision to disclose AAS use is not one taken lightly.  A theoretical model is offered 
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through the Disclosure Processes Model (Chaudoir & Fisher, 2010).  This model 
contextualises the when and why of disclosure processes in stigmatised populations.  
In line with this model, participants’ accounts of controlling disclosure revolved 
around anticipating negative effects, such as anticipated stigma, miscategorisation as 
an ARD user and withholding of medical care.  Similarly, a balancing act of 
anticipated stigma versus inappropriate medical care is congruent with the avoidant-
process mechanism in the Disclosure Processes Model. 
One important element which was evident in participants’ accounts was the 
interplay between knowledge and power.  In line with a recent systematic review and 
thematic synthesis, patient knowledge was not enough to participate in a shared-
decision making medical interaction (Williams, Elwyn, & Edwards, 2014).  Power 
was also necessary for patients to feel involved in their care.  Several accounts show 
a clear perception of a power imbalance from AAS users; this took the predominant 
form in their inability to relate to clinicians, as well as experiences consisting of 
request refusals and perception of doctors as service gatekeepers. 
5.5.1.2.  Doctor perspectives.  Doctors’ accounts established that medical 
professionals operate in a very structured way as often as is permissible; 
documentation such as National Institute for Health and Care Excellence (NICE) 
guidelines provide a valuable heuristic for doctors to refer to when treating certain 
conditions.  A lack of guidelines or resources available for medical practitioners 
means there is little to no standardisation of care when working with AAS users. 
Individual experience combined with clinical knowledge of AAS use means 
the perspective each doctor brings to the clinical interaction is undoubtedly more 
subjective than before.  Combined with a lack of clinical guidelines and resources, 
these factors combine to create a potential role quandary as doctors are uncertain as 
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to what is defined as appropriate care for AAS-using patients.  Experience through 
exposure was cited as being important for clinician confidence.  Specifically, a lack 
of clinical exposure was associated with decreased clinical confidence and a lack of 
resources.  The importance of exposure for clinical confidence is not novel; 
intergroup contact has been shown to improve clinician confidence through 
familiarity and increasing knowledge (Pescosolido & Manago, 2018).  The 
participant who had regular non-clinical contact with AAS users felt confident when 
treating them.  They were also more adamant in separating them from ARD users.  In 
contrast, those with limited contact with AAS users expressed greater uncertainty.  
Using clinical heuristics in the face of uncertainty is a well-documented process 
(Eddy, 1984).  However, this risks oversimplification through gross categorisation of 
identities which clash with patient self-perceptions, thereby contributing to poor 
engagement.   
Medical providers’ accounts are consistent with accounts revolving around a 
doctors’ role in shared decision-making practices.  A study examining doctor role 
identities (Yagil & Medler-Liraz, 2015) outlined a process of role adoption 
depending on numerous factors.  Multiple identities and clinical roles were present 
within these accounts, most notably through the difference in perspective regarding 
their role with AAS users.   
5.5.2.  Strengths and limitations of this study 
This study is the first to explore and offer insights into this complicated 
clinical interaction.  UK-wide purposive sampling, both online and in-person, helped 
obtain a wide range of experiences and perspectives.  This diversity in perspectives 
ensured that theoretical saturation was reached.  Recruiting doctors with a variety of 
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experiences with AAS users helped gather a broad set of perspectives and explore the 
impact of contact on doctor confidence. 
Limitations of this study include the all-male participant group for AAS 
users.  This could be due to the increased number of AAS users being male, or 
female AAS users perhaps being less likely to seek help from doctors for medical 
problems.  Female AAS users might have a different experience with doctors; 
however, due to their rarity, it was not possible to obtain their perspective. 
5.6.  Conclusions and areas for further research 
Understanding each side of this clinical interaction is a step towards 
potentially informing public policy and healthcare professionals concerning the 
needs of AAS using patients.  This study offered an opportunity for a niche and 
concealed community to share their experiences and perspectives.  By doing so, 
doctors and other healthcare professionals can begin understanding the specific 
challenges facing AAS users when seeking medical help.  In turn, doctor-specific 
challenges are uncovered and offer an opportunity for doctors to reflect on the 
challenges of resource allocation and clinical uncertainty.  Further perspective 
uncovers the roles of patient autonomy and doctors within the interaction with a 
stigmatised, health-literate patient. 
Much remains to be done to help build clinical confidence with doctors 
working with similar unfamiliar patient cohorts.  In an age with growing access to 
information sources and a growing desire for patient autonomy, there remains a need 
to clarify the doctors’ role in these interactions.  Future studies could further explore 
stigma-management processes within AAS users.  This information would provide a 
greater understanding of population-specific effective harm reduction measures.  The 
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focus should remain on improving access to healthcare services and offer guided 
AAS cessation if deemed necessary. 
In a broader context, the findings of this qualitative study raise potential 
queries regarding doctors’ preparedness for potential future drug decriminalisation 
initiatives; within the context of the “pseudo” decriminalisation of AAS (due to its 
legality for personal possession), the challenges faced by these medical professionals 
raise further questions concerning the impact on medical practice changes in drug 
policy could have.  We anticipate these challenges will be relatable to many other 
practitioners reading this study.   
What this study adds 
The aim of this study was to explore the influential factors upon the clinical 
interaction as defined and focused on by participants.  The key elements of risk 
within this study focus primarily on issues relating to stigma and uncertainty.  The 
primary different in this study is the context of risk differing from the other two 
chapters and the introduction of an out-group perspective regarding risk and PED 
use.  The effects of clinical uncertainty have a demonstrable effect on the interaction 
for PED-users, resulting in patient uncertainty.   
This chapter concludes the empirical studies within this thesis.  What remains 
is the contextualisation of the findings within each study through the use of a 




Chapter 6: Discussion 
The aim of this thesis, broadly, was to explore the perceptions, navigation and 
experience of risks associated with PED use.  These results will be contextualised 
through the lens of the Risk Society Model (RSM) as outlined in the introduction 
(Beck, 1992). Reflections upon the ethical facets associated with researching the very 
topic of PED use and being a cultural insider will be offered as well.  
6.2.   The experience of risk 
The use of qualitative methods meant lived experience was a core component 
of every empirical chapter.  The experience of risk was defined by the perception and 
navigation of risks.  This section highlights how the perception of risk can be 
discussed from a sociocultural perspective and how risk is navigated through the use 
of control.   
6.2.1 Risk perception: A social-constructionist approach 
The results from each empirical chapter demonstrate how risk perception is a 
highly individualised process dependent on several personal and sociocultural 
factors.  The use of a social constructionist approach to hazard navigation is, 
therefore, pertinent for this thesis.  A social-constructionist approach to risk 
questions the problematising of risk, alongside suggesting that risk may be a matter 
of individual perception (Beck, 1992).  Fox’s (2002) paper asserts that hazards are 
constructed socially:   
We may accept that discarded needles and other sharps (possibly 
infected by blood-products) exist as real objects, but in and of themselves, 
these objects do not constitute a hazard.  They become hazardous under 
certain circumstances, principally if conditions arise such that they may come 
into contact with and pierce the skin of a person in their vicinity.  And we 
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know this event is hazardous, not through some ’natural’ quality of this event, 
but because we appraise it as undesired or adverse, based on bodies of 
knowledge about blood and the risks of infection associated with various 
blood-borne diseases such as hepatitis B and HIV.  The transformation of an 
‘inert’ object into one possessing hazardous characteristics  thus occurs only 
as a result of our evaluations of risk, that is, the likelihood of an adverse 
result from an incident.  Such evaluation may be based on anecdote or 
personal experience of danger or security.  More formally, it may be based 
on a particular ’discourse’ (an authoritative body of knowledge): that of risk 
assessment.  Thus it is only in the analysis of risks that the hazard comes into 
existence: if the risk is assessed as zero or close to zero, the inert object 
would remain just that (regardless of whether it ’really’ does possess 
hazardous characteristics).  (Fox, 2002, p. 170, italicised emphasis added).   
This understanding of hazard and risk applies to PED use: in and of themselves, 
PEDs are inert objects.  However, under certain circumstances, and depending on our 
bodies of knowledge and experience, they can become hazardous substances.  This is 
ascertained through the process of risk assessment.  Throughout the three empirical 
chapters, risk assessment occurred on an individual level.  In Chapter 3, the risk 
assessment of AAS use was influenced heavily by societal perceptions of the 
feminine body.  For the women in the study, their ideas of femininity stemmed from 
societal norms.  However, each woman had different boundaries and perspectives as 
to what elements of femininity they were comfortable with “losing” and which 
elements could not be compromised, no matter what.  What it meant to be feminine 
for each participant heavily influenced their perception of the hazard of virilisation 
and, therefore, acceptable risks of side effects.  Besides, the occurrent of virilisation 
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was not the only hazard to consider; the temporal element of permanence was an 
additional hazard.  Thus, risk assessment accounted for their goals, compound 
strength, individual tolerance and their personal boundaries of acceptable and 
unacceptable side effects.   
Chapter 4 outlined the hazard and risk perception associated with 2,4-DNP 
use.  The primary risk here ties into the possibility of dying from the 2,4-DNP use.  
Again, we see an element of permanence; the uncomfortable nature of side effects is 
a hazard considered “worth the price” for the sake of almost effortless and consistent 
body fat loss with the risk of irreversible hyperthermia and death.  Personal values 
and attitudes towards their drug use informed their perception of their 2,4-DNP use.  
Their use of knowledge resources, such as the Internet and the wider PED-using 
community, informed their perspectives on 2,4-DNP use.  Interestingly enough, this 
is evident through the understanding that participants would not tell other individuals 
to use 2,4-DNP; the notable point here is there is a difference in risk assessment 
between personal use and “encouraging” someone else to use 2,4-DNP.  The 
difference in opinions concerning whether they would tell someone else to use 2,4-
DNP can be reflective of how individual the risk-assessment, and indeed perception, 
can be within this context.   
Chapter 5 describes a complex interplay of the individual factors influencing 
risk and hazard perception for AAS-using patients and doctor participants.  Hazards 
for PED-using participants primarily revolved around experiencing stigma and 
possibly not obtaining the care they required from medical practitioners.  Risk 
assessment and the negative societal perception culturally inform hazard perception 
of PED use and drug use in general.  Individual factors amongst AAS users include 
their own AAS knowledge and prior experience with clinicians.  For clinicians, the 
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primary hazard was the danger of enabling PED use.  Clinicians struggled with the 
lack of guidelines and information available; thus, they felt they were entering the 
unknown.  In particular, a clinician’s personal experience and perspective of their job 
role influenced their clinical decision making substantially.   
Therefore, instead of adopting a singular approach to hazard and risk 
perception and management (as per the “scientific” approach outlined in Beck 1992), 
risk perception is a complicated process influenced by many personal and 
sociocultural factors.  Each individual has their values, boundaries and priorities with 
which to analyse the hazards and benefits of PED use.  This extends beyond the 
PED-using community; we can also see this amongst the doctor participants within 
chapter 5.  To ignore the sociocultural perspectives that each physician has would 
ignore some crucial insights into their clinical decision-making.   
6.2.2.  Risk navigation: The element of control 
Risk perception is highly individualised; as mentioned previously, personal and 
sociocultural factors play a large role regarding what participants perceive to be an 
acceptable risk and what is unacceptable.  Building from this notion of risk 
perception is the navigation of risk through control.  Whilst this element of exerting 
control is more universal across participant accounts, the specific acts of exerting 
control remain very individualised and dependent on personal choices and 
experiences.  The navigation of risk through exerting control could be considered a 
method of anchoring self-identity; control entails implementing and adhering to or 
even reframing personal boundaries in the context of unwanted change, which in turn 
help retain an individuals’ sense of self and identity.  This relates to the body 
remaining an anchor within an increasingly uncertain society; control is a form of 
self-expression and identity, expressed in different ways due to many individual 
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influential factors.  What may be one person’s perception of “control” is another 
individual’s perception of “risk”.  This is a direct effect of the risk perception and 
identification processes explored earlier.     
Throughout all three studies, we can see control being exerted in a myriad of 
ways and how a lack of control can create challenges and difficulties.  
6.2.2.1.  Navigating risk relating to physical side effects.  In empirical 
chapter 3, the primary risk associated with PED use was namely that of virilisation 
associated with AAS use.  Yet, participants still understood this possibility and 
continued to use AAS for their end goals.  In line with a sociocultural perception of 
risk, the hazard in question (permanent virilisation) had differing levels of risk 
(probability of occurrence) attached depending on the participant’s boundaries and 
goals.  Additionally, different participants had different boundaries and ways of 
mitigating this hazard as much as possible.  Participants took control over their 
dosages, compounds used and the advice they obtained from the community and 
other sources.  Particularly with coming off, for participants, it was an active 
decision-making process which was carefully considered and made for their own 
personal reasons.  Nevertheless, side effects still occurred.  Overall, the experiences 
are a complicated mixture of positive and negative viewpoints; the increase in 
strength and lean body mass was overshadowed by the development of masculinising 
features for some.  For some, their personal boundaries of “acceptable” side effects 
were violated, leading to a drastic shift in identity to compensate.  This deviation 
from their identity is uncomfortable and forces some participants to change their 
perception of their own gender identity.  The concepts of biographical flow and 
biographical disruption in chapter 3 contextualise the narratives presented of this 
phenomenon.  In the context of control, this could be seen as taking ownership of 
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their identity either through stopping AAS use to retain a feminine identity or 
reframing their own identity.   
Chapter 4 outlines the risks associated with 2,4-DNP use.  Within this cohort, 
the primary risk was the possibility of death.  2,4-DNP is a compound which, as of 
now, does not have an antidote in the event of an overdose.  Each participant, again, 
took measures to mitigate their own risks associated with 2,4-DNP use and its risks.  
Just as with the female participants in chapter 2 controlling the dosages, compounds 
used and acceptable side effects, participants controlled their dosages, diet, training 
and environment very carefully when using 2,4-DNP.  This careful control exhibited 
concerning their 2,4-DNP use demonstrates the respect they hold for the compound 
and its lethality.    
Through mitigating physical side effects, PED-using participants reinforced 
their identity of individuals focused on being safe and in control.  The mitigation of 
side effects involved controlling dosages, choice of substances and cycle lengths 
amongst other factors.  The implementation of limits and, when considered 
necessary, the creation of new limits is indicative of a paradoxical process of “static 
flexibility”;  adhering to certain personal limits, yet willing to reframe and shift in the 
context of new information or bodily changes.  This concept of “doing it properly” 
ties in with similar principles covered in Monaghan (2002) and is a key factor in 
differentiating these individuals from “users” to “abusers” as defined by individuals.  
However, risks to identity still remain, as will be explained next.     
153 
 
6.2.2.2.  Navigating risk to identity.  All three studies discussed the 
relationship between risk and identity.  Of note, one consistent finding from each 
study is how the experience of stigma is considered a psychological hazard for PED 
users.  This finding corroborates the finding in Monaghan (2002) regarding stigma 
and PED use and builds on the principle of being safe and controlled individuals.   
As described in chapter 5 and previously explored throughout, PED-using 
participants do not perceive themselves as “drug users” in the same vein as 
recreational drug users.  PED-using participants describe the anger and discomfort 
experienced when being labelled a “drug user” alongside recreational drug users by 
doctors.  For these participants, PED use is a form of self-improvement and a 
purposeful, goal-oriented process.  Whether this is through aesthetic, occupational or 
performative goals, PEDs themselves are an instrument utilised for the purpose of 
self-set goals.  Thus, the separation between PED “users” and recreational drug users 
who are termed “junkies” within this study is apparent.  This separation corroborates 
the experiences outlined in Monaghan (2002).  This identity differentiation has been 
seen previously in other non-PED contexts, namely under the name discursive 
discrimination (Rødner, 2005; Boreus, 2004). 
The concept of discursive discrimination within a drug-use context has been 
explained in greater depth in Rødner (2005).  This study outlined the difference 
between self-presentation and the concept of the “Other”.  The concept of the Other 
was outlined in Boreus (2004) through a process called “othering”.  In short, 
individuals in the study overemphasised good properties and actions and 
underrepresented bad behaviour during the self-presentations.  Concurrently, they 
emphasised the bad behaviour and actions of “the others” and underrepresented the 
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good behaviour and action of “the others”.  Any similarities were consequently 
downplayed, or not even mentioned at all.   
Of note is the particular point about this identity separation from recreational 
drug users as a response to a hostile social environment which attaches negative traits 
to drug use.  This is further enforced by the accounts given by physician participants, 
which tended to be negative about recreational drug using patients.  Thus, for AAS-
using patients, this separate identity is indicative of moving away from the 
perception of “deviance” and all that is associated with drug use to form a positive 
self-identity.  PED users outline how their use is defined by research, careful control 
and mitigating risks associated with PED use.  Of note is the association of PED use 
with self-improvement, a positive goal and motivation for participants.  Recreational 
drug users are termed to be “junkies”, alongside associations with being a “drain” on 
society, being diseased (through addiction), being dependent and other similar ideas.   
Yet there was no mention of non-PED drug users who instrumentalise their drug use 
for self-improvement purposes.  This could perhaps be due to the “Othering” process 
outlined above and how similarities are downplayed or not mentioned at all.   
This identity separation makes further sense in the context of empirical 
chapter 5.  Doctors with limited or no exposure to AAS users associated them under 
the same umbrella as recreational drug users.  However, the perceptions and attitudes 
towards recreational drug users was almost entirely negative.  Thus, the identity 
separation of PED “user” rather than “drug abuser” is understandable amongst a 
population who anticipate negative reactions and stigma due to their PED use.  For 
these participants, the experience of stigma and the negative associations with being 
a “drug user” are noticeable throughout their accounts.  It goes without saying that 
the experience of unwanted stigma within their interactions is a highly negative one.  
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Encountering stigma can be embarrassing, upsetting and cam create a negative 
emotional effect.  Additionally, experiencing or anticipating stigma can negatively 
impact engagement with medical and harm reduction services.  This is demonstrated 
through how participants treated disclosure as a risky process.  Participants mitigated 
this risk through controlling disclosure of their use.  This is in accordance with the 
Disclosure Processes Model (DPM), outlined previously in chapter 5.  Similar 
processes can be found within empirical chapter 3, as some female participants 
outline how they control who knows about their AAS use.  However, whether this is 
due to the stigma associated with female use specifically or AAS use in general 
remains a topic for further research to clarify.    
PED-using individuals mitigate the psychological risk of stigma and 
associated harms through a complex identity construction; one which focuses on 
labelling themselves as responsible, controlled users who do their research and are 
able to contribute to the society they live in.  Their aims are for the purposes of self-
motivation and, in some cases, self-expression of their desire to mould their body as 
they see fit.  This is a clear antithesis to the identity of the stereotypical “drug user” 
as defined by society, alongside the negative connotations which arise from that 
label.   
The same identity trait of “being responsible” extends to the doctor 
participants within chapter 5.  Doctor participants had clear cut ideas of what it 
meant to be a doctor, and what this role entails.  In line with their self-perceived 
identities were their ideas of appropriate care; what does enabling mean versus 
management? For some, being a responsible doctor meant not going beyond what 
they would consider to be professional duties, for fear of stepping over professional 
boundaries.  Yet this was clearly inconsistent, as what constituted to be professional 
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boundaries were very individualised and dependent on a number of factors such as 
experience and resources.   
6.2.2.3.  Navigating risk via knowledge and information gathering.  The 
experiences of information gathering and analysing were outlined in a multitude of 
ways throughout each study – some female AAS users describe how they did 
extensive research before “diving into” the unknown of this new path, whilst some 
preferred adopting a more “experiential” learning style.  Doctors and AAS-using 
patients outline how they got their information about AAS, though to a lesser extent 
than in the other empirical chapters.  In chapter 4, results from the 2,4-DNP 
qualitative chapter outlined how participants managed their online information intake 
and sources carefully.  Control extends beyond controlling dosages and disclosure; 
control also exemplifies where participants got their information from concerning 
PED use.   
In line with another element of risk society, Giddens (1999) discusses the 
concept of globalisation.  Globalisation is defined as the strengthening of global 
social relations connecting distant locations to the extent that events occurring 
thousands of miles away impact local occurrences and events (Giddens, 1999).  In 
this context, we can use the cyber-networks and improved information access for our 
participants as an example.  Participants derived their information from diverse 
sources.  Thanks to the Internet, journal articles and academic book chapters can be 
accessed as easily as “community experts” from across the world.  Nevertheless, in 
line with Beck’s (1991) risk society, this increasing technological advance has 
brought its own challenges.  This is arguably the key unexpected risk associated with 
PED use.  Conventional wisdom would not necessarily place having greater 
information and resources as a potential risk; on the contrary, it would be seen as a 
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benefit.  However, now faced with more information than ever before, the risk lies 
with carefully choosing the correct information sources.  Which sources of 
information are correct?  Which individual to trust?  How do I know this advice will 
not harm me?  With greater choice comes, in a way, greater risk.  Whilst a participant 
might have been exposed to a limited information pool previously, advocating for 
“gentler” cycles, they might now come across communities that advocate for harsher 
and, potentially, dangerous cycles.  They might access information they are unable to 
interpret appropriately, such as journal articles.  They might gain greater access to 
compounds through an improved network of vendors.  The associated risks with this 
are numerous; what is the purity of the substances?  What about the dosages?  How 
do I know what I am getting?  These questions were outlined throughout.  Chapter 3 
outlines how female participants demonstrated this aspect through doing extensive 
research and choosing sources they trusted.   
Nevertheless, the specific impact of the Internet within the context of AAS 
use and risk, whilst it has been elucidated to a degree in all three studies, is 
challenging to pinpoint clearly.  Future efforts need to be made in order to 
understand the impact greater accessibility to other communities and information 
sources can have concerning PED use.   
6.3.  Limitations and reflections 
This section will briefly outline some limitations associated with the 
empirical works, as well as provide in-depth reflections on the ethics of researching 
PED use and being a cultural insider.  
6.3.1. Limitations  
Chapter-specific limitations are outlined in more detail within each empirical 
chapter. The  primary limitation of the work presented in this thesis is locality of the 
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participants.  Participants were recruited from around the world, primarily using 
online recruitment methods.  As thus, the legislative context is dependent upon their 
location throughout.  Nevertheless, the worldwide perspectives obtained throughout 
these works highlight strong similarities in experiences, regardless of legislative 
context.  Several aspects of the PED-using experience and risk perspective are 
universal, transcending locality and legislation.  
An additional limitation to consider is the typology of participants 
interviewed within these studies. PED users are a broad category of individuals – as 
outlined in each empirical study, each individual makes particular choices and 
decisions regarding their PED use. However, the individuals who volunteered to 
participate within these interviews were, on the whole, self-aware and highly 
conscious of their decision to use PEDs. Aside from one or two individual, every 
PED-using participant discussed the in-depth research they conducted and the 
measures they took to mitigate their harms. Oftentimes, they were experienced PED 
users as well, educated and aware of the risks and hazards associated with their use. 
While the aim of qualitative research is not to generalise to an entire population, 
more perspectives from newer users or those who have a different perspective on 
PED use would have provided accounts from other typologies of PED users. 
Nevertheless, the unintentional focus on these participants has provided greater 
clarity and perspective on what harm reduction and risk mitigation strategies look 
like, as well as potentially providing ideas for practitioners on facilitating within-
community experts and educators to promote such practices to those who may be less 
inclined to mitigate the risks associated with PED use. It should also be reiterated 
that the aim of qualitative research is not to generalise to an entire population – 
rather, the aim is to understand in a specific context a particular experience from an 
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individual’s perspective. A similar point can be extrapolated to physicians in 
empirical chapter 3 – physicians on the whole had little to no clinical experience with 
PED users, except for one individual who had non-clinical experience and exposure 
to PED users. Though one physician was contacted who worked extensively with 
PED-using patients, the conversation was not in a research context and thus could 
not be incorporated into the final analysis. A future study examining the perspectives 
and experiences of physicians working directly with PED users could be conducted 
to determine what clinical exposure and greater awareness can do for this particular 
interaction.  
6.3.2. Reflections on the ethics of researching PED use 
It is important to consider the broader ethical issues which in the context of 
PED use research. Aside from the more specific ethical considerations discussed in 
each empirical study, there are greater overarching facets to be considered. With this 
in mind, one example comes to mind.  
I had signed up for a network with other academics and professionals who 
were working in the realm of human enhancement drug use. My interest in 
researching 2,4-DNP from a harm reduction perspective was therefore made public. 
Shortly after, I received an email from an academic working in toxicology, 
exclaiming their surprise at me receiving ethical approval to do research with such a 
powerful and dangerous compound. They strongly stated their disapproval and 
suggested research with this particular substance should not occur due to the risk it 
poses.  
In my mind, researching these substances seemed straightforward – one of 
the reasons I wanted to do this research was to benefit the community. After all, a 
hallmark of ethical research is the benefit it offers to the community it is researching 
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(Liamputtong, 2007a). Yet questions came into my mind: what did it mean to be 
ethical? Why was researching these substances not considered ethical by some 
people?  
To examine this further, we need to consider the concepts of ethics and 
morality as applied to research. It is widely acknowledged there are three 
overarching components relating to ethics in research: autonomy, beneficence (and 
non-maleficence) and justice (Orb, Eisenhauer, & Wynaden, 2001). Autonomy is 
stated as recognising the rights of participants; their rights to voluntarily participate 
or decline participation, the right to withdraw from the study at any point without 
obligation to give a reason and without threat of repercussions. Beneficence outlines 
that the research must have benefits which outweigh the risks and be worthwhile in 
and of itself (Marshall, Singer, & Clatts, 1999; Orb et al., 2001). Related to this, non-
maleficence is the principle that possible harms must be mitigated and prevented 
where possible (Carpenter, 2018). Justice relates to the principle of sharing and 
fairness, stating that participants must not be exploited and abused during the 
research process (Carpenter, 2018; Marshall et al., 1999; Orb et al., 2001). Of these 
broad principles outlined, the focus of this particular section will be on autonomy 
and beneficence, in order to explore the ethics of researching PED use. The ethical 
principle of justice has been expanded throughout the thesis through the outlines of 
procedural ethical protocols.  
It is imperative to explore some potential reasons why these substances 
should not be researched in this capacity. Two key objections will be noted here and 
subsequently critiqued, through the lens of the principles of beneficence and 
autonomy. The first objection is a ideological extrapolation of the immorality placed 
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upon PED use by society. The second objection arises from the interaction I 
described earlier.  
Objection 1: Using these substances is immoral, ergo they should not be 
researched.   
Though this objection might seem very extreme, it is akin to the argument 
that those who use these substances (and ARDUs as well) should “just stop using 
them”. Not researching a phenomenon on the basis of morality is, at best, a tenuous 
objection and at worst an immoral and unethical objection, thus violating the ethical 
principle of beneficence. Morality is a fluid concept, ever-changing and adapting 
throughout time (Marshall et al., 1999). Why is PED use immoral in particular? 
Because it could be considered “cheating”? Is it cheating if participants compete in 
untested federations or use it without competing in any discipline at all? What rules 
have they violated?  
This trail of thought potentially deprives participants of sharing their 
experiences and perspectives and works to stigmatise these behaviours, thus 
impacting help-seeking and creating other negative outcomes for participants 
(Marshall et al., 1999). This is a clear violation of the non-maleficence principle.  
Objection 2: Using these substances is dangerous. Ergo, we should not 
research them for this reason.  
As researchers, we must exhibit caution with the notion of research enabling 
such behaviours. This objection risks expressing ignorance and imposing a 
paternalistic outlook. The notion of paternalism and drug-use research has been 
explored in the context of addiction studies (Pickering, 2018). As qualitative 
researchers, it is imperative that care is taken to not make assumptions for 
participants and individuals within the community, thus violating the ethical 
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principle of autonomy. It is the researcher’s duty to respect the fact that these 
participants have made the decision to use PEDs and conducted the appropriate 
research to do so. They are aware, more often than not, of the risks and hazards 
surrounding the use of these substances, as outlined from the results of the empirical 
work within this thesis. Qualitative research gives participants the opportunities to 
share their experiences and perspectives. Particularly from a harm reduction 
paradigm, it is imperative we accept that participants and others within the 
communities will use PEDs. As researchers, we must move away from a 
prohibitionist and reductive risk approach and move towards collaborating with these 
communities to understand the use better and explore their experiences in an 
empowering manner. This can help not only shed light on their experiences and 
perspectives, but also help shape the care they may receive from medical 
professionals and others in that area.  
In summary, I suggest that not researching PED use in a harm reduction 
context is unjust and unethical. Research has previously shown how depriving 
similar populations the opportunity to participate in research can result in further 
harms to these groups (Bell & Salmon, 2012). It deprives participants of their 
opportunity to share their perspective and experiences, thus removing lay 
experiential accounts from the literature. It removes individual autonomy from 
participants, making the decision on their basis that their use is dangerous and 
morally wrong. It is also paternalistic and patronising, imposing moral and ethical 
values on their behaviour from a prohibitionist and protectionist perspective. 
Reflecting on the aforementioned experience now, several years later from 
the first-year PhD student I was at the time, it is clearer that it is a matter of 
perspective. This particular academic may not have considered it ethical due to his 
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perspective; as a toxicologist, they would be considering the substance from the 
angle of the death and destruction it has the potential to cause. Yet, this runs the real 
risk of preventing meaningful research and accounts to exist which can influence 
harm reduction and healthcare decisions, as well as provide information to a 
community committed to being educated about their PED use.   
6.3.3. Reflections on being a cultural insider  
At this stage in the thesis, it is important to reflect on the role of being a “cultural 
insider” (Suwankhong & Liamputtong, 2015). For example; What does it mean to be 
an “insider”? What benefits did it lend me in this research? What are the pitfalls?  
Discussions revolving around insider and outsider perspectives in qualitative 
research has been ongoing and continues to be extensively discussed (Dhillon & 
Thomas, 2019; Suwankhong & Liamputtong, 2015). The term “cultural insider” 
denotes a researcher who is “inside” the community or population they are studying 
– also known as a “native researcher” (Suwankhong & Liamputtong, 2015). Being a 
cultural insider is said to offer a range of benefits which are conducive for qualitative 
research; namely, the cultural commonalities associated with a particular population 
lend an advantage in terms of having an underlying and in-depth understanding of 
behaviours, values, beliefs and knowledge (Dhillon & Thomas, 2019; Suwankhong 
& Liamputtong, 2015). However, it is not without its challenges either, particularly 
in an ethical context (Dhillon & Thomas, 2019).  
At this point, it is important to establish how I am an insider – as previously 
established, I was a competitive powerlifter at a high level for a number of years. I 
am privileged enough to have peers within the community who I know well and have 
had sustained engagement over a period of years. In the beginning of my research 
journey, I struggled with the insider/outsider dilemma – being from a positivist 
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background, I was intent on keeping my two identities separate, to “reduce bias”. 
However, I realised this would not work particularly well while recruiting for the 
first study I conducted (the qualitative 2,4-DNP study). Below, I discuss a particular 
experience in this context in greater detail from a diary I maintained:  
I could feel my heart beating in my mouth. My hands went clammy, 
my mind was filled with a buzzing noise of sorts. I’m pretty sure I even 
started sweating. A strange fight-or-flight feeling overtook my body. I 
thought I had done ok – clearly not. Why was this happening? Why was I 
feeling a knot in the pit of my stomach?  
You would think I was talking about being in a competition. In fact, I was 
attempting to recruit from a performance enhancing drug forum for a study. 
However, it had gone down faster than a lead balloon. The members were 
extremely suspicious (“definitely from the BBC, ignore them”) verging on 
almost caustic and interrogatory. It was in the beginning of my academic 
career – not the best introduction. I realised, very quickly, that I had gone 
about this totally the wrong way.  
This was the incident that lead me to think about my role as an 
athlete/researcher. I thought to be totally objective, and distanced, I would 
merely write a short sentence about the study, offering no insight to myself. 
Boy, was I wrong. It completely changed my perception of recruitment in the 
community; this was MY community, one I am a member of. How would I 
feel if someone did something similar to me?  
My partner raised similar questions: ‘What on earth were you thinking? That 
was a stupid approach, and you know it.’ Deep down, I felt shame and 
anxiety. Was it going to be this difficult?    
 
I had to totally reconsider my approach to recruitment after this. I went on 
another forum. This time, I took the time to create an account, contribute to 
the discussions where possible. Not only because I have ‘lurked’ (read: didn’t 
take part in discussions), but because it was a smaller, more intimate 
discussion.  
This time, I came prepared with all the documents: ethical approval, my 
university card, the ethical protocol, any document they might care to read. I 
went to the administrator (or gatekeeper) of the group. I wrote a longer, more 
detailed account of who I was (both as an athlete and a researcher), why I was 
doing this, what this study would entail, and other pieces of information. I 
made clear that I was not a journalist. I asked for permission to recruit from 
that group. I felt that similar sense of dread and anxiety creeping up. But I 
had to bite the bullet, and just do it. After all, you only fail if you don’t even 
try, right?  
‘Let me talk to the others, and see what they say’ they said. And so I waited. I 
kept contributing, and anxiously waited and waited. But it worked – I was 
given permission to recruit from the forum! To say I was delighted was an 
understatement.  
This time, I put a huge amount of effort into the recruiting talk. I was very 
clear and concise, I offered proof of my identity. And even then, people were 
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sceptical. People from the other forum were exclaiming they had ‘run me out’ 
of the other one, and they would ‘run me out’ of this one too. However, I 
knew I had shown the gatekeepers proof. I was more solid in my foundation 
and my information. This time I was not scared off. I explained, clearly, what 
I was wanting to do and they were welcome to look at the documents I 
provided the gatekeepers. They never took me up on that.  
 
This situation led me to evaluate my role as a researcher and athlete – how do 
I deal with a community of which I am a member, that I have friends in? 
Through the above venture, I made new connections, new friends. And 
maybe some might say that is a violation of researcher boundaries. However, 
in a discipline where it is exceedingly difficult to recruit from (and has been 
noted many times), forming personal connections with people is important. 
They want to know you are genuine, that you understand their points of view, 
that, most importantly perhaps, you won’t demonise them. The gym-going 
community are deliberately secretive for a reason; the constant stigmatisation 
of their activities have led them to be hostile and aggressive towards 
‘outsiders’, whom they perceive might share the same negative viewpoints as 
the non-gym going population.  
From my first attempts, I felt shame partly because I was an outsider in my 
own community – I was seen as a researcher first, as I did not disclose my 
athletic side. After that incident, I am more open to any potential participants. 
I tell them who I am, what sports I do, and emphasise that I am also a 
researcher. I cannot give them advice on certain elements of their sport, but 
we do have discussions on various topics. I aim to make them understand that 
I am not judgemental, I understand some of their thought processes. I make 
an effort with the gatekeepers of each group.  
 
This experience highlights the benefits which arise from being a “cultural 
insider” in this context. Due to my sustained engagement within this community, I 
have come to understand how their perceptions, attitudes and knowledge of PED use 
have come about, and have listened to many conversations surrounding the risks and 
hazards associated with their PED use. There is trust on both sides of the researcher-
participant interaction as they don’t fear stigmatisation or facing judgement. They 
feel their perspectives and experiences will be understood better and perhaps, in their 
eyes, portrayed in a fairer light. My understanding of the compounds that members 
of the community would use, alongside dosages and cycles and the purposes behind 
these cycles, meant participants could discuss their use without “sanitising” terms or 
experiences in greater depth than someone who may not have this knowledge.  
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And yet, being a cultural insider is not without its difficulties and pitfalls. For 
example, it is all too easy to take a phenomena or experience for granted due to your 
repeated exposure to it (Suwankhong & Liamputtong, 2015). There are two key 
methods I utilised to help combat this: firstly, the inclusion and perspective of co-
authors who are “outsiders” in the communities being researched. The benefit of 
having an “outsider” perspective is clear – they are able to see experiences or 
phenomena in a different context, having had no prior engagement or experiences 
with this particular community. This is important, particularly in the context of 
disseminating results to outgroup populations and communities who will benefit 
greatly from understanding these experiences. Each of the empirical studies within 
this thesis were conducted alongside co-researchers who did not engage with this 
community, and thus can be considered “cultural outsiders”.  
Despite being a cultural insider with the PED-using community, I also 
experienced what it meant to be a cultural outsider in the final empirical study. I am 
not a medical doctor – however, both of my parents are medical doctors. I have 
grown up with a simultaneously distant and detailed understanding of what it means 
to be a doctor within the NHS – distant because I am not a doctor and thus do not 
understand the day-to-day life from a direct experiential perspective. Yet, it is still 
detailed, as I am privy to the discussions of the day-to-day events from a young age, 
perhaps moreso than the general population. As has been outlined previously, being 
an insider/outsider can perhaps be considered a continuum (Dhillon & Thomas, 
2019). This was highlighted for me through the final empirical study – that perhaps 
being a cultural insider is not as essential for all research populations. In the context 
of the doctor/AAS study, perhaps it was not as imperative to be a cultural insider – 
for example, doctors are not stigmatised for being a doctor, whereas PED-using 
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individuals are stigmatised due to their use. Certain points I picked up on during 
interviews were points they had never considered before – we were able to explore 
them on account of my outsider perspective. 
The second method is the use of bracketing interviews. Bracketing, as defined 
by Ashworth (1999), is the ongoing process of revealing the lived experiences of 
people by setting aside the researcher’s presuppositions and “ready-made” answers. 
This is particularly relevant in the context of researchers who have lived experience 
or a pre-existing exposure or knowledge to the area of study (McNarry, Allen-
Collinson, & Evans, 2019) – while being a cultural insider can offer numerous 
benefits as outlined earlier, there are also particular challenges which arise from 
being familiar with the phenomenon in question. The aim of bracketing in the 
research context being studied is to help reflect on, and be critical of, my exposure 
and knowledge of the topics which were being studied currently as a result of my 
connections within the powerlifting and bodybuilding communities. Throughout the 
thesis, I had two bracketing interviews – one undertook exploring my perspectives on 
being an insider and a female powerlifter alongside research. The second one was 
taken prior to the IPA study. The aim for both of these was to reflect on and expand 
on my exposure and experiences with the topics of AAS use in these contexts, as 
well as my role as a researcher. Similar to McNarry, Allen-Collinson, and Evans 
(2019), these interviews gave me the opportunity to be reflexive and critical of my 
underlying experiences and perspectives. For example, an excerpt from the first 
bracketing interview I had explores my feelings quite succinctly:  
So it’s kind of like trying to maintain, it’s kind of the weird kind of balance 
between objectivity and also being introspective [mm-hmm], like, and what, which 
bits do you pick to be objective about, which bits do you pick about kind of being 
maybe a little bit more personal about, you know. And how do you make sure the 
two kind of mix in a nice, fluid way as opposed to kind of being too objective so 
yeah, talk enough about the personal stuff or being too personal and not being 
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objective enough because the last thing I want to do as a research is kind of try to sell 
something. I’m not trying to sell anything. I’m just here to tell a story, to tell a 
narrative from my perspective which may or may not be applicable to most people 
though I think some elements are quite common, are quite universal amongst other 
competitors and I kind of approach it from that angle. So it’s something I have to 
always bear in mind when I have a thought and I’m like, ‘Am I, is this being 
unnecessarily opinionated or is this actually a valid kind of observation? Am I 
casting judgement on this observation or am I keeping completely neutral as it 
were?’   
 
Reading this again, the challenges I faced revolved around the battle of 
“objectivity” versus “subjectivity”. This psychological tug of war is not a new 
concept – qualitative research welcomes the insider perspective and acknowledges 
how underlying life experiences and exposure to research phenomena can shape 
researcher analyses and perspectives (McNarry et al., 2019). Whether a qualitative 
researcher can ever be truly neutral is heavily debatable. Yet, as outlined by this 
interview, perhaps it is not about being more “objective” or “less” objective. It is 
about recognising our underlying experiences and perspectives which might impact 
our analyses and our reflections on the phenomenon at hand. These bracketing 
interviews help clarify the clashes in our mind between being a researcher and being 
a cultural insider. Without a doubt, the bracketing interviews helped clarify my 
position and my goals with the research, as well as consider how specific 
understandings or experiences might shape the end result. As a novice qualitative 
researcher, it was important I engage in the self-reflexive and critical processes 
associated with being the tool of data collection as the interviewer. Bracketing 
interviews helped me in this regard immeasurably.  
Ultimately, being a cultural insider has been a benefit throughout this thesis. I 
was able to access individuals and communities who may not have been so 
forthcoming for an “outsider researcher”. And yet, I was still able to benefit from 
outsider researcher perspectives and the fresh perspectives they can provide. Being a 
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cultural insider can have many benefits in the context of researching stigmatised 
groups (Liamputtong, 2007a). However, it is important to conduct “cross-cultural” 
work to bring fresh perspectives that someone who has been within the community 
for so long may have missed. Engaging in bracketing interviews has been a positive 
experience, helping clarify my positions and my understandings. Both identities have 
their benefits and their pitfalls – integrating both perspectives has helped create more 
holistic narratives which can potentially benefit a wider readership.  
6.4.  Practical implications and future directions 
One question remains; what meaningful and practical messages can be 
obtained from this thesis?  The answers to this are provided by the participants.  In 
line with co-productive principles outlined in chapter 1, these practical implications 
are derived through giving participants the opportunity to share their experiences and 
perspectives.   
For PED-using participants, medical interventions need to take advantage of a 
group who consider themselves proactive regarding their health and their PED use.  
Thereby, effective interventions should ideally include service design and provision 
separate to those distributed to other drug users.  This would account for the identity 
separation from those who use recreational drugs.  Furthermore, efforts should be 
made to include more community leaders to drive harm reduction initiatives.  These 
individuals can help bridge the gap between non-community healthcare workers 
(such as doctors) and those within the community.  After all, they have outlined the 
importance of relatability and lived experience when it comes to getting their 
information.  Other interventions which can help improve the health outcomes of 
these individuals could be to conduct monitoring blood tests and other similar 
measures.  This will help highlight any potential health risks much earlier than would 
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otherwise be detected and give a chance for PED users to mitigate these potential 
issues.   
From a clinician’s perspective, educational resources and knowledge should 
be provided.  This should consist not only of information about PEDs, but also 
concerning the typologies and perceptions of those who use PEDs to help facilitate 
an improved clinical interaction.  Information on what patients who use PEDs want 
and guidance concerning appropriate management techniques would be beneficial for 
doctors encountering this clinical cohort.  This could help give clinicians the tools 
and knowledge to work with a PED-using patient and thereby reduce clinical 
uncertainty.   
Aside from the specific directions outlined in each empirical chapter, some 
general recommendations could be made.  For example, future research could 
include investigating the element of stigma and PED use in much greater depth.  
Throughout each study, the impact of stigma on disclosure was clearly outlined; yet, 
much of the information was focused on the use of PEDs in elite sports, rather than 
on a “grassroots” level.  One potential  research idea could include evaluating the 
presentation of PEDs throughout the media and exploring discourses associated with 
PEDs, either nationally or globally.  This would provide a deeper insight into the 
societal perceptions of PED use and the effects this can have on PED-users.  Whilst 





Chapter 7: Final reflections  
The questions asked within this thesis were simple: how is risk perceived, 
experienced and navigated in a PED-use context?  Before undertaking this research, I 
felt there were two sides of me; one was the competitor who was embedded within 
the community as a peer and friend long before undertaking this research.  The other 
side was of the academic; I felt I had to uphold a stance of objectivity and distance.  
This created an inner clash between these facets of my identity; how could I 
consolidate them whilst conducting this research?  While undertaking literature 
reviews, the amount of information available on PEDs was vast, almost 
insurmountable in amount.  Yet, very little of it comprised of actual, lived experience 
of individuals who use these compounds.  Amongst the case studies of death or 
severe injury, the animal studies, in vitro studies concerning PED use, there was very 
little literature available concerning the lived experience of PED use.  I could not 
understand how polarised the literature was.  Considering the potential side effects, 
would we not want to help individuals who use these substances?  If so, how do we 
help them?  How can we make recommendations without understanding their 
perspectives and experiences?  How the outgroups might perceive risk and hazards 
does not appear to be the same as those within the community who use PEDs.  
Thereby, this was the key “problem” I was intent on rectifying.  Qualitative inquiry 
has given me the opportunity for those within this hard-to-reach population to share 
their thoughts, perspectives and lived experiences.  My position within the 
community gave me a unique ability to access participants who would otherwise be 
inaccessible.  This is a privileged position which I am aware of.  
The primary finding from all three chapters boils down to this; risks are not 
so black and white; instead, they exist in a “grey area” which is shaped by the 
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individual’s experiences, knowledge, understanding, and other facets of  their 
persona and sociocultural environment.  Navigating the risks associated with PED 
use is not as simple as merely mitigating the physical side effects.  How can the 
hazard of experiencing stigma be mitigated?  How does a PED user combat the 
overwhelmingly negative perspectives placed on these actions?  What about the risk 
of being mislabelled as a recreational drug user, or worse, a “junkie”?  These insights 
would not have been obtained if qualitative work had not been conducted to explore 
their very perceptions and experiences.  Lived experience is a powerful tool in 
understanding phenomena as complex as this in great detail.  Understanding how 
they navigate the risks provides a solution to a very tricky problem; for example, to 
mitigate the side effects encountered from their PED use, it is very easy for an 
“outsider” to state that they should simply “stop using PEDs”.  Objectively speaking, 
this is one way of dealing with it.  However, what this work outlines is how 
ineffective this approach is; often, PED use is an informed decision made after doing 
copious amounts of research.  To tell an individual who has made this choice to “just 
stop” is, at best, ignorant.  At worst, it is invalidating.  Navigating the risks 
associated with these substances goes beyond “stopping”.  Rather, an agreement 
needs to be made on an individual level and working with the individual, rather than 
generalising them as one homogenous group of “drug users”.  It is my intention that 
the findings in this thesis perhaps give the reader some insight into the complex 
interplay of decisions that have to be made by the PED user, the tight controls and 
boundaries put in place and the importance placed upon being a responsible “user” 
rather than a “drug user”.  Even outside of the community, I want the reader to 
understand how upbringing and sociocultural context can play a role in perceptions 
and attitudes towards PED use in the absence of direct contact.  I want the reader to 
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understand how powerful experience is in shaping perceptions and attitudes; for 
example, consider the doctors who had experience with PED users compared to those 
who did not.  Experience has a large impact on breaking down barriers and enabling 
cohesive, collaborative dialogue to begin which is truly inclusive of the “other side”.  
Future directions should include more qualitative work uncovering experiences and 
perspectives within this community.  In particular, more work on female PED users 
is required – notably, understanding the context of their use, motivations and other 
aspects of the female experience.    
In a world that is, paradoxically, both risk-averse and risk-abundant, 
discussions concerning what “should” be allowed and what “shouldn’t” be permitted 
are still rampant.  Caught up in this discussion are those who wish to exercise their 
right to bodily modification on their terms.  The voices and perspectives of those 
who use PEDs have, for a large part, been largely ignored in favour of a polarised 
negative account of PED use.  For a long time, the medicalised and negative 
perception of PEDs has been disseminated widely, trickling through various 
pathways to the general public.  It is hoped the stories and perspectives presented 
within this thesis will give some food for thought for those who are not in the 
community and help expand the understanding of PED use and risk from being a 
polarised “one size fits all” approach to a complex interplay of many different factors 
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(Eliciting the lifeworld 
in Natural Attitude) 
Descriptive/narrativ
e context questions  
“can you 
describe…”  
Tell me about your 
experience with using AAS 
Tell me what led you to 
come off AAS the first time? 
Tell me what led you to 
come off AAS the most 
recent time?  
How does that first 
experience compare with 











phenomenon (Modes of 




of modes of 
appearing   
Tell me how you prepare for 
coming off AAS  
Tell me about what coming 
off AAS is like.   
What is it like after you have 
come off AAS?  
What is easy or difficult 
about coming off AAS? 
How does it compare to 











“what would you 
do…” 
“how would your 
experience be 
different if…” 
Examples: How would your 
experience differ if you were 
under the care of a doctor?  
How would it feel if you 
were younger/older/wanting 
a baby/did it against your 
will etc  
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Appendix D: Interview schedule for empirical chapter 4 (study 2) 
Interview  
Thank you for taking part in this study.  I am going to ask you some questions regarding 
your experience with DNP.  I will audio record your answers.  My research group is 
interested in understanding why people use DNP and finding out how we can protect 
your health and wellbeing and minimise harm.  I value your experience and will not 
judge you in any way.  I also guarantee complete confidentiality.  Any private 
information you provide (names, places, etc.) will be deleted from the transcription.  The 
information we gather may be used to produce a scientific paper.  Parts of your answers 
may be used as examples within the manuscript.  I want to clarify though that the 
information we gather will be interpreted as a whole and we are not interested in 
analysing you individually.  We guarantee that your identity will be kept completely 
anonymous and will be safeguarded.  Please confirm that you consent. 
1. When did you start training and what were your reason[s] for starting?' 'Do those
reasons still motivate you to train or have your goals changed? 
2. What PED do you currently use?
3. When did you start using PEDs? What were your reasons for doing so?
4. How did you get to know about DNP?
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5. Where did you learn how to use it?
6. What was the main reason you started using DNP?
7. Can you describe the first time you used DNP?
8. Have you had any previous experience with any other appearance enhancing
drugs? 
9. Were you concerned about any repercussions that could have risen?
10. How did you assure that the pills were actually DNP?
11. Were you aware of the other uses of DNP?
12. What did you want to gain from DNP?
13. What was the purpose of adding DNP as a supplement to your regime?
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14. How did DNP change your physique?
15. How did you plan your DNP cycles?
16. Can you describe the side effects arising from the beginning, during and after of
the DNP cycle? 
17. When did side effects first appear?
18. Have you researched about any of DNP side effects?
19. Were there any changes in your mode of consumption since you started using
DNP? 
20. Were you using any other recreational drugs, steroids or supplements while on
DNP? 
21. How did you get a hold of DNP?
22. How much would an average DNP cycle cost?
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23. Can you describe what the intake limit of your body is?
24. How does your bodybuilding community react towards you using DNP?
25. What do untrained people think about you using DNP?
26. Were friends and family aware of your use of DNP?
27. What is your opinion towards DNP?  (Have/would you recommend it to
anybody?) 
28. What misconception have you found that people have about DNP?









Use of other drugs 
Knowledge of DNP 
Peers 
Purchase 
Appendix E: Participant demographic questionnaire for empirical chapter 4 (study 2) 
Collector:  






Appendix F: Codebook for empirical chapter 4 (study 2) 
Codes  
Each quote is approximately 10 words 
Motivation 
- for working out (Any quote or reference to participant’s reasons for training using their
current style) 
- Motivation for athletic background sport IF they did one (why did they get into that
sport?) 
- Motivation for using DNP – why did they start using DNP?
- If they would do DNP again – motivation for using DNP in the future
- for using PEDs – why did they start using PEDs?
General information 
- duration of current style of training (any quote or reference to how long they have been
training in their current style for) 
- training background (i.e.  bodybuilder, powerlifter, recreational etc).
- Athletic background – Did they do any sports before their current style of training? If
yes, how long did they do sports for prior to weightlifting etc?  
- How did they get into their style of lifting from that background? For example, if
wrestler, would use weights to get better at wrestling, then started doing more lifting.     









- fulfilment of expectations
Side effects 
-Physiological (i.e.  body temperature, hyperhidrosis, allergies etc)
-Mental (lethargy, depression, etc)
Effects 
-aesthetic effects




Use of other drugs 
-AAS/other PEDs/fat burners
-Recreational drugs i.e.  alcohol, marijuana etc whilst on DNP
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-recreational drug use whilst on other PEDs (if any)
- recreational drug use whilst off-cycle
- not really drugs but use of supplements during cycle
- use of supplements off cycle (any multivitamins etc)
- medicinal drugs?  i.e.  antihistamines etc for allergic reaction to DNP
- are they on a cycle now?
-what cycle are they on? – which drugs do they currently use
- what was the first PED they used
Knowledge of DNP 
- other uses of DNP (i.e.  as an industrial compound)
- where did information originate from? Sources can include the internet
- if they have knowledge about other uses of DNP – did this change their mind to use it?
If not, why not? 
Peers 
- views of their bb community towards DNP use
- informing friends/family
- thoughts on society’s views towards DNP use
- thoughts on misconceptions towards DNP
Purchase 
- cost of DNP and total cycle
- where they purchased it from
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- purchase from peers
- purchase from internet
- ease of purchase?
- issue of scamming by dealers
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Appendix H: Interview schedule for empirical chapter 5 (study 3) 
Question Category AAS users Doctors  
Context Tell me about your AAS use 
history.    
Tell me about your experiences 
with drug users 
 Tell me what you know about 
AAS 
Tell me what you know about 
AAS. 
 What problems/benefits do 
you feel your AAS use brings 
you?  
Tell me about your experiences 
with AAS users.   
 Tell me about your 
experiences with doctors in 
general (feelings – 
good/bad/neutral, etc).   
How often do you encounter 
AAS users in your daily 
practice?  
Perceptions of PEDs – 
problems and management 
Why do you think people start 
using AAS? 
Why do you think people start 
using AASs?   
 How did you obtain your 
AAS? How do you feel about 
obtaining it through that way? 
How do you think AAS users 
obtain their AAS? How do you 
feel about it? 
 How do you feel about AAS 
use?  
How do you feel about AAS 
use? 
 Do you feel your AAS use is 
similar to that of other drug 
users? Why/why not? 
Do you feel their use is similar 
to that of other drug users? 
Why/why not? 
 If you have any problems with 
AAS use, would you see your 
doctor about them? Why/why 
not? 
What medical problems can 
arise from AAS use? Do you 
feel you can manage these 
sufficiently? Why/why not? 
Perception of experiences Do you think there are any 
difficulties in obtaining 
medical care as an AAS user? 
Why/why not? 
Are there any specific 
difficulties when treating AAS 
users compared to other 
patients? If yes, why? 
Perceptions of the community  How do you feel the AAS 
using community feel about 
doctors in general?  
How do your colleagues feel 
about AAS use? Are you aware 
of their views?  
 Do you feel there is a certain 
perception of AAS users from 
doctors? If so, what is it and 
why? 
How are doctors perceived by 
the AAS using community, in 
your opinion?  
  In general, do you feel there is a 
certain perception of AAS users 




Appendix I: Demographics questionnaire  for empirical chapter 5 (study 3) 
Alphanumerical identifier: 
AAS USER/ DOCTOR (Circle appropriate answer) 
Your Gender: Male/Female/Other/prefer not to answer 




- Asian or Asian British 
Attitudes on disclosing use  How do you feel about 
disclosing your use to your 
doctor?  
Some patients might struggle to 
disclose their use.  Why might 
this be, do you think? 
 In hindsight, would you 
disclose/not disclose? 
Why/Why not?  
As a medical practitioner, what 
do you think can be done to 
help patients disclose their use? 
 Would you tell others to 
disclose their use to their 
doctor? Why/why not?  
 
Expectations/Knowledge How do you feel about your 
current knowledge of AAS? 
What about the community’s 
knowledge in general? 
What do you feel about your 
current medical knowledge 
level regarding AAS and 
associated harm reduction 
techniques? What do you think 
about the medical community’s 
knowledge about these?  
 What do you expect your 
doctor to know about AAS? 
How do you feel about the 
medical community’s 
knowledge about AAS? 
What do you think AAS users 
know about AAS? How do you 
feel about the community’s 
knowledge levels?  
 How do you feel about the 
current medical resources 
available to AAS users?  
If they had any questions about 
AAS use, which resources 
would you direct them to? What 
do you think about these 
resources?   
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- Black or Black British 
- Chinese 
- Other ethnic group  
Educational level attained: 
- Primary school 
- GCSEs or equivalent 
- A-Levels or equivalent 
- University undergraduate programme 
- University post-graduate programme 
- Doctoral degree 
